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ABSTRACT		
Background/Aim:	Diabetic	retinopathy	(DR)	is	a	leading	cause	of	vision	impairment,	characterised	by	vascular	damage	and	neurodegeneration.	Anti	vascular	endothelial	growth	factor	(VEGF)	drugs	have	revolutionised	the	management	of	the	most	common	cause	of	vision	impairment	in	DR,	diabetic	macular	oedema	(DMO).	These	drugs	have	been	shown	to	restore	vision	in	DMO	and	to	induce	regression	of	vascular	changes	in	DR.	Despite	anti-VEGF	therapy,	a	proportion	of	patients	may	have	persistent	DMO.	The	aim	of	the	work	detailed	in	this	thesis	is	to	investigate	the	effect	of	switching	therapy	between	two	anti-VEGF	drugs	for	persistent	DMO	and	to	assess	the	potential	effects	of	anti-VEGF	drugs	in	modulating	neurodegeneration	in	DR	through	production	of	neurotrophic	factors.		
Methods:	A	prospective,	single-arm,	open-label	clinical	trial	of	patients	with	persistent	DMO	despite	prior	treatment	with	bevacizumab	was	conducted.	Patients	were	switched	in	therapy	to	aflibercept	and	reviewed	every	4	weeks	for	48	weeks.	Primary	outcomes	were	change	in	best-corrected	visual	acuity	(BCVA)	and	central	macular	thickness	(CMT).	Secondary	functional	and	anatomical	outcomes	included	microperimetry,	quality	of	life,	ultrawidefield	photography	and	fluorescein	angiography	(FA).	Diabetic	conditions	were	simulated	in	vitro	using	ARPE-19	cell-line	culture.	Once	conditions	were	established,	production	of	neurotrophic	factors	was	quantified	using	enzyme-linked	immunosorbent	assay	
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(ELISA)	under	normal	and	simulated	diabetic	conditions	with	and	without	the	addition	of	anti-VEGF	drugs.			
Results:	There	was	a	significant	improvement	in	primary	visual	and	anatomical	outcomes.	Segmentation	and	fixation	artifacts	on	automated	OCT	calculations	were	increased	in	the	presence	of	DMO.	Peripheral	ischaemia	identified	on	FA	was	associated	with	a	poorer	baseline	vision	and	greater	vision	gain.	Microperimetry	outcomes	correlated	with	objective	and	subjective	vision	outcomes.	There	was	downregulation	of	pigment	epithelium	derived	factor	(PEDF)	expression	in	hypoxic	states	in	the	in	vitro	model	compared	to	control.	In	the	absence	of	hypoxia,	the	addition	of	anti-VEGF	drugs	all	led	to	a	significant	downregulation	of	PEDF.	Brain	derived	neurotrophic	factor	(BDNF)	secretion	was	downregulated	in	high	glucose	states	and	upregulated	in	hypoxia.	Placental	growth	factor	(PlGF)	was	not	detected	as	secreted	by	ARPE-19	as	measured	by	ELISA.		
Conclusions:	Intravitreal	aflibercept	was	effective	in	improving	anatomical	and	visual	outcomes	among	patients	with	incomplete	response	to	intravitreal	bevacizumab.	Peripheral	ischaemia	may	be	an	important	biomarker	to	response	in	patients	with	persistent	DMO.	Microperimetry	may	provide	important	information	about	subjective	visual	function	not	well	assessed	with	visual	acuity.	Neurotrophic	factor	secretion	may	be	effected	by	the	diabetic	state,	having	consequences	for	long-term	vision	outcomes.	 	
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Chapter	1:	Anti-VEGF	drugs	for	Diabetic	Eye	Diseases		The	management	of	diabetic	retinopathy	has	seen	a	paradigm	shift	through	the	identification	of	vascular	endothelial	growth	factor	(VEGF)	as	a	key	mediator	of	disease.	The	introduction	of	anti-VEGF	drugs	has	subsequently	revolutionised	outcomes	in	this	potentially	blinding	disease.		This	chapter	summarises	the	role	of	anti-VEGF	drugs	in	the	management	of	diabetic	eye	diseases,	presenting	long-term	findings	from	key	randomised	clinical	trials	and	discussing	the	future	role	of	VEGF-targeted	therapy.	The	concept	of	refractory	disease	is	introduced	which	will	be	explored	in	more	depth	in	Chapter	2.			The	material	presented	in	this	chapter	has	been	published	in	peer	review	literature	as,	and	are	reproduced	from:		
• Bahrami	B,	Hong	T,	Gilles	MC,	Chang	A.	Anti-VEGF	Therapy	for	Diabetic	Eye	Diseases.	Asia	Pac	J	Ophthalmol	(Phila).	2017	Nov-Dec;6(6):535-545.		
• Chang	AA,	Hong	T,	Ewe	SY,	Bahrami	B,	Broadhead	GK.	The	role	of	aflibercept	in	the	management	of	diabetic	macular	edema.	Drug	Des	Devel	Ther.	2015	Aug	6;9:4389-96.	 	
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ABSTRACT	Diabetic	retinopathy	(DR)	is	a	leading	cause	of	vision	impairment	and	blindness	in	the	working-age	population.	The	identification	of	vascular	endothelial	growth	factor	(VEGF)	as	a	key	mediator	in	the	pathogenesis	of	DR	has	revolutionised	the	management	of	this	vision-threatening	disease.	There	is	now	strong	evidence	supporting	intravitreal	anti-VEGF	therapy	as	first	line	in	the	management	of	sight-threatening	diabetic	macular	oedema	(DMO),	as	well	as	a	growing	body	of	evidence	to	support	the	use	of	anti-VEGF	drugs	for	proliferative	DR.	This	chapter	summarises	the	role	of	VEGF	in	DR,	the	evidence	for	anti-VEGF	therapy,	safety	considerations	and,	the	future	of	anti-VEGF	therapy	for	the	management	of	DR.		 	
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BACKGROUND	Diabetic	retinopathy	(DR)	is	a	leading	cause	of	vision	impairment,	affecting	93	million	people	worldwide.	[1]	Of	these,	28	million	have	vision-threatening	DR.	Vision	loss	in	DR	is	most	commonly	due	to	diabetic	macular	odema	(DMO),	but	may	also	be	a	consequence	of	complications	of	proliferative	DR	(PDR),	such	as	vitreous	hemorrhage	from	neovascularization,	tractional	retinal	detachment	or	neovascular	glaucoma.		An	improved	understanding	of	the	complex	pathophysiology	of	DR	has	identified	vascular	endothelial	growth	factor-A	(VEGF)	as	a	key	mediator	of	the	progression	to	advanced	disease.	[2,	3]	Development	of	drugs	which	target	VEGF	have	revolutionised	the	management	approach	in	DMO	and	have	an	expanding	growing	role	in	the	management	of	DR.	These	anti-VEGF	drugs	have	been	reported	to	be	safe	and	effective	through	multiple	clinical	trials.	Despite	their	efficacy,	there	are	a	proportion	of	patients	who	have	an	incomplete	response	to	therapy.	Future	strategies	to	manage	DR	include	alternate	methods	of	blocking	the	VEGF	pathway	with	increased	efficacy	and	reduced	number	of	treatments.			 	
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PATHOPHYSIOLOGY	OF	DIABETIC	RETINOPATHY	The	mechanisms	resulting	in	the	development	and	progression	of	DR	are	multifactorial,	complex	and	incompletely	understood.	Whilst	primarily	thought	of	as	a	microvasculopathy,	there	is	increasing	evidence	to	suggest	neuronal	and	glial	dysfunction	are	consequences	of	DR	independent	of	vascular	damage.	[4,	5]	Consequently,	the	pathogenesis	of	DR	should	consider	the	interactions	of	neuronal,	glial,	and	vascular	cells	as	part	of	a	neurovascular	unit	affected.	[6]		Important	systemic	risk	factors	for	DR	include	duration	of	diabetes,	glycemic	control,	type	of	diabetes	and	hypertension.	[1,	7,	8]	Hyperglycemia	is	a	key	component	in	the	development	of	DR	and	is	thought	to	lead	to	alteration	of	biochemical	pathways	in	the	retina,	resulting	in	inflammation	and	oxidative	stress.	[9-14]	Cytokines	such	as	interleukin	(IL)-6,	IL-1	beta,	tissue	necrosis	factor-alpha	and	monocyte	chemoattractant-1	are	upregulated	as	part	of	this	response,	as	are	angiogenic	factors	such	as	angiopoetin-2,	erythropoietin	and	VEGF.	[14,	15]	These	secreted	factors	lead	to	blood-retinal	barrier	(BRB)	breakdown	and	increased	permeability	of	retinal	vessels	resulting	in	DMO	and	to	neovascularization,	the	hallmark	of	PDR.	These	pathways	will	be	reviewed	in	further	depth	in	Chapter	2.		Of	the	cytokines	and	growth	factors	upregulated	in	DR,	VEGF	has	been	identified	to	play	a	critical	role.	There	are	five	members	of	the	VEGF	family	in	humans:	VEGF-A	(commonly	referred	to	as	VEGF),	VEGF-B,	VEGF-C,	VEGF-D	and	placental	growth	factor	(PlGF).	[16]		
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VEGF-A	is	a	45	kDa	heparin-binding	homodimeric	glycoprotein	and	is	secreted	by	glia,	ganglion	cells,	endothelial	cells,	astrocytes	and	the	retinal	pigment	epithelium	(RPE).	[17,	18]	This	factor	has	essential	physiological	roles	in	vascular	development	and	important	roles	in	neuronal	survival.	There	are	four	main	isoforms	of	VEGF-A	that	bind	and	activate	the	tyrosine	kinase	VEGF	receptor	(VEGFR)-1	and	VEGFR-2,	which	are	both	mainly	expressed	on	the	cell	surface	of	the	vascular	endothelium.	VEGFR-2	is	thought	to	be	responsible	for	the	pathological	mitogenic	and	microvascular	permeability	effects	of	VEGF-A.	[19,	20]	Levels	of	intravitreal	VEGF-A	are	strongly	correlated	with	advancing	DR	and	DMO.	[2,	21]		The	other	members	of	the	VEGF	family	have	less	important	roles	in	vascular	development	but	may	play	a	role	in	DR.	PlGF	binds	to	VEGFR-1	and	produces	transphosphorylation	of	VEGFR-2,	amplifying	VEGF-A	driven	angiogenesis	and	BRB	breakdown	through	VEGFR-2.	[22]	In	vitro	and	in	vivo	studies	support	the	role	of	PlGF	in	DR.	[23]	Exogenous	PlGF	added	to	human	RPE	culture	and	injected	into	rat	eyes	has	been	shown	to	impair	outer	BRB	function.	[24]	PlGF	knockout	in	an	Akita	mouse	model	of	diabetes	has	been	shown	to	prevent	DR.	[25]	Higher	vitreous	levels	of	PlGF	are	found	with	increasing	levels	of	retinal	ischemia	seen	in	advanced	DR.	[26]		There	is	limited	evidence	to	suggest	that	VEGF-B,	which	also	binds	to	VEGFR-1,	is	involved	in	the	pathogenesis	of	DR.	VEGF-B	overexpression	in	mice	via	gene	transfer	resulted	in	increased	choroidal	and	retinal	neovascularization.	[27]	However,	levels	of	VEGF-B	in	vitreous	fluid	of	patients	with	PDR	are	not	raised	
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compared	to	non-diabetic	controls.	[28]	It	has	been	reported	that	VEGF-B	prevents	hyperglycemia-induced	retinal	apoptosis.	[29]		VEGF-C,	which	binds	to	both	VEGFR-2	and	VEGFR-3,	has	important	roles	in	adult	angiogenesis	and	lymphangiogenesis.	VEGF-C	expression	is	increased	in	diabetic	retina	and	in	vitro	has	been	shown	to	potentiate	the	angiogenic	effects	of	VEGF-A	on	VEGFR-2.	[30]	Blocking	VEGF-A	in	the	retina	may	lead	to	compensatory	upregulation	of	VEGF-C,	which	will	in	turn	compensate	for	reduced	signaling	through	VEGFR-2.	[31]	Single	nucleotide	polymorphisms	in	the	VEGF-C	gene	have	been	associated	with	presence	of	DR	and	DMO	in	white	patients	with	diabetes,	further	enhancing	the	evidence	that	VEGF-C	may	influence	the	development	and	progression	of	DR.	[32]		 	
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EVOLUTION	OF	THERAPIES	FOR	DIABETIC	RETINOPATHY	Strategies	for	managing	sight-threatening	DR	have	evolved	over	the	past	four	decades.	Well-established	therapies,	such	as	laser	photocoagulation	and	intravitreal	corticosteroid	therapy,	may	indirectly	affect	the	VEGF	pathway	and	signaling.		
Laser	photocoagulation	Retinal	photocoagulation	revolutionised	the	management	of	both	PDR	and	DMO	following	landmark	clinical	trials	in	the	1970s	and	1980s.	The	Diabetic	Retinopathy	Study	(DRS)	established	that	panretinal	photocoagulation	(PRP)	could	reduce	the	rates	of	severe	vision	loss	in	PDR	by	more	than	50%	over	a	period	of	two	years.	[33]	The	destruction	of	photoreceptors	in	areas	of	hypoxia	and	subsequent	reduced	oxygen	consumption	is	believed	to	reduce	the	production	of	VEGF	driving	neovascularization.	[34]	Levels	of	intravitreal	VEGF	are	reduced	following	PRP	for	PDR,	supporting	this	hypothesis.	[2]			The	Early	Treatment	Diabetic	Retinopathy	Study	(ETDRS)	demonstrated	focal/grid	macular	laser	photocoagulation	could	reduce	the	rates	of	vision	loss	in	in	clinically	significant	DMO	by	half.	[35]	Whilst	the	mechanisms	of	focal	laser	are	also	unclear,	it	is	hypothesised	that	laser	interaction	with	the	RPE	alters	the	expression	of	cytokines	such	as	pigment	epithelium	derived	factor	(PEDF),	a	counter-regulator	of	VEGF.	[36-40]		
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These	laser	procedures	are	not	without	associated	risks	and	side	effects,	including	loss	of	the	peripheral	visual	field,	pain	during	the	procedure,	severe	vision	loss	if	the	fovea	is	targeted	and	rupture	of	Bruch’s	membrane.	[40]	Alternate	laser	therapy	for	DMO	is	discussed	in	further	depth	in	Chapter	2.		
Corticosteroid	therapy	Corticosteroids	were	the	initial	intravitreal	pharmacotherapy	studied	for	the	management	of	DMO.	[41,	42]	These	drugs	inhibit	the	expression	and	action	of	cytokines,	inhibit	leukocyte	recruitment	and	maintain	the	BRB	through	enhancement	of	endothelial	cell	tight	junctions.	[15,	43,	44]	They	may	also	modulate	VEGF	gene	expression	or	modulate	signaling	downstream	from	the	VEGFR-2.	[45,	46]			Corticosteroids	are	less	widely	utilised	for	primary	management	of	DMO	due	to	their	ocular	side	effect	profiles,	which	includes	raised	intraocular	pressure	and	accelerated	cataract	formation.	[47,	48]	However,	they	remain	an	important	treatment	modality	for	a	disease	that	can	be	challenging	to	manage.	The	role	of	these	drugs	will	be	discussed	in	further	depth	in	Chapter	2.			 	
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ANTI-VEGF	DRUGS	The	three	most	widely	used	anti-VEGF	drugs	are	bevacizumab	(Avastin,	Genentech,	San	Francisco,	CA,	USA),	ranibizumab	(Lucentis,	Genentech,	San	Francisco,	CA,	USA)	and	aflibercept	(Eylea,	Regeneron,	Tarrytown,	NY,	USA).			Pegaptanib	sodium	(Macugen,	Eyetech	Pharmaceuticals,	Cedar	Knolls,	NJ,	USA)	is	an	aptamer	that	selectively	binds	the	VEGF-A	165	isoform	and	has	some	efficacy	in	the	management	of	DMO	and	PDR.	[49,	50]	Use	of	pegaptanib	in	DR	is	not	widespread	due	to	access	and	availability	of	alternate	and	perhaps	more	effective	anti-VEGF	agents.	These	drugs	are	summarised	in	Table	1.1.		Bevacizumab	is	a	149	kDa,	full-length	monoclonal	antibody	to	all	isoforms	of	VEGF-A.	This	drug	was	developed	for	its	anti-angiogenic	effects	in	neoplastic	disease	and	proved	revolutionary	as	an	adjunct	to	chemotherapy	in	prolonging	survival	in	metastatic	cancer.	[51]	It	is	not	formulated	for	intravitreal	use	and	consequently	is	most	commonly	prepared	by	compounding	pharmacies.			Ranibizumab	is	a	48	kDa	monoclonal	antibody	fragment	that	binds	to	all	isoforms	of	VEGF-A.	It	lacks	the	IgG	Fc	segment	that	full-length	antibodies	have,	and	consequently,	it	has	the	lowest	molecular	weight	of	these	three	inhibitors.	The	smaller	size	of	this	drug	provides	a	potential	advantage	in	terms	of	retinal	penetration.	[52]	The	absence	of	an	Fc	segment	avoids	the	theoretical	interaction	of	ranibizumab	with	Fc	receptors	on	immune	cells,	which	could	lead	to	cytotoxicity.	[53]		
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Aflibercept	is	a	115	kDa	fusion	protein,	combining	the	second	binding	domain	of	VEGFR-1	and	the	third	binding	domain	of	VEGFR-2.	These	are	fused	to	the	Fc	segment	of	human	IgG1	and	the	molecule	acts	as	a	decoy	receptor,	binding	all	isoforms	of	VEGF-A,	VEGF-B	and	PlGF.	[54]	Aflibercept	may	also	bind	galectin-1,	a	protein	that	is	physiologically	expressed	throughout	the	retina	but	upregulated	in	PDR.	[55,	56]	It	has	angiogenic	effects	and	protein	levels	are	elevated	in	eyes	with	PDR,	with	no	correlation	to	VEGF-A	levels.	[56,	57]		
Pharmacokinetics	Pharmacokinetics	of	intravitreal	aflibercept	(2.0	mg)	have	been	compared	to	that	of	ranibizumab	(0.5	mg)	and	bevacizumab	(1.25	mg)	in	a	study	of	56	patients	with	neovascular	age-related	macular	degeneration	(nAMD).	[58]	Systemic	exposure	to	aflibercept	was	higher	than	that	of	ranibizumab,	with	maximum	serum	concentration	five-	and	seven-fold	greater	after	the	first	dose	and	third	doses	respectively	and	minimum	serum	concentration	37-	and	53-fold	greater	after	the	first	and	third	doses,	respectively.	Additionally,	there	was	accumulation	of	both	aflibercept	and	bevacizumab	after	three	intravitreal	injections	but	not	ranibizumab.	Aflibercept	was	also	the	most	potent	of	these	three	drugs	in	reducing	plasma-free	VEGF	with	levels	undetectable	from	3	hours	post-dose	to	greater	than	1	week	post-dose.	It	is	postulated	that	the	Fc	fragment	present	in	both	the	bevacizumab	and	aflibercept	molecules	extends	their	serum	half-life,	accounting	for	these	differences.	[59]	The	clinical	significance	of	this	is,	however,	yet	to	be	elucidated.		
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Drug	clearance	from	the	vitreous	of	the	eye	occurs	across	the	retina	through	the	choroidal	circulation	and	through	diffusion	into	the	anterior	chamber	to	exit	via	the	trabecular	meshwork.	[60]	There	are	no	published	reports	about	the	intravitreal	half-life	of	aflibercept	in	humans;	however,	there	have	been	two	rabbit	models	estimating	this	through	immunoassay	and	radioisotope	imaging	techniques	as	between	4.5	days	and	4.58	days.	[61]	Given	the	anatomic	and	biological	differences	between	humans	and	rabbits,	the	half-life	is	expected	to	be	longer	in	humans,	suggested	to	be	9	days	based	on	its	intermediate	molecular	size	between	ranibizumab	and	bevacizumab.	[60]	Further	mathematical	modeling	suggests	that	aflibercept	is	able	to	maintain	significant	intraocular	binding	activity	up	to	10–12	weeks	after	a	single	injection.			
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Table	1.1:	Summary	of	different	anti-VEGF	drugs		
Drug	name	 Structure	 Mechanism	of	action	 Molecular	Size	 Intravitreal	half-life	 US	FDA	Approved	
Indications	Pegaptanib	(Macugen,	EyeTech	Pharmaceuticals)	 Pegylated	RNA	aptamer	 Binds	VEGF-165	isoform	of	VEGF-A	 50	kDa	 10	days	 nAMD	Bevacizumab	(Avastin,	Genentech)	 Full	length	monoclonal	antibody	to	VEGF-A	 Binds	all	VEGF-A	isoforms	 149	kDa	 7.0	days	*	 Metastatic	colorectal	cancer,	non-small	cell	lung	cancer,	glioblastoma,	metastatic	renal	cell	carcinoma,	cervical	cancer,	ovarian,	fallopian	tube	or	peritoneal	cancer	Ranibizumab	(Lucentis,	Genentech)	 Monoclonal	antibody	fragment	to	VEGF-A	 Binds	all	VEGF-A	isoforms		 48	kDa	 2.5	days	*	 nAMD,	RVO,	DMO,	mCNV,	DR	Aflibercept	(Eylea,	Regeneron)	 Fusion	protein	of	binding	domains	of	VEGFR-1	and	-2,	contains	Fc	portion	
Decoy	receptor	for	all	isoforms	of	VEGF-A,	VEGF-B	and	PlGF	 115	kDa	 3.6	days	*	 nAMD,	RVO,	DMO	nAMD=	neovascular	age	related	macular	degeneration,	RVO=	retinal	vein	occlusion,	DMO=	diabetic	macular	oedema,	DR=diabetic	retinopathy,	mCNV=myopic	choroidal	neovascularisation	*	from	rabbit	animal	model	data	[62]	
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ANTI-VEGF	THERAPY	FOR	DIABETIC	MACULAR	OEDEMA	Landmark	clinical	trials	have	demonstrated	the	efficacy	of	intravitreal	bevacizumab,	ranibizumab	and	aflibercept	in	the	management	of	DMO.	The	results	of	these	trials	are	summarised	in	Table	1.2.			
Anti-VEGF	vs.	Laser	The	Bevacizumab	or	Laser	Treatment	(BOLT)	randomised	trial	compared	the	effect	of	1.25mg	bevacizumab	to	macular	laser	as	a	control	over	a	two-year	period.	[63]	Bevacizumab	was	given	as	three	loading	doses	six	weeks	apart	and	subsequently	on	an	as	needed	basis	every	six	weeks.	Laser	was	administered	at	baseline	with	retreatment	every	16	weeks	as	needed.	There	was	a	significant	improvement	in	vision	and	a	non-significant	reduction	in	central	macular	thickness	(CMT)	in	the	bevacizumab	group	at	one	and	two	years.			Ranibizumab	has	been	evaluated	against	laser	in	the	RISE/RIDE,	RESTORE,	READ-2,	REVEAL	and	Diabetic	Retinopathy	Clinical	Research	network	(DRCR.net)	Protocol	I	studies.	[64-68]	All	of	these	trials	demonstrated	superiority	of	ranibizumab	to	laser	for	vision	gains	and	improvement	in	CMT	after	a	12	month	period,	which	was	maintained	over	36	months	in	the	RISE/RIDE,	RESTORE	and	READ-2	studies	and	over	5	years	for	the	Protocol	I	study.	Additionally,	the	Protocol	I	study	demonstrated	no	benefit	of	prompt	laser	as	an	adjunct	to	intravitreal	ranibizumab	therapy	with	some	suggestion	that	this	could	in	fact	limit	visual	gain	at	3	years.	[69]			
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Aflibercept	was	assessed	initially	in	the	phase	II	DA	VINCI	study.	Four	different	dosing	regimens	were	compared	and	demonstrated	no	anatomical	or	visual	difference	between	4-weekly	and	8-weekly	administration	of	the	drug,	following	a	loading	dose.	[70]	All	aflibercept	arms	of	the	study	were	superior	to	laser	only	treatment.	The	phase	III	VISTA/VIVID	studies	with	the	efficacy	similar	between	4-weekly	and	8-weekly	dosing,	a	benefit,	which	was	maintained	over	a	three	year,	follow-up.	[71]			Baseline	glycemic	control	does	not	seem	to	have	a	bearing	on	response	to	therapy	with	anti-VEGF	drugs	as	reported	in	the	RISE/RIDE	and	VISTA/VIVID	studies.	[72,	73]	This	may	contrast	with	laser	therapy,	which	had	poorer	visual	and	anatomical	outcomes	with	an	increasing	glycosylated	hemoglobin	level	in	the	VISTA/VIVID	studies.	[73]		
Dose	Variation	The	0.3mg	and	0.5mg	arms	of	RISE/RIDE	had	similar	vision	and	anatomical	outcomes	at	3	years	of	follow	up.	[64]	The	READ-3	study	compared	the	effects	of	0.5mg	and	2.0mg	ranibizumab	administered	monthly	for	six	doses	and	subsequently	on	an	as	needed	basis.	[74]	The	mean	visual	gain	after	two	years	of	therapy	was	greater	in	the	0.5mg	arm	than	the	2.0mg	arm	(11.1	vs.	6.8	letters,	p=0.02)	with	no	anatomical	difference	noted.	[74]	The	results	of	these	studies	suggest	that	peak	of	the	dose-response	curve	for	ranibizumab	is	at	least	at	0.5mg	and	perhaps	even	0.3mg.		
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Similarly,	the	phase	II	DRCR.net	Protocol	H	study	demonstrated	no	meaningful	anatomical	or	visual	differences	between	1.25mg	and	2.5mg	of	bevacizumab	administered	as	two	doses	six	weeks	apart.	[75]	These	results	were	also	validated	in	a	randomised	controlled	trial,	which	also	found	no	differences	between	1.25mg	and	2.5mg	doses.	[76]	Response	to	bevacizumab	in	this	study	was	more	marked	in	treatment	naïve	patients	compared	to	those	with	previous	therapy,	regardless	of	dose	used.	[76]		
Anti-VEGF	vs.	corticosteroid	The	DRCR.net	Protocol	I	study	compared	combined	4mg	intravitreal	triamcinolone	(Trivaris,	Allergan,	Inc.,	Irvine,	CA)	and	laser	to	0.5mg	ranibizumab.	[47]	All	intravitreal	drugs	were	given	as	three	loading	doses	four	weeks	apart	and	subsequently	on	an	as	needed	basis	every	four	weeks.	After	two	years	of	treatment,	visual	improvement	was	significantly	better	in	the	ranibizumab	arms	(7±13	letter	change,	p=0.01	and	10±15	letter	change,	p=0.0001)	but	not	the	triamcinolone	arm	(0±21	letter	change,	p>0.05)	compared	to	laser	control.	However,	subgroup	analyses	of	pseudophakic	eyes	showed	similar	improvements	with	ranibizumab	groups	as	in	the	triamcinolone	group	(8±12	and	7±9	vs	8±9	letter	change	respectively)	at	one-year.	Half	of	participants	in	the	triamcinolone	arm	experienced	a	significant	elevation	in	IOP	compared	with	9%	and	11%	in	the	ranibizumab	and	laser	arms	respectively.	Additionally,	59%	of	participants	in	the	in	the	triamcinolone	arm	required	cataract	surgery	compared	with	14%	in	both	the	ranibizumab	and	laser	arms.			
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The	BEVORDEX	study	compared	bevacizumab	to	a	slow-release	intravitreal	dexamethasone	implant	(DEX	implant;	Ozurdex,	Allergan	Inc.,	Irvine,	CA).	[48]	Treatments	were	given	on	an	as	needed	basis,	every	4	weeks	in	the	bevacizumab	arm	and	every	16	weeks	in	the	DEX	implant	arm.	After	two	years	of	treatment,	there	was	no	significant	difference	in	vision	gain	or	reduction	in	CMT	between	the	two	groups.	Eyes	randomised	to	DEX	implant	required	fewer	injections	in	both	the	first	and	second	year	of	treatment	compared	to	bevacizumab	(mean	2.8	vs.	9.1	injections	in	the	first	year,	2.2	vs.	4.8	in	the	second	year).	Subgroup	analysis	demonstrated	similar	visual	outcomes	for	pseudophakic	eyes	randomised	to	DEX	implant	compared	with	bevacizumab,	with	worse	outcome	for	phakic	eyes.	Topical	ocular	hypotensives	to	manage	an	intraocular	pressure	rise	were	required	in	22%	of	patients	in	the	DEX	implant	arm	compared	to	none	in	the	bevacizumab	arm.	[48]		
Comparison	of	different	anti-VEGF	drugs	The	DRCR.net	Protocol	T	compared	the	safety	and	efficacy	of	1.25mg	bevacizumab,	0.3mg	ranibizumab	and	2.0mg	aflibercept	for	DMO.	[77]	Drug	was	administered	every	four	weeks	unless	vision	was	20/20	or	better,	CMT	was	below	threshold	and	there	was	no	worsening	or	improvement	in	response	to	the	past	two	injections.	The	two-year	results	from	this	study	showed	that	there	was	no	overall	difference	between	the	three	agents	in	terms	of	visual	outcome.	[78]	Both	ranibizumab	and	aflibercept	arms	had	improved	reduction	of	the	CMT	compared	to	the	bevacizumab	arm.	There	was	no	significant	difference	in	injection	number	over	the	two-year	study	period	between	the	three	groups.	
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	Aflibercept	had	improved	visual	outcomes	to	both	bevacizumab	and	ranibizumab	at	one-year	follow	up	in	patients	with	poorer	baseline	visual	acuity	(less	than	69	letters),	with	no	difference	between	bevacizumab	and	ranibizumab.	Gains	at	one	year	were	18.9	letters	with	aflibercept,	11.8	letters	with	bevacizumab	and	14.2	letters	with	ranibizumab	(p<0.001	aflibercept	vs.	bevacizumab,	p=0.003	aflibercept	vs.	ranibizumab,	p=0.21	for	ranibizumab	vs.	bevacizumab).	However,	the	difference	between	aflibercept	and	bevacizumab	was	the	only	significant	comparison	at	the	two-year	follow	up	point	(mean	18.1	vs.	13.3	letter	gain,	p=0.02).	Patients	randomised	to	aflibercept	were	less	likely	to	require	rescue	laser	treatment	than	either	of	the	other	groups.	[78]			
Delaying	treatment	Delaying	anti-VEGF	treatment	in	patients	with	DMO	by	more	than	12	months	appears	to	result	in	poorer	long-term	outcomes.	Patients	initially	randomised	to	laser	in	the	RESTORE	trial	who	were	switched	to	ranibizumab	after	12	months	had	similar	visual	and	anatomical	outcomes	at	36	months	of	follow	up	compared	to	patients	initially	receiving	ranibizumab.	[66]	However,	in	the	RISE/RIDE	and	VISTA/VIVID	studies,	patients	who	were	initially	randomised	to	laser	treatment	and	received	delayed	anti-VEGF	after	24	months	did	not	achieve	the	same	degree	of	vision	gain	as	those	initially	randomised	to	the	drug	arms	of	those	trials.	[64,	71]		
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Table	1.2:	Key	randomised	controlled	trials	of	anti-VEGF	drugs	for	the	management	of	diabetic	macular	oedema	
Study	Name	 Population	
size	(study	
eyes)	
Follow-
up	
duration	
(months)	
Inclusion	Criteria	 Treatment	arms	 Mean	Vision	Change	
(letters)	
Mean	CMT	
Change	(µm)	
Proportion	
of	eyes	with	
regression	of	
DR	
BOLT	[63]	 80	 24	 VA	20/40	to	20/320,	CMT	>270µm	 Bevacizumab	(1.25mg	q6)	 8.6±9.1	 -146±171	 31.4%	Laser	therapy	 -0.5±10.6	 -118±112	 20%	
RISE	[64]	 377	 36	 VA	20/40	to	20/320,	CMT	≥275	µm	 Ranibizumab	(0.3mg	q4)	 11.0±12.9	 -261.2±196.2	 38.5%	Ranibizumab	(0.5mg	q4)	 14.2±12.8	 -269.1±178.9	 40.9%	Sham	*	 4.3±14.9	 -200.1±215.6	 24.3%	
RIDE	[64]	 382	 36	 VA	20/40	to	20/320,	CMT	≥275µm	 Ranibizumab	(0.3mg	q4)	 11.4±16.3	 -261.8±180.8		 39.3%	Ranibizumab	(0.5mg	q4)		 10.6±12.9	 -266.7±207.8		 37.8%	Sham	*	 4.7±13.3	 -213.2	±193.5	 23.4%	
RESTORE	[66]	 208	 36	 VA	20/32	to	20/160		 Ranibizumab	(0.5mg	q4)		 8.0±1.1	(SE)	 -142.1	 14.8%	Ranibizumab	(0.5mg	q4)	+	Laser	 6.7±1.1	(SE)	 -145.9	 28.3%	Laser	alone**	 6.0±1.1	(SE)	 -142.7	 16.0%	
READ-2	[67]	 74	 36	 VA	20/40	to	20/320	CMT	≥250	µm	 Ranibizumab	(0.5mg	q8	after	two	loading	q4	doses)	 10.3	 -132	 Not	reported	Ranibizumab	(0.5mg	q12)	+	Laser	 8.9	 -243	Laser	alone	***	 1.4	 -163	
REVEAL	[68]	 396	 12	 VA	20/32	to	20/160	 Ranibizumab	(0.5mg	q4)	 6.6±7.7	 -134.6	 Not	reported				
Ranibizumab	(0.5mg	q4)	+	Laser	 6.4±10.7	 -171.8	Laser	alone	 1.8±8.3	 -57.2	
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Protocol	I	
[65]	
235	 60	 VA	20/32	to	20/320	 Ranibizumab	(0.5q4)	+	Prompt	laser	 8±13	 -167±168	 Not	reported	Ranibizumab	(0.5mg	q4)	+	Deferred	laser	 10±13	 -165±165	
DA	VINCI	[70]	 176	 12	 VA	20/40	to	20/320	CMT	≥250	 Aflibercept	(0.5mg	q4)	 11.0	 -165.4	 40%	Aflibercept	(2mg	q4)	 13.1	 -227.4	 31%	Aflibercept	(2mg	q8)	 9.7	 -187.8	 64%	Aflibercept	(2mg	PRN)	 12.0	 -180.3	 32%	Laser	 -1.3	 -58.4	 12%	
VISTA	[71]	 461	 36	 VA	20/40	to	20/320		 Aflibercept	(2mg	q4)	 10.5	 -200.4	 29.9%	Aflibercept	(2mg	q8)		 10.4	 -190.1	 34.4%	Laser****	 1.4	 -109.8	 20.1%	
VIVID	[71]	 404	 36	 VA	20/40	to	20/320		 Aflibercept	(2mg	q4)	 10.3	 -215.2	 44.3%	Aflibercept	(2mg	q8)		 11.7	 -202.8	 47.8%	Laser****	 1.6	 -122.6	 17.4%	
BEVORDEX	
[48]	
68	 24	 VA	20/40	to	20/400	CMT	>250µm	 Bevacizumab	(1.25mg	q4	PRN)		 9.6	(95%	CI	6.9-12.3)		 -122	^	 Not	reported	Dexamethasone	(0.7mg	q16	PRN)	 6.9	(95%	CI	2.7-11.1)	 -187	^	
Protocol	T	
[78,	79]	
609	 12	 VA	20/32	to	20/320	 Aflibercept	(2mg	q4)		 13.3±11.1	 -169±138	 24.8%	Bevacizumab	(1.25mg	q4)		 9.7±10.1	 -101±121	 22.1%	Ranibizumab	(0.3mg	q4)	 11.2±9.4	 -147±134	 31.0%	
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DR=diabetic	retinopathy,	VA=visual	acuity,	CMT=central	macular	thickness,	q(x)=every	(x)	weeks,	PRN=as	required,	SE=standard	error,	CI=confidence	interval.	*	Sham	patients	eligible	for	switch	to	active	therapy	at	month	24.	**Laser	group	eligible	for	0.5mg	q4	ranibizumab	from	month	12.	***Laser	group	eligible	for	0.5mg	ranibizumab	from	month	6.	****	Laser	group	eligible	for	2mg	aflibercept	q8	from	week	24.	^	12	month	anatomical	outcome,	24	month	thickness	not	quantitatively		
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ANTI-VEGF	FOR	REFRACTORY	DMO	Despite	the	efficacy	of	anti-VEGF	drugs	for	managing	DMO,	there	are	a	proportion	of	patients	who	have	an	incompletely	respond	to	therapy.	From	Protocol	T,	the	rates	of	meeting	failure	criteria	between	weeks	24	and	1	year	for	aflibercept,	bevacizumab	and	ranibizumab	were	27%,	41%	and	37%	respectively.	[77]		Incomplete	response	to	therapy	poses	a	clinical	challenge,	and	several	strategies	have	been	proposed	to	manage	these	patients	including	switching	to	corticosteroid	drugs,	increasing	dose	of	anti-VEGF	drug,	combination	therapy	and	switching	between	anti-VEGF	drugs.			The	REEF	study	evaluated	patients	who	had	incomplete	response	to	bevacizumab	and	switched	these	patients	to	0.5mg	ranibizumab.	[80]	The	dose	of	ranibizumab	was	increased	to	2.0mg	if	there	was	residual	oedema	or	less	than	10%	improvement	in	CMT	after	three	months	of	therapy.	After	switch	76%	of	participants	had	anatomical	and	visual	improvement	with	0.5mg	ranibizumab.	Of	the	remainder	of	the	patients	who	subsequently	had	a	dose	increase	(n=6)	50%	had	further	anatomical	improvement.		Other	retrospective	series	have	shown	visual	and	CMT	improvement	in	switching	therapy	from	bevacizumab	to	ranibizumab	for	patients	with	incomplete	response.	[80-83]	Similarly,	switching	from	either	bevacizumab	or	ranibizumab	to	aflibercept	may	have	a	benefit	in	improving	CMT.	[83-86]	 	
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EFFECT	OF	ANTI-VEGF	ON	THE	SEVERITY	OF	DIABETIC	
RETINOPATHY	Trials	of	anti-VEGF	drug	for	DMO	have	shown	additional	benefit	in	leading	to	an	improvement	in	DR	severity	score	(DRSS).	DRSS	is	based	on	clinically	observable	signs	such	as	hemorrhages,	microaneurysms	and	intraretinal	microvascular	abnormalities.	Reversal	of	these	changes	supports	the	importance	of	VEGF	in	the	pathogenesis	of	the	disease	and	suggests	that	reversibility	of	vascular	damage	may	be	possible.			The	two-year	outcomes	of	RISE/RIDE	trials	showed	the	cumulative	probability	of	progression	of	DR	was	11.2-11.5%	in	the	ranibizumab	arms	compared	to	33.8%	in	the	sham	treatment	arm.	[87]	Median	DRSS	remained	unchanged	in	the	sham	arm	but	improved	by	two	steps	in	both	ranibizumab	treatment	arms.	Similarly,	in	the	148-week	analysis	of	the	VISTA/VIVID	trials,	17.4-20.1%	of	patients	receiving	laser	had	an	improved	DRSS	compared	with	29.9-47.8%	of	patients	receiving	aflibercept	when	censoring	for	rescue	treatment.	[71]		There	were	greater	improvements	in	DRSS	in	the	ranibizumab	and	aflibercept	arms	in	the	Protocol	T	study,	compared	to	the	bevacizumab	arm	at	12	months.	[79]	This	difference	was	not	maintained	at	two	years	of	follow	up,	however,	improvements	were	associated	with	a	higher	number	of	intravitreal	injections.	DRSS	was	more	markedly	improved	in	the	aflibercept	arm	compared	to	both	ranibizumab	and	bevacizumab	in	patients	with	PDR.	This	may	be	explained	by	the	effect	of	aflibercept	on	inhibiting	galectin-1	as	previously	discussed.	[56]		
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Anti-VEGF	for	PDR	Early	studies	observed	that	bevacizumab	may	be	effective	as	an	adjunct	or	an	alternative	to	PRP	for	the	regression	of	PDR.	[88]	Subsequently,	two	randomised	clinical	trials	have	reported	the	efficacy	of	anti-VEGF	drugs	to	PRP	for	the	management	PDR,	summarised	in	Table	1.3.		The	DRCR.net	Protocol	S	was	a	two-year	study	of	patients	with	treatment-naïve,	high-risk	PDR	randomised	to	receive	either	0.5	mg	ranibizumab	as	frequently	as	every	four	weeks	or	PRP	completed	in	one	to	three	visits.	[89]	Patients	who	had	concurrent	DMO	were	also	recruited	to	this	study.	At	two	years	follow-up,	ranibizumab	had	non-inferior	outcomes	to	PRP	in	terms	of	visual	acuity.	Additionally,	there	was	less	development	of	DMO,	peripheral	field	loss	and	need	for	vitrectomy	in	the	ranibizumab	arm.	This	study	is	collecting	efficacy	and	safety	data	for	five	years	until	2018.	Safety	evaluation	was	challenging	in	these	patients	as	half	of	the	participants	in	the	PRP	group	subsequently	received	ranibizumab	for	DMO	so	there	was	no	control	group	without	ranibizumab	exposure.	[90]		CLARITY	was	a	randomised	controlled	trial	comparing	2.0mg	intravitreal	aflibercept	to	PRP	for	the	management	of	high-	and	low-risk	PDR.	[91]	Patients	with	DMO	were	excluded	to	avoid	confounding	of	visual	outcomes	and	patients	previously	treated	with	PRP	were	included.	Patients	randomised	to	the	aflibercept	arm	were	given	three	loading	injections	four	weeks	apart	followed	by	
	 -46-	
injections	every	four	weeks	on	an	as	needed	basis.	The	patients	who	received	aflibercept	had	improved	vision	outcomes	at	the	52-week	primary	outcome	time	point..	At	the	52-week	point,	30	patients	in	the	PRP	group	(29%)	had	developed	DMO	compared	to	12	patients	(11%)	of	the	aflibercept	group.	Total	regression	of	neovascularization	favored	the	aflibercept	group,	as	did	the	total	DR	severity.		The	cost	of	repeated	anti-VEGF	drug	administration	is	an	important	consideration	in	the	management	of	PDR,	with	PRP	being	a	highly	cost	effective,	once-off	therapy.	[92]	The	cost-benefit	of	such	treatment	may	not	be	viable	for	ranibizumab	for	cases	of	PDR	alone	but	may	be	acceptable	for	cases	with	concurrent	DMO.	[93]	There	are	other	important	considerations	such	as	the	effect	of	withdrawing	anti-VEGF	therapy,	compliance	and	potential	complications	in	situations	of	missed	follow-up	with	intravitreal	injection.			
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Table	1.3:	Summary	of	key	randomised	controlled	trials	assessing	anti-VEGF	drugs	for	the	management	of	proliferative	diabetic	retinopathy	(PDR).			
	VA=visual	acuity,	CMT=central	macular	thickness,	q(x)=every	(x)	weeks,	PRN=as	required,	SE=standard	error,	PRP=panretinal	photocoagulation,	CI=confidence	interval			
Study	Name	 Population	
size	(study	
eyes)	
Follow-
up	
duration	
(months)	
Inclusion	
Criteria	
Treatment	arms	 Mean	Vision	Change	
(letters)	
Mean	CMT	Change	
(µm)	
Regression	of	
neovascularisation	
at	last	follow	up	
Protocol	S	
[89]	
394	 24	 VA	≥20/320	 Ranibizumab	(0.5mg	q4	PRN)	 2.8	(95%	CI	0.4	to	5.2)	 -47	(95%	CI	-61	to	-33)	 35%	PRP	 0.2	(95%	CI	-1.9	to	2.3)	 -3	(95%	CI	-15	to	9)	 30%	
CLARITY	[91]	 232	 12	 VA	≥20/80		 Aflibercept	(2mg	q4	PRN	after	three	loading	q4	doses)	 1.3	(0.6	SE)	 -8.9	(2.3	SE)	 64%	PRP	 -2.9	(0.7	SE)	 24.0	(5.5	SE)	 34%	
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ANTI-VEGF	FOR	COMPLICATIONS	OF	PROLIFERATIVE	DIABETIC	
RETINOPATHY	
Vitreous	Hemorrhage	Intravitreal	bevacizumab	may	assist	in	PDR	complicated	by	vitreous	hemorrhage	(VH)	by	reducing	the	need	for	vitrectomy	and	reducing	vitreous	clear	up	time.	Vitrectomy	was	required	in	10%	of	eyes	that	had	received	bevacizumab	compared	to	40%	of	those	who	had	been	managed	with	observation	for	12	weeks	in	a	case-control	study.	[94]	Vitreous	clear	up	time	was	11.9±9.5	weeks	in	the	bevacizumab	group	compared	with	18.1±12.7	weeks	in	the	control	group	(p=0.02).	Thirty-one	of	forty	patients	(77.5%)	received	only	one	injection	in	the	follow	up	period.		Intravitreal	ranibizumab	(0.5mg)	was	compared	with	saline	for	the	management	of	PDR	related	VH	in	the	DRCR.net	Protocol	N.	[95]	Following	three	intravitreal	injections	four	weeks	apart,	primary	outcomes	were	assessed	after	16	weeks	in	this	randomised	controlled	trial	of	261	eyes.	There	were	lower	rates	of	recurrent	VH,	improved	visual	acuity	and	PRP	completion	rates	in	the	ranibizumab	groups.	However,	rates	of	vitrectomy	were	not	statistically	different	at	16	weeks	between	the	ranibizumab	(12%)	and	saline	(17%)	groups	(4%	difference,	95%	CI	-4-13%).		Intravitreal	aflibercept	is	being	compared	to	prompt	vitrectomy	and	PRP	for	the	management	of	VH	in	PDR	in	the	DRCR.net	Protocol	AB	(NCT02858076).	The	
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longer-term	data	from	this	two-year	study	will	provide	important	guidance	for	the	role	of	medical	and	surgical	management	of	this	complication	of	PDR.		
Surgical	Adjuvant	Intravitreal	bevacizumab	administered	as	a	surgical	adjuvant	has	been	shown	to	reduce	postoperative	VH,	reduce	surgical	time,	lower	complications,	and	lead	to	improved	post-operative	visual	acuity	in	patients	with	PDR	undergoing	vitrectomy.	[96-98]	Ranibizumab	has	also	been	studied	for	this	indication	in	two	smaller	studies	with	similar	benefits.	[99,	100]		Timing	of	delivery	of	pre-operative	anti-VEGF	drug	may	be	important	in	this	indication.	Too	short	an	interval	may	be	insufficient	to	induce	regression	of	neovascularization	to	assist	in	surgery.	[101]	Too	long	an	interval	may	lead	to	fibrovascular	contraction	and	be	associated	with	tractional	retinal	detachment.	[102]	Patients	randomised	to	receive	intravitreal	bevacizumab	5-10	days	prior	to	vitrectomy	had	less	intraoperative	complications	and	improved	visual	outcomes	at	six	months	follow	up	compared	to	those	patients	receiving	bevacizumab	1-3	days	prior	to	vitrectomy,	suggesting	a	longer	interval	may	be	optimal.	[103]		
Neovascular	Glaucoma	Neovascular	glaucoma	(NVG)	can	be	a	complication	of	PDR	and	is	associated	with	increased	levels	of	intraocular	VEGF.	[104]	Intravitreal	bevacizumab	has	been	shown	to	lead	to	regression	of	neovascularization	of	the	iris	and	angle	and	
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assist	in	controlling	IOP	in	multiple	studies	of	NVG,	though	most	of	these	studies	included	etiologies	other	than	PDR.	[105]			Bevacizumab	delayed	the	need	for	glaucoma	surgery	in	a	retrospective,	comparative	case	series	of	163	eyes	with	NVG	treated	with	and	without	intravitreal	bevacizumab.	[106]	This	effect	was	more	marked	in	eyes	that	received	PRP	in	addition	to	intravitreal	bevacizumab,	suggesting	PRP	may	have	additional	therapeutic	benefit	in	managing	NVG.	Supporting	this,	combination	of	bevacizumab	with	PRP	led	to	a	significant	reduction	in	intraocular	pressure	and	regression	of	neovascularization	in	a	retrospective,	consecutive	case-control	study	of	23	patients	receiving	either	combination	bevacizumab	and	PRP	or	PRP	alone	as	treatment	of	NVG.	[107]		Aflibercept	was	shown	to	be	effective	in	the	causing	regression	of	neovascularization	of	the	iris	and	the	angle	in	four	cases	of	NVG,	two	of	which	were	related	to	PDR.	[108]	The	PDR	patients	required	eight	injections	each	over	a	12-month	follow-up	period.		
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SAFETY	CONSIDERATIONS	VEGF	has	extensive	physiologic	roles,	both	locally	in	the	eye	as	well	as	systemically.	[16,	109]	Consequently,	disruption	of	these	pathways	through	pharmacological	intervention	may	be	of	concern.		
Systemic	Adverse	Events	There	has	been	well-documented	increased	risk	of	hypertension,	[110,	111]	arterial	and	venous	thromboembolism,	[112,	113]	cardiac	ischemia,	[114]	bleeding,	[111,	115]	and	delayed	wound	healing	in	studies	of	anti-VEGF	drugs	used	systemically	for	cancer	therapy.	[116]	However,	multiple	randomised	clinical	trials	and	meta-analyses	have	failed	to	demonstrate	an	increase	in	these	systemic	adverse	events	when	anti-VEGF	drugs	are	administered	as	intravitreal	injection	compared	to	placebo.	[117,	118]			The	reported	safety	profile	of	intravitreal	anti-VEGF	may	be	confounded	by	the	exclusion	of	patients	with	prior	history	of	stroke	or	myocardial	infarction	from	these	trials.	This	is	especially	relevant	in	patients	with	diabetes	who	have	a	higher	risk	of	cardiovascular	events	than	that	of	the	general	population.	A	meta-analysis	of	patients	with	a	higher	baseline	stroke	risk	receiving	ranibizumab	demonstrated	a	higher	stroke	risk	compared	with	placebo	in	patients	receive	therapy	for	neovascular	age-related	macular	degeneration	(nAMD)	(OR	7.7;	95%	CI,	1.2-177).	[119]		
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More	aggressive	treatment	with	monthly	dosing	of	anti-VEGF	drug	in	DMO	may	be	associated	with	increased	systemic	adverse	events.	[120]	Patients	receiving	monthly	aflibercept	or	0.5mg	ranibizumab	for	24	months	had	increased	risk	of	death	compared	to	laser	(OR	2.98;	95%	CI,	1.44-6.14;	P = .003)	having	cerebrovascular	accident	(OR,	2.33;	95%	CI,	1.04-5.22;	P = .04)	or	vascular	death	(OR,	2.51;	95%	CI,	1.08-5.82;	P = .03)	in	a	meta-analysis	of	RISE/RIDE	and	VISTA/VIVID	data.	[120]		When	comparing	anti-VEGF	drugs,	the	two-year	outcomes	of	the	Protocol	T	study	found	a	higher	rate	of	non-fatal	stroke	and	vascular	death	in	the	ranibizumab	arm	compared	to	the	aflibercept	arm.	[78]	However,	the	rates	of	these	cardiovascular	adverse	events	(12%)	were	higher	in	this	study	than	other	studies	of	ranibizumab	(3-9%),	leading	the	authors	to	concede	that	this	finding	may	represent	a	type	II	error.	[78,	121,	122]		
Ocular	adverse	events	Every	intravitreal	injection	carries	the	risk	of	endophthalmitis.	A	meta-analysis	of	16	trials	of	intravitreal	therapy	found	52	cases	from	a	total	of	105,536	injections,	a	rate	of	0.049%.	[123]	Additionally,	this	study	found	that	streptococcal	isolates	were	much	higher	than	with	intraocular	surgery,	suggesting	that	minimizing	oropharyngeal	droplet	transmission	could	be	a	strategy	for	reducing	rates	of	endophthalmitis.	[123]	Though	rates	lower	than	this	have	been	reported	in	institutional	audits,	[124,	125]	when	considering	
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treatment	often	requires	repeated	injection	cumulative	risk,	per-patient	rates	over	two	years	may	approach	1%.	[126]		As	there	is	no	commercial	intravitreal	preparation	of	bevacizumab,	special	consideration	is	required	for	the	safety	of	this	drug,	as	it	needs	to	be	prepared	by	compounding	pharmacies.	The	quality	of	drug	can	vary	between	compounding	pharmacies.	[127]	Contamination	during	compounding	can	have	catastrophic	consequences,	with	several	reports	of	endophthalmitis	from	contaminated	batches	of	drug.	[128]	Counterfeit	preparations	may	be	associated	with	poorer	quality	control	and	higher	rates	of	endophthalmitis.	[129]	Inadequate	purification	of	preparations	can	also	lead	to	culture	negative	endophthalmitis.	[130]		Rhegmatogenous	retinal	detachment	(RD)	is	a	rare	complication	of	intravitreal	injection	and	is	thought	to	occur	either	as	a	result	of	direct	trauma	during	the	injection	procedure	or	disruption	of	the	vitreous	gel	triggering	posterior	vitreous	detachment.	The	rate	of	RD	was	5	in	35,942	injections	(0.013%),	all	occurring	between	2	and	6	days	following	injection,	in	a	multicenter	case	series.	[131]		Increased	risk	of	raised	intraocular	pressure	(IOP)	has	been	reported	in	eyes	receiving	multiple	anti-VEGF	injections.	[132,	133]	Comparing	treated	to	untreated	eyes	of	patients	with	nAMD,	there	were	greater	odds	(5.75	95%	CI,	1.19-27.8;	P	=	0.03)	of	experiencing	an	elevation	in	IOP	greater	than	5	mmHg	in	those	who	had	received	29	or	more	injections	compared	with	12	or	fewer	injections	in	one	study.	[132]	The	mechanisms	by	which	these	injections	can	
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cause	raised	IOP	are	unclear	but	these	findings	highlight	the	importance	of	monitoring	the	IOP	of	patients	receiving	long-term	intravitreal	anti-VEGF	drug.		There	is	concern	that	anti-VEGF	therapy	may	have	pro-fibrotic	and	exacerbating	effects	on	PDR.	Several	studies	have	shown	increased	fibrosis	in	patients	who	had	received	intravitreal	bevacizumab	prior	to	vitrectomy	for	PDR.	[134,	135]	This	is	thought	to	be	the	result	of	an	angio-fibrotic	switch	where	there	is	a	shift	to	increased	expression	of	connective	tissue	growth	factor	with	VEGF	blockade.	[135]		Due	to	the	physiological	role	of	VEGF	as	a	neurotrophic	factor,	there	are	theoretical	safety	concerns	for	long-term	use	of	these	inhibitors.	[136]	Sustained	neutralization	of	VEGF	has	been	shown	to	cause	retinal	neurodegeneration	[137]	and	signaling	through	VEGFR-2	is	essential	for	Müller	cell	survival.	[138]		Clinical	evidence	in	humans	is	scant	and	hard	to	establish,	given	part	of	the	pathology	of	DR	is	neurodegeneration.	However,	some	clinical	data	suggests	that	anti-VEGF	drugs	may	have	positive	effects	on	the	neural	retina.	Restoration	of	foveal	photoreceptors,	demonstrated	on	optical	coherence	tomography,	has	been	observed	in	patients	following	12	months	of	treatment	with	ranibizumab.	[139]		Worsening	of	macular	ischemia	due	to	blocking	of	the	physiological	effect	of	VEGF	is	another	theoretical	concern	and	potential	contraindication	with	administration	of	anti-VEGF	drug.	[140]	There	was	no	difference	in	progression	of	macular	ischemia	in	analysis	of	the	BOLT	study	with	administration	of	
	 -55-	
bevacizumab	compared	to	laser	control.	[141]	Besides	this	study,	there	is	a	lack	of	data	on	progression	of	macular	ischemia	studies	in	randomised	trials	comparing	anti-VEGF	drugs	to	a	sham	or	laser	control.		
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FUTURE	ANTI-VEGF	STRATEGIES	Future	anti-VEGF	strategies	aim	to	reduce	the	need	for	frequent	intravitreal	injection,	thus	reducing	the	burden	of	treatment	as	well	as	the	cumulative	risk	for	adverse	events	such	as	endophthalmitis	and	retinal	detachment.	They	may	provide	a	management	option	for	treatment	resistant	patient.		
Anti-VEGF	antibodies	and	proteins	Brolucizumab	is	a	single	chain,	antibody	fragment	with	a	molecular	weight	of	26kDa,	almost	half	of	that	of	ranibizumab.	The	theoretical	advantages	of	a	smaller	molecular	are	better	penetration	of	ocular	tissues,	faster	clearance	and	lower	systemic	exposure.	Phase	I/II	data	showed	that	brolucizumab	was	non-inferior	to	ranibiuzmab	for	the	management	of	nAMD	with	a	possible	longer	treatment	interval	and	an	acceptable	safety	profile.	[142]	Phase	III	studies	comparing	this	antibody	to	aflibercept	for	nAMD	(NCT02434328	and	NCT02307682)	will	complete	data	collection	in	2017	and	are	expected	to	serve	as	the	basis	for	future	trials	for	managing	DMO.		Similar	to	aflibercept,	conbercept	(Chengdu	Kanghong	Biotech	Co.,	Ltd.,	Sichuan,	China)	is	a	fusion	protein	of	the	second	binding	domain	of	VEGFR-1	and	the	third	and	the	fourth	binding	domains	of	VEGFR-2	fused	to	the	Fc	region	of	human	IgG.	A	retrospective	study	of	51	patients	with	DMO	treated	with	conbercept	with	or	without	macular	grid	laser,	showed	an	improvement	in	both	visual	and	anatomical	outcomes	after	12	months	of	therapy.	[143]	It	is	currently	being	
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evaluated	against	macular	laser	photocoagulation	for	DMO	in	a	randomised	controlled	trial	(NCT02194634).		Designed	ankyrin	repeat	proteins	(DARPins)	are	small,	non-immunoglobulin	proteins	that	bind	target	proteins	with	high	affinity	and	specificity.	Abicipar	pegol	(Molecular	Partners,	Zurich,	Switzerland;	marketed	by	Allergan,	Dublin,	Ireland).	A	phase	I/II	study	of	this	DARPin	for	DMO	demonstrated	maximal	vision	improvement	at	12	weeks	following	injection,	though	the	rates	of	ocular	inflammation	were	high	amongst	these	patients	(61%).	[144]	This	high	rate	of	inflammation	was	thought	to	be	secondary	to	impurities	in	the	preparation	and	future	studies	of	abicipar	corrected	this.	An	updated	preparation	of	abicipar	pegol	is	under	investigation	in	phase	III	randomised	controlled	trials	for	AMD	in	the	SEQUOIA	(NCT02462486)	and	CEDAR	(NCT02462928)	studies.	These	studies	are	evaluating	an	extended	treatment	interval	of	12	weeks	and	it	is	expected	that	future	phase	III	studies	for	DMO	would	evaluate	a	similar	protocol.		
Gene	Therapy	Gene	therapy	targeting	the	VEGF	pathway	has	been	evaluated	in	patients	with	nAMD.	In	a	phase	I	study,	nine	patients	had	subretinal	injections	of	a	recombinant	adeno-associated	vector	(rAAV)	encoding	soluble	Flt-1	(sFlt-1).	[145]	The	protein	that	is	transduced	is	the	soluble	form	of	VEGFR-1.	Consequently,	VEGF-A,	VEGF-B	and	PlGF	are	bound	in	much	the	same	way	as	aflibercept.	No	major	concerns	were	noted	in	this	study	and	many	patients	did	
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not	require	rescue	intravitreal	anti-VEGF	therapy.	By	targeting	VEGF,	this	therapy	may	provide	an	effective	means	for	treating	DMO	and	PDR.		
Alternate	drug	delivery	methods	Controlled	drug	delivery	systems	may	provide	a	solution	to	the	frequency	for	which	drugs	need	to	be	administered.	Anti-VEGF	loaded	nanoparticles	have	been	shown	to	reduced	diabetes-induced	vascular	leakage	in	mice.	[146]	These	drug	delivery	systems	enhance	the	half-life	of	a	drug	but	also	increase	solubility,	protect	it	against	oxidation.	Other	polymers	have	also	been	trialed	in	animal	studies	and	may	present	a	more	efficient	method	of	administering	treatment.	[6]		Mechanical	devices	such	as	a	surgically	implanted	pump	may	provide	a	means	of	delivering	up	to	100	programmable	doses	of	intravitreal	drug.	[147]	One	such	subconjunctivally-implanted	device	was	loaded	with	ranibizumab	and	well	tolerated	in	a	three-month	pilot	study	of	11	patients	with	DMO.	[147]			 	
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SUMMARY	The	pathophysiology	of	DR	is	incompletely	understood.	However,	clinical	experience	with	anti-VEGF	drugs	has	shown	that	it	is	a	powerful	mediator	of	disease.	The	introduction	of	pharmacological	anti-VEGF	therapy	has	revolutionised	the	management	of	DMO	although	managing	persistent	disease	is	a	common	challenge.	Anti-VEGF	drugs	may	play	an	important	role	in	the	management	of	advanced	DR	and	PDR	in	the	future.	Future	anti-VEGF	therapies	for	DR	may	utilize	advanced	methods	of	drug	delivery	and	newer	drugs	may	target	VEGF.			 	
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Chapter	2:	Diabetic	Macular	Oedema:	Pathophysiology,	Management	Challenges	and	Persistent	Disease		
	The	overall	application	of	anti-VEGF	drugs	in	diabetic	eye	diseases	was	summarised	in	the	preceding	chapter.	In	this	chapter	there	is	a	focus	on	the	pathophysiology	of	diabetic	macular	oedema	as	well	as	the	evolution	in	the	diagnosis,	prognosis	and	management	of	this	condition.			The	theme	of	refractory	disease	is	explored	further	with	a	systematic	review	of	the	literature	and	a	qualitative	presentation	of	clinical	data	regarding	the	definition	and	management	of	DMO	persisting	after	anti-VEGF	treatment.			The	material	presented	in	this	chapter	has	been	published	in	peer	review	literature	as,	and	is	reproduced	from:		
• Bahrami	B,	Zhu	M,	Hong	T,	Chang	A.	Diabetic	macular	oedema:	pathophysiology,	management	challenges	and	treatment	resistance.	Diabetologia.	2016	Aug;59(8):1594-608.			 	
	 -61-	
BACKGROUND	Diabetic	macular	oedema	 (DMO)	 is	a	 leading	cause	of	vision	 loss	and	 the	most	common	 cause	 of	 vision	 loss	 in	 diabetic	 patients,	 affecting	 an	 estimated	 21	million	 people	 worldwide	 in	 2010.	 [1,	 148]	 DMO	 typically	 affects	 adults	 of	 a	working	 age,	 having	 not	 only	 direct	 costs	 to	 the	 healthcare	 system	 but	 also	indirect	costs	incurred	by	productivity	lost	at	work.	[148,	149]			The	prevalence	of	DMO	varies	amongst	the	diabetic	population,	affecting	14.3%	and	5.6%	of	type	1	and	type	2	diabetic	patients	respectively.	Duration	of	diabetes	is	 a	 risk	 factor,	with	 3.2%	 of	 those	 living	with	 diabetes	 for	 less	 than	 10	 years	affected	compared	to	20.0%	of	those	having	diabetes	for	greater	than	20	years.	The	 prevalence	 of	 DMO	 is	 also	 higher	 among	 those	 with	 poorer	 HbA1C,	hypertension	and	serum	cholesterol	greater	than	4.0	mmol/L.	[1]			The	 diagnosis	 and	 management	 of	 DMO	 was	 standardised	 by	 the	 Early	Treatment	 of	 Diabetic	 Retinopathy	 Study	 (ETDRS)	 report	 number	 1.	 [35]	Macular	focal/grid	laser	photocoagulation	was	found	to	halve	the	rate	of	vision	loss	in	DMO	over	three	years.	Macular	laser	therapy	consequently	remained	the	standard	of	care	for	DMO	for	over	two	decades.		In	recent	decades,	the	pathophysiological	pathways	involved	in	the	development	of	DMO	have	been	better	identified.	Consequently,	new	classes	of	therapies	have	been	 studied	 and	 developed	 in	 addition	 to	 macular	 laser,	 initially	 intravitreal	corticosteroids	and	subsequently	anti-vascular	endothelial	growth	factor	(VEGF)	drugs.	 Furthermore,	 imaging	 advances	 with	 optical	 coherence	 tomography	
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(OCT)	 and	 fluorescein	 angiography	 (FA)	 has	 allowed	 for	 improved	 diagnosis,	assessment	of	prognosis	and	monitoring	response	to	therapy.		Despite	 these	 advances,	 there	 remain	 a	 proportion	 of	 patients	 who	 do	 not	adequately	 respond	 to	 current	 standard	 of	 care	 pharmacological	 therapeutic	options.	 This	 phenomenon	may	 be	 termed	 treatment-resistant	 DMO,	 however,	there	is	no	consensus	as	to	what	constitutes	treatment-resistant	DMO.		Indicators	 commonly	 used	 to	 measure	 treatment	 effectiveness	 are	 duration,	number	and	response	to	previous	treatments	in	conjunction	with	vision,	central	macular	 thickness	 (CMT)	 and	 residual	 oedema	presenting	within	 or	 under	 the	retina.	Although	clinical	trial	data	guides	the	prevalence	of	treatment	resistance	with	pharmacotherapy	based	on	these	criteria,	these	indicators	have	limitations.	For	example,	improvement	in	visual	acuity	can	be	dependent	on	baseline	visual	acuity,	 that	 is,	 there	 is	 less	 vision	 to	 be	 regained	 in	 a	 patient	 with	 a	 better	presenting	visual	acuity.	CMT	values	differ	depending	on	the	OCT	machine	used	as	well	as	the	presence	of	pathology.	[150]	This	will	be	the	focus	of	Chapter	4	of	this	thesis.		In	 the	 Diabetic	 Retinopathy	 Clinical	 Research	 network	 (DRCR.net)	 Protocol	 I	study,	 treatment	 success	was	defined	as	visual	acuity	equivalent	 to	20/20	or	a	CMT	 less	 than	 250	 microns.	 Approximately	 75%	 of	 patients	 were	 incomplete	responders	 to	 this	 criteria	 following	 four	 loading	 doses	 of	 ranibizumab	 at	 16	weeks	of	 follow-up.	Despite	 additional	 laser	 therapy	being	given	 to	 all	 arms	 in	this	 study,	 40-50%	of	 participants	 in	 the	 ranibizumab	 and	 triamcinolone	 arms	
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were	incomplete	responders	following	12	months	of	therapy.	[151]	These	rates	did	not	change	significantly	at	two	years	of	follow	up	suggesting	that	response	is	likely	to	be	seen	following	4-12	months	of	therapy.	Similar	rates	of	response	to	anti-VEGF	drugs	have	been	found	in	the	DRCR.net	Protocol	T	study.	[77]	As	such,	reasonable	criteria	for	treatment	resistance	based	on	trial	data	would	be	at	least	4-6	 treatments	 with	 intravitreal	 pharmacotherapy	 with	 at	 least	 six	 months	 of	follow	up	and	significant	residual	oedema	visualised	on	OCT.			Treatment-resistance	 likely	 reflects	 the	 complex	pathophysiology	of	DMO.	This	Chapter	 summarises	 the	 pathophysiology	 of	 DMO,	 mechanisms	 of	 action	 for	established	therapies	and	reviews	case	series	and	trials	 for	the	management	of	treatment-resistant	DMO.			 	
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METHODS	A	 systematic	 literature	 search	 was	 performed	 using	 MEDLINE	 (from	 1966	 to	February	 2016)	 and	 EMBASE	 (from	 1950	 to	 February	 2016).	 Keywords	 used	included;	 refractory,	 recalcitrant,	 treatment-resistant,	 switching,	 pathogenesis,	VEGF,	 risk	 factors,	 genetics,	 steroid,	 laser,	 vitrectomy,	 optical	 coherence	tomography,	 fluorescein	 angiography	 and	 diabetic	 macular	 oedema.	 The	reference	 lists	 of	 cited	 papers	 were	 examined	 to	 find	 additional	 articles	 of	relevance.	 Only	 papers	 published	 in	 English	 from	 peer-reviewed	 articles	 and	original	 descriptions	 were	 included	 and	 there	 was	 no	 restrictions	 applied	 to	study	type.		 	
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PATHOPHYSIOLOGY		The	pathophysiology	of	DMO	is	multifactorial	and	complex,	involving	mechanical	and	biochemical	pathways	triggered	by	hyperglycaemia.	Better	understanding	of	these	pathways	has	led	to	the	development	of	effective	therapies,	including	laser	photocoagulation,	 vitreoretinal	 surgery	 and	 systemic	 and	 ophthalmic	pharmacotherapy.		The	 common	 pathway	 that	 leads	 to	macular	 oedema	 in	 DMO	 as	well	 as	 other	exudative	 retinal	 conditions	 is	 breakdown	 of	 the	 blood-retinal	 barrier	 (BRB).	[152]	 The	 BRB	 consists	 of	 the	 inner	 BRB	 and	 the	 outer	 BRB,	 which	 exist	 to	maintain	 homeostasis	 in	 the	 neural	 tissue.	 The	 inner	 BRB	 is	 formed	 by	 tight	junctions	 between	 retinal	 endothelial	 cells,	 the	 surrounding	 basal	 lamina,	pericytes,	 astrocytes	 and	 microglia.	 The	 outer	 BRB	 is	 formed	 by	 the	 tight	junctions	between	retinal	pigment	epithelium	(RPE)	cells.	 Impaired	 integrity	of	the	 BRB	 leads	 to	 leakage	 of	 plasma	 solutes	 into	 the	 interstitial	 spaces	 causing	oedema	through	increased	osmotic	pressure.	Fluid	subsequently	accumulates	in	different	spaces	within	and	underneath	the	retina	as	demonstrated	in	Figure	2.1.		Disruption	 of	 the	BRB	 in	 diabetic	 retinopathy	 (DR)	 results	 from	 the	 release	 of	inflammatory	 cytokines	 and	 growth	 factors	 released	 in	 states	 of	 chronic	hyperglycaemia.	 Important	 implicated	 factors	 include	VEGF-A,	placenta	growth	factor	 (PlGF),	 interleukin	 (IL)	 -8,	 IL-6,	 IL-1	 beta,	 tumour	 necrosis	 factor-alpha	and	matrix	metalloproteinases.	[152-154]			
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Hyperglycaemia	mediated	activation	of	several	identified	biochemical	pathways	promotes	 formation	of	 these	 factors.	These	mechanisms	 include	 increased	 flux	through	the	polyol	pathway,	activated	protein	kinase	C	(PKC)	and	the	formation	of	advanced	glycation	end	products	(AGEs).		Aldose	reductase	utilises	nicotinamide	adenine	dinucleotide	phosphate	(NADPH)	to	reduce	excess	glucose	to	sorbitol	in	the	polyol	pathway.	Whilst	some	sorbitol	is	 oxidised	 to	 fructose	 by	 sorbitol	 dehydrogenase	 through	 the	 use	 of	nicotinamide	 adenine	 dinucleotide	 (NAD+),	 the	 majority	 remains	 unchanged.	The	 consumption	 of	 NADPH	 in	 this	 pathway	 prevents	 the	 regeneration	 of	glutathione	and	other	free	radical	scavengers,	increasing	oxidative	stress	on	the	cell.	[155]		Increased	 diacylglycerol	 is	 produced	 in	 hyperglycaemic	 states.	 This	 activates	PKC,	 the	 beta	 isoform	 of	 which	 is	 found	 in	 high	 concentrations	 in	 the	 retina.	[156]	 Activated	 PKC	 beta	 mediates	 retinal	 vascular	 permeability	 leading	 to	hypoxia	 and	 upregulates	 VEGF	 signaling	 pathways	 further	 leading	 to	 BRB	impairment.	[3]		Hyperglycaemia	also	causes	non-enzymatic	glycation	of	plasma	proteins	and	the	basal	lamina,	which	lead	to	the	production	of	AGEs.	Accumulation	of	AGEs	in	the	vitreous	 causes	 cross-linking	 of	 collagen,	 leading	 to	 an	 abnormally	 adherent	vitreo-retinal	interface.	[157]	These	mechanical	forces	contribute	to	DMO.	AGEs	also	bind	to	AGE	receptors	in	Müller	cells	causing	upregulation	of	nuclear	factor-κB,	 increasing	 transcription	 of	 inflammatory	 cytokines	 and	 VEGF.	 [158]	 BRB	
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function	may	 be	 affected	 directly	 by	AGE-mediated	 altering	 of	 transmembrane	proteins	such	as	integrins.	[152]			The	 pathophysiology	 of	 DMO	 is	 a	 multifactorial	 process.	 Disease	 that	 is	refractory	 to	 a	 particular	 approach	 to	 treatment	 may	 reflect	 a	 failure	 to	recognise	 one	 or	 a	 combination	 of	 the	 pathways	 involved	 or	 upregulation	 of	alternate	growth	factors	as	discussed	further	below.	[153,	159]			Many	 authors	 have	 attempted	 to	 identify	 and	 treat	 treatment	 resistant	 DMO.	These,	including	their	criteria	for	defining	treatment	resistance	are	summarised	in	Table	2.1.		 	
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Figure	2.1:	Optical	coherence	tomography	(OCT)	in	a	patient	with	diabetic	macular	oedema	involving	the	fovea.		OCT	provides	an	ultrastructural	overview	of	the	retina	similar	to	a	histological	section.	Note	the	presence	of	subretinal	fluid	(SRF)	accumulating	above	the	retinal	pigment	epithelium	(RPE)	and	intraretinal	fluid	(IRF).			
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Table	2.1:	Overview	of	studies	of	diabetic	macular	oedema	resistant	to	therapy	with	anti-VEGF	or	steroid	drugs	
	
Author	 Number	of	
eyes	
Definition	of	
treatment-resistance	
Inclusion/Exclusion	
Criteria	
Design	 Intervention	 Mean	follow-
up	
Outcome	Alshahrani	2016	[160]	 26	(26	subjects)	 At	least	6	intravitreal	injections	of	bevacizumab,	ranibizumab	or	aflibercept	over	six	months	
CMT>350μm,	no	improvement	of	2	or	more	lines	on	Snellen	chart	
Retrospective	case	series	 Dexamethasone	implant	 6	months	 Reduced	CMT	and	improved	BCVA	at	1	and	3	months	
Bansal	2015	[161]	 67	(52	subjects)	 At	least	3	bevacizumab/	triamcinolone	injections	and	at	least	3	sessions	focal/grid	laser	
CMT>300μm,	intravitreal	injection	within	last	3	months	 Retrospective	case	series	 Dexamethasone	implant	 24	weeks	 Reduced	CMT	and	improved	BCVA,	Maximal	benefit	at	6	weeks	Ciulla	2015	[81]	 33	(22	subjects)	 Mean	5.1	treatments	with	macular	laser,	intravitreal	bevacizumab,	triamcinolone,	or	dexamethasone	implant		
Persistent	DMO	for	6	months	despite	at	least	two	prior	treatments	
Retrospective	series	 Intravitreal	ranibizumab	0.3mg	 48	weeks	 Reduced	CMT	and	improved	BCVA	
Dhoot	2015	[80]	 43	(43	subjects)	 Intravitreal	bevacizumab,	at	least	2	prior	injections	7	weeks	apart	within	1	year	of	baseline	visit	
CMT>300μm	Intravitreal	steroid/laser	within	6	months	
Prospective	cohort	study	 Intravitreal	ranibizumab	0.5mg	for	3	injections	If	non-responsive	then	2.0mg	injections	from	month	3	onwards	
12	months	 Reduced	CMT	and	improved	BCVA,	half	of	those	swapped	to	higher	dose	ranibizumab	responsive	
Dutra	Meideros	2014	[162]	 58	(58	subjects)	 Intravitreal	anti-VEGF,	triamcinolone,	pars	plana	vitrectomy,	macular	laser	
CMT>250μm	No	treatment	in	prior	three	months	 Retrospective	case	series	 Dexamethasone	implant	 6	months	 Reduced	CMT	and	improved	BCVA,	
	 -70-	
Escobar	2015	[163]	 40	*	(76	eyes	from	76	patients	analysed,	40	of	which	were	treatment-resistant)	
Any	two	of:	intravitreal	injections	(not	specified),	vitrectomy,	laser	photocoagulation	
CMT>300	μm,	treatment	within	past	3	months	excluded,	known	steroid	responders	excluded	
Prospective	cohort	study	 Dexamethasone	implant	with	PRN	laser	photocoagulation		Retreatment	with	dexamethasone	implant	from	3	months	onwards	as	per	study	protocol	
6	months	 Reduced	CMT	and	improved	BCVA,	
Gutierrez-Benitez	2015	[164]	 14	(14	subjects)	 Intravitreal	ranibizumab	as	monotherapy	or	in	combination	with	other	treatment	
No	decrease	in	CMT	or	stabilisation	of	BCVA	following	ranibizumab	therapy	
Retrospective	case	series	 Dexamethasone	implant	 7.6	months	 Improved	CMT	and	BCVA	
Hanhart	2015	[82]	 8	(5	subjects)	 Intravitreal	bevacizumab,	at	least	2	prior	injections	 CMT>325	μm	Previous	steroid	therapy	 Retrospective	case	series	 Intravitreal	ranibizumab	 541	days	 Improved	CMT,	non-significant	BCVA	gain	Haritoglou	2006	[165]	 51	(51	subjects)	 Macular	laser,	intravitreal	triamcinolone,	or	vitrectomy	
No	treatment	in	preceding	6	months	 Prospective	cohort	study	 Intravitreal	bevacizumab,	single	dose	 12	weeks	 Improved	CMT	and	BCVA	Jeon	2014	[166]	 20	(20	subjects)	 At	least	3	monthly	injections	of	intravitreal	bevacizumab	 No	treatment	in	preceding	2	months		 Prospective	cohort	study	 Intravitreal	triamcinolone	 3	months	 Improved	CMT	and	BCVA,	CMT	gains	not	sustained	at	3	months	Kim	2012	[167]	 46	(41	subjects)	 Macular	laser,	intravitreal	triamcinolone	or	a	combination	of	the	two	
CMT	>250	μm,	visual	acuity	>20/40	 Retrospective	case	series	 Vitrectomy,	intravitreal	triamcinolone	and	laser	
3	years	 Improved	CMT	and	BCVA	
Kim	2015	[168]	 20	(20	subjects)	 Two	or	more	consecutive	bevacizumab	injections	 CMT>300	μm	or	<150	μm	reduction	in	CMT	 Retrospective	case	series	 Intravitreal	triamcinolone	 3	months	 Improved	CMT	and	BCVA,	BCVA	gains	not	sustained	at	3	months		
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Lazic	2014	[169]	 16	(15	subjects)	 At	least	3	monthly	injections	of	intravitreal	bevacizumab	with	or	without	previous	laser	
CMT>225	μm,	DMO	previously	treated	with	steroid	No	treatment	in	preceding	1	month		
Prospective	cohort	study	 Dexamethasone	implant	 4	months	 Improved	CMT	and	BCVA,	not	sustained	at	4	months	follow	up	
Lim	2015	[84]	 21	(19	subjects)	 At	least	3	prior	injections	of	intravitreal	bevacizumab	or	ranibizumab		
No	defined	anatomical	or	visual	criteria	 Retrospective	chart	review	 Intravitreal	aflibercept	 5	months	 Improved	CMT	and	BCVA	
Maturi	2015	[170]	 40	(30	subjects)	 Intravitreal	bevacizumab	with	or	without	macular	laser	 CMT	>250	μm	HbA1c>10	Known	steroid	response	not	responding	to	2	topical	meds	20/32	to	20/320	Anti	VEGF	in	past	4	weeks,	intravitreal	steroid	in	past	8	weeks,	laser	in	past	16	weeks		
Prospective,	single-masked,	randomised,	controlled	trial	
Intravitreal	bevacizumab	+/-	dexamethasone	implant	
12	months	 Improved	CMT,	no	change	in	BCVA	at	12	months	
Ornek	2008	[171]	 17	(16	subjects)	 Macular	laser	and	intravitreal	triamcinolone		
None	reported	 Prospective	cohort	study	 Intravitreal	bevacizumab	 6	weeks	 70%	improved	vision	at	6	weeks	
Rahimi	2015	[85]	 50	(37	subjects)	 At	least	4	prior	intravitreal	injections	with	bevacizumab	or	ranibizumab	
No	reduction,	incomplete	resolution,	or	an	increase	in	CMT	from	baseline			
Retrospecive	case	series	 Intravitreal	aflibercept	 4.6	months	 Significant	improvement	in	CMT,	BCVA	improvements	non-significant	
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Totan	2015	[172]	 30	(30	subjects)	 Three	prior	injections	with	intravitreal	bevacizumab	 CMT	>275	μm	previous	vitrectomy	panretinal	or	grid	laser	photo-	coagulation	(within	3	months	prior	to	investigation)		previous	steroid	treatment	
Prospective	cohort	study	 Dexamethasone	implant	 6	months	 Improved	CMT	and	BCVA	at	3	months,	BCVA	gains	lost	at	6	months	
Wood	2015	[86]	 14	 Regular	intravitreal	ranibizumab	and/or	bevacizumab	 Persistent	retinal	fluid	 Prospective	cohort	study	 Intravitreal	aflibercept	 1	month	 Improved	CMT,	no	change	in	BCVA	Yolcu	2014	[173]	 25	(25	subjects)	 Bevacizumab	(at	least	2	injections)	and	triamcinolone	 CMT>500	μm,	exclusion	criteria	laser	within	6	months,	vitreoretinal	surgery,	FAZ>	800	μm,	hypertension,	HbA1c>8%	Only	pseudophakic	eyes	
Prospective	cohort	study	 Combination	intravitreal	bevacizumab	and	triamcinolone	
12	months	 Improved	CMT	and	BCVA	
Yuksel	2013	[174]	 71	(59	subjects)	 Macular	laser	with	or	without	intravitreal/subtenon	triamcinolone	injection	
CMT>300	μm	Vitrectomy	exclusion	criteria	 Retrospective	case	series	 Intravitreal	bevacizumab	 9	months	 Improved	CMT	and	BCVA	Zhioua	2015	[175]	 13	(12	subjects)	 Monthly	injections	of	intravitreal	ranibizumab	for	6	months	 CMT>300	μm	BCVA	≤	20/40	HbA1c>8.5	Macular	photocoagulation	in	preceding	12	months	
Retrospective	case	series	 Dexamethasone	implant	 9	months	 Improved	CMT	and	BCVA	
	BCVA=	best-corrected	visual	acuity,	CMT=central	macular	thickness,	HbA1c=glycated	haemoglobin		
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IMAGING	IN	DIABETIC	MACULAR	OEDEMA	The	 diagnosis	 and	 management	 of	 DMO	 is	 facilitated	 by	 multiple	 imaging	techniques.	Fundus	FA	visualises	the	retinal	vasculature	and	identifies	lesions	of	DR,	areas	of	ischaemia	demonstrated	by	capillary	dropout	and	areas	of	impaired	BRB	 function	 demonstrated	 by	 leakage	 of	 dye.	 It	 can	 aid	 in	 predicting	 the	prognosis	and	response	to	treatment	in	DMO.	An	illustration	of	this	is	degree	of	capillary	non-perfusion	and	macular	 ischaemia	demonstrated	with	an	enlarged	foveal	avascular	zone.		With	 development	 of	 ultra-widefield	 imaging,	 FA	 can	 be	 performed	 with	visualisation	of	up	to	200	degrees	of	the	retina	(Figure	2.2).	Extensive	ischaemia	in	the	retinal	periphery	has	been	associated	with	recalcitrant	disease	and	ultra-widefield	 FA	 (UWFA)	may	 aid	 in	 the	 identification	 of	 DMO	 that	 is	 likely	 to	 be	treatment-resistant.	[176]	UWFA	outcomes	will	be	the	topic	of	Chapter	5	of	this	thesis.		Optical	 coherence	 tomography	 (OCT)	 utilises	 interference	 of	 light	 to	 produce	high-resolution	 ultrastructural	 images	 of	 the	 macular	 region.	 These	 images	produce	cross-sectional	visualisation	of	oedema,	similar	to	a	histological	section	(Figure	 2.1).	 OCT	 technology	 has	 developed	 significantly	 in	 recent	 years.	 The	resolution	 and	 acquisition	 speed	 of	 scanning	 has	 improved	 from	 early	 time	domain	 OCT	 to	 current	 spectral	 domain	 OCT	 (SD-OCT).	 SD-OCT	 allows	 for	improved	axial	resolution	and	imaging	deeper	structures	including	the	choroid,	which	can	be	affected	in	DMO.	[177]	Coupled	with	eye	tracking,	newer	machines	
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allow	 for	 reliable	 and	 reproducible	 quantifiable	 measurements	 of	 the	 central	macular	 thickness	 (CMT).	 OCT	 biomarkers,	 such	 as	 subretinal	 fluid	 (SRF),	disorganization	of	 the	 inner	retinal	 layers	(DRIL),	 inner	segment	ellipsoid	(ISe)	band	and	external	 limiting	membrane	 (ELM)	 integrity	have	all	been	correlated	with	visual	acuity	 (Figure	2.3).	 [178-181]	Serial	 imaging	with	OCT	 is	 critical	 in	the	 management	 of	 DMO.	 Indeed,	 the	 ETDRS	 criteria	 for	 clinically	 significant	macular	 oedema	 is	 becoming	 less	 relevant	 as	OCT	has	 established	 itself	 as	 the	new	reference	standard	for	the	diagnosis	and	monitoring	of	DMO.	[182]			Recognising	morphological	biomarkers,	such	as	those	on	OCT	or	FA,	may	become	an	 important	 factor	 in	predicting	which	patients	 are	 likely	 to	have	 recalcitrant	disease,	 guiding	 individual	 treatment	 regimens.	 [183]	 Future	 improvements	 in	imaging,	 such	 as	 OCT	 angiography,	 which	 non-invasively	 visualises	 retinal	capillary	layers	may	play	a	role	in	the	diagnosis,	monitoring	and	management	of	DMO.	[184]		
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Figure	2.2:	Ultra-widefield	FA	of	a	patient	with	severe	non-proliferative	diabetic	retinopathy	and	DMO.		There	is	significant	leakage	of	dye	into	the	macula	(arrowhead)	and	areas	of	capillary	non-perfusion	corresponding	to	ischaemic	retina	(arrows).	The	discrete	dots	seen	throught	the	image	correspond	to	microaneurysms.	
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Figure	2.3:	Optical	coherence	tomography	biomarkers	correlated	with	vision	outcomes	in	diabetic	macular	oedema.		Illustrated	here	with	arrows	are	 (A)	disorganization	of	 the	 inner	 retinal	 layers	(DRIL),	 (B)	 inner	 segment	 ellipsoid	 (ISe)	 band	 disruption	 and	 (C)	 external	limiting	 membrane	 (ELM)	 disruption.	 Figure	 2.1	 illustrates	 subretinal	 fluid	(SRF).	 	
A 
B 
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ENVIRONMENTAL	AND	GENETIC	FACTORS	Hypertension,	established	cardiovascular	disease,	advanced	DR	and	proliferative	DR	 (PDR)	 has	 been	 associated	with	 diffuse	DMO	 in	 retrospective	 series.	 [185]	Despite	this	correlation,	blood	glucose,	blood	pressure	and	lipid	control	found	no	benefit	 in	 modifying	 disease	 prognosis	 in	 DMO	 in	 the	 prospectively	 designed	Action	 to	 Control	 Cardiovascular	 Risk	 in	 Diabetes	 (ACCORD)	 study	 of	 patients	with	type	2	diabetes.	[186]			Recent	 meta-analysis	 of	 randomised	 clinical	 trials	 of	 lipid	 control	 showed	 no	strong	 relationship	 between	 dyslipidaemia	 and	 DMO.	 [187]	 However,	 statins	may	 have	 an	 independent	 effect	 on	 stabilising	 the	 BRB	 through	 reduction	 of	retinal	 vascular	 inflammation	 rather	 than	 by	 their	 lipid	 lowering	 effect	 alone.	[188]			Fenofibrate,	which	is	thought	to	exert	its	therapeutic	effect	on	DR	through	non-lipid	 biochemical	 pathways,	 has	 shown	 some	 promise	 in	 the	 management	 of	DMO.	 The	 Fenofibrate	 Intervention	 and	 Event	 Lowering	 in	 Diabetes	 (FIELD)	study	demonstrated	participants	who	received	fenofibrate	as	opposed	to	placebo	were	less	likely	to	require	laser	therapy	for	both	proliferative	DR	as	well	as	DMO.	[189]	In	the	ACCORD	Eye	Study,	participants	who	used	fenofibrate	had	reduction	in	 the	 progression	 of	 DR	 compared	 with	 placebo,	 although	 this	 study	demonstrated	 no	 benefit	 in	 the	 improvement	 of	 DMO.	 [190]	 The	 addition	 of	fenofibrate	and	statins	 to	 the	management	of	patients	with	 treatment-resistant	DMO	may	be	a	consideration	for	treating	physicians.		
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Many	 clinical	 trials	 evaluating	 the	 treatment	 of	 DMO	 exclude	 patients	 with	uncontrolled	 diabetes	 based	 on	 their	 glycated	 haemoglobin	 (HbA1c).	 This	selection	bias	makes	management	of	these	patients	especially	challenging	given	the	 scant	 evidence	 to	 support	 the	use	of	 therapies.	Additionally,	 these	patients	may	represent	a	significant	proportion	of	those	with	recalcitrant	disease.	While	the	 role	 of	 systemic	 medical	 therapy	 for	 DMO	 is	 unclear,	 preventing	 the	progression	of	retinopathy	should	be	a	clear	goal	in	the	management	strategy	of	all	 diabetic	 patients,	 especially	 given	 the	 association	 between	 HbA1c	 and	worsening	retinal	ischaemia.	[191]			There	 are	 disparities	 in	 risk	 of	 developing	 DR	 amongst	 patients	 of	 different	ethnic	 groups,	 even	 when	 environmental	 factors	 are	 corrected	 for.	 These	differences	 may	 be	 explained	 by	 a	 genetic	 predisposition	 to	 disease.	Polymorphisms	 in	 the	 VEGF	 gene	 have	 been	 shown	 to	 be	 associated	 with	severity	of	DR	and	have	been	associated	with	an	increased	risk	of	development	of	 DMO.	 [192,	 193]	 Additionally,	 polymorphisms	 in	 the	 AKR1B1	 gene	 that	encodes	 for	 aldose	 reductase	 have	 been	 associated	 with	 DR	 development,	irrespective	 of	 ethnic	 background.	 [194]	 Further	 studies	 examining	 genetic	factors	 associated	 with	 DMO	 may	 lead	 to	 improved	 diagnosis	 and	 tailored	treatments	 for	 this	 condition.	 These	 factors	 may	 also	 be	 determinants	 for	response	to	treatment	and	contribute	to	treatment	resistance.	 	
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LASER	THERAPY	The	 ETDRS	 demonstrated	 that	 focal/grid	 argon	 laser	 photocoagulation	 of	macular	lesions	led	to	a	significant	reduction	in	vision	loss	in	eyes	with	“clinically	significant	macular	oedema”.	[35]	This	was	defined	as	retinal	thickening	within	500	 µm	 of	 the	 macular	 center,	 hard	 exudates	 within	 500	 µm	 of	 the	 macular	centre	 with	 adjacent	 retinal	 thickening	 and/or	 one	 or	more	 disc	 diameters	 of	retinal	 thickening,	 part	 of	 which	 is	 within	 one	 disc	 diameter	 of	 the	 macular	centre.	 Figure	 2.4	 is	 a	 fundus	photography	 illustrating	 an	 example	 of	 clinically	significant	DMO	prior	to	and	following	ETDRS	guided	laser	photocoagulation.			Whilst	the	rate	of	vision	loss	was	halved	in	this	study,	visual	improvements	were	modest	or	non-existent.	Vision	improvements	are	seen	in	approximately	15%	of	patients	after	3	years	of	follow	up.	[195]	By	vision	criteria,	treatment-resistance	with	macular	laser	therapy	reaches	rates	of	85%.		Macular	 laser	 photocoagulation	 improves	DMO	 through	 a	 number	 of	 proposed	mechanisms.	 Firstly,	 photoreceptors	 and	 RPE	 cells	 are	 destroyed	 via	 a	photothermal	 mechanism,	 thus	 reducing	 oxygen	 consumption.	 This	 reduced	oxygen	 consumption	 in	 the	 outer	 retina	 is	 postulated	 to	 increase	 oxygen	 flux	from	the	choroid	to	the	 inner	retina,	 thus	 leading	to	arteriolar	constriction	and	decreased	 Starling	 forces	 driving	 oedema.	 [196]	 Secondly,	 photocoagulation	induces	 changes	 to	 the	 RPE	 cells	 causing	 their	 proliferation	 and	 release	 of	cytokines	such	as	TGF-beta,	which	antagonise	the	effects	of	VEGF.	[197]	Finally,	there	 can	 be	 direct	 ablation	 of	 microaneurysms	 contributing	 to	 oedema	identified	as	leaking	on	FA.	
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	Macular	laser	photocoagulation	has	the	risk	of	causing	several	sight-threatening	complications	 including	 scotoma,	 choroidal	 neovascularisation	 and	 subretinal	fibrosis.	[198]	Given	these	risks	and	the	availability	of	anti-VEGF	drugs,	macular	focal/grid	 laser	 is	now	generally	 reserved	 for	non-centre	 involving	DMO.	From	the	 three	 year	 results	 of	 the	DRCR.net	 Protocol	 I	 study,	 use	 of	 focal/grid	 laser	may	even	lead	to	poorer	long-term	visual	outcomes	in	patients	with	DMO	when	initiated	at	the	same	time	as	anti-VEGF	therapy.	[69]		Recent	 advances	 in	 technology	have	 led	 to	 the	development	 of	 lasers	 different	wavelengths,	lower	energies,	duration	of	pulses	and	pattern	deliveries	aiming	to	target	pathology	directly.	This	aims	to	reduce	collateral	damage	to	the	retina	and	surrounding	structures.		Diode	 lasers	 with	 a	 shorter	 pulse	 length	 are	 one	 such	 example,	 which	 are	effective	 in	 the	 management	 of	 DMO.	 A	 twelve-month	 randomised	 controlled	trial	 compared	 conventional	 argon	 laser	 with	 micropulse	 diode	photocoagulation	 for	 the	 management	 of	 clinically	 significant	 DMO	 and	 found	anatomical	and	functional	outcomes	to	be	similar.	[199]	The	photothermal	effect	of	these	micropulse	lasers	is	designed	to	be	confined	to	the	RPE	and	may	spare	complications	associated	with	photoreceptor,	ganglion	cell	 loss	and	nerve	 fibre	layer	damage.	These	therapies	may	also	be	more	comfortable	for	the	patient	as	choroidal	 heating	 is	 less	 likely	 to	 occur.	 Whether	 micropulse	 laser	 can	 be	effective	as	an	adjunct	to	other	therapies	for	DMO	is	yet	to	be	investigated.		
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Future	 directions	 for	 laser	 photocoagulation	 include	 treatment	 of	 peripheral	ischaemia	 identified	 on	 ultra-widefield	 FA.	 These	 ischaemic	 areas	 have	 been	have	been	hypothesised	to	drive	DMO	in	treatment-resistant	cases	and	laser	may	have	a	future	role	in	management	of	resistant	patients.	[176,	191]		 	
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Figure	2.4:	Fundus	photograph	demonstrating	clinically	significant	macular	oedema	(a)	before	and	(b)	after	ETDRS-guided	laser	photocoagulation.		Note	the	presence	of	hard	exudates	associated	with	retinal	thickening	within	500	μm	of	the	macular	centre,	as	well	as	other	changes	of	diabetic	retinopathy	including	retinal	haemorrhages	and	microaneurysms	
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SURGICAL	MANAGEMENT	The	vitreous	body	is	variably	attached	to	the	inner	limiting	membrane	(ILM)	of	the	 neurosensory	 retina	 at	 macula.	 Over	 time	 this	 vitreoretinal	 adhesion	 can	weaken	 and	 the	 vitreous	 pulls	 away	 from	 the	 macula.	 If	 this	 separation	 is	complete,	then	it	is	termed	a	posterior	vitreous	detachment	(PVD).	If	incomplete,	remaining	 adhesions	 in	 a	 partial	 PVD	 can	 cause	 traction	 at	 the	 macula	 in	 a	condition	termed	vitreomacular	traction	(VMT).		Vitreoretinal	 interface	 abnormalities	 such	 as	 these	 may	 be	 part	 of	 the	pathophysiology	 of	DMO	 and	 related	 to	AGE	mediated	 pathways	 as	 previously	described.	DMO	associated	with	a	thickened	and	taut	posterior	vitreous	face	and	VMT	 has	 been	 shown	 to	 be	 responsive	 to	 vitrectomy.	 [200]	 In	 this	 surgical	procedure,	 the	 vitreous	 body	 is	 surgically	 removed.	 Vitreomacular	 adhesion	without	traction	has	also	been	associated	with	DMO.	[201]	Vitrectomy	causing	a	PVD	has	been	shown	to	improve	visual	and	anatomical	outcomes	in	cases	of	non-tractional	DMO,	and	enzymatic	PVD	may	play	a	future	role	in	the	management	of	treatment-resistant	 DMO.	 [202]	 The	 ILM	 may	 act	 as	 a	 diffusion	 barrier	 to	mediators	such	as	VEGF,	and	peeling	this	as	part	of	vitrectomy	may	also	improve	anatomical	outcomes	in	treatment-resistant	DMO.	[203]		Furthermore,	 vitrectomy	 is	 postulated	 to	 improve	 DMO	 through	 increasing	oxygen	 delivery	 to	 ischaemic	 areas	 via	 two	 mechanisms.	 [196]	 Firstly,	 the	vitreous	 is	 replaced	 by	 less	 viscous	 aqueous	 humour,	 which	 increases	 the	diffusion	 capacity	 of	 oxygen	 as	 well	 as	 other	 molecules	 as	 per	 Fick’s	 law.	Secondly,	 fluid	 currents	within	 the	 vitreous	 cavity	 are	more	 efficiently	 able	 to	
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transport	oxygen	 from	well-perfused	areas	 to	 ischaemic	retina.	This	concept	of	vitreoperfusion	 and	 microplasmin	 induced	 PVD	 increasing	 intravitreal	 oxygen	levels	have	been	demonstrated	in	animal	models,	supporting	this	theory.	[204]		Vitrectomy	may	 be	 considered	 in	 cases	 refractory	 to	 treatment	 with	 repeated	pharmacotherapy	 and	 especially	 in	 cases	 where	 there	 is	 vitreomacular	attachment	or	VMT.	As	monotherapy,	vitrectomy	is	insufficient	to	manage	DMO	as	 it	 fails	 to	 address	 the	 continual	 production	 of	 growth	 factors	 and	 cytokines	implicated	 in	 the	 pathogensis.	 A	 systematic	 review	 and	 meta-analysis	 of	vitrectomy	in	eyes	without	epiretinal	membranes	or	traction	showed	anatomical	improvement	in	DMO	at	six	months	follow	up.	However,	at	12	months	this	effect	was	 lost	 and	 there	was	a	 suggestion	 that	 they	 could	 lead	 to	 inferior	 functional	outcomes	as	compared	with	laser.	[205]		Conversely,	 removing	 the	 vitreous	 may	 have	 implications	 complicating	 the	management	 of	 DMO.	 The	 half	 life	 and	 intravitreal	 concentrations	 of	 injected	intravitreal	 drugs	 is	 significantly	 reduced	 in	 vitrectomised	 eyes	 suggesting	reduced	efficacy	of	these	treatments.	[206]	One	study	has	demonstrated	poorer	visual	acuity	and	CMT	with	anti-VEGF	therapy	in	vitrectomised	eyes.	[207]		 	
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ANTI-INFLAMMATORY	THERAPY	Inflammation	 plays	 a	 key	 role	 in	 the	 pathogenesis	 of	 DMO	 with	 increased	expression	 of	 inflammatory	 mediators,	 leukocyte	 adhesion,	 complement	activation,	 macrophage	 infiltration	 and	 acute	 phase	 proteins.	 [154,	 208]	Accumulation	 of	 leucocytes	 coincides	 with	 vascular	 dysfunction	 leading	 to	breakdown	 of	 the	 BRB,	 premature	 cell	 injury	 and	 death	 and	 ischaemia.	 [209]	Experimental	 data	 also	 shows	 that	 by	 blocking	 leucocyte	 adhesion,	 BRB	breakdown	and	endothelial	cell	injury	are	prevented.	[210]		
	
Corticosteroids	Treatment	of	DMO	with	corticosteroids	has	been	shown	to	reduce	 the	vitreous	levels	 of	 inflammatory	 cytokines	 and	 VEGF.	 [211]	 Glucocorticoids	 function	 by	reducing	inflammation	and	maintaining	the	BRB	through	increased	expression	of	tight	junction	proteins.	[212]		Three	 types	 of	 corticosteroids	 have	 been	 evaluated	 for	 DMO	 in	 clinical	 trials:	triamcinolone	 (Kenalog-40	 (Bristol-Myers	 Squibb,	 Princeton,	 NJ),	 Triescence	(Alcon,	 Ft.	Worth,	 TX),	 Trivaris	 (Allergan,	 Irvine,	 CA)),	 dexamethasone	 implant	(Ozurdex,	 Allergan,	 Irvine,	 CA)	 and	 fluocinolone	 implant	 (Retisert,	 Bausch	 +	Lomb,	Rochester,	NY	and	Iluvien,	Alimera	Science,	Alpharetta,	GA).			Macular	 laser	has	been	compared	with	 intravitreal	 triamcinolone	 for	DMO	 in	a	prospective,	 randomised	 controlled	 trial	 of	 84	 eyes.	 [213]	 The	 triamcinolone	group	 demonstrated	 a	 significant	 gain	 in	 vision	 at	 2	 years	 at	 the	 expense	 of	
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increased	 cataract	 formation	 and	 elevated	 intraocular	 pressure	 (IOP),	 both	common	 adverse	 events	 in	 trials	 evaluating	 intravitreal	 steroids.	 [214]	 Similar	results	have	been	found	in	other	studies	comparing	triamcinolone	to	laser.	[215,	216]			In	a	randomised	controlled	trial	of	171	eyes,	0.35mg	and	0.7mg	dexamethasone	implants	were	evaluated	for	DMO.	[217]	Whilst	there	were	significant	reductions	in	 CMT,	 the	 best-corrected	 visual	 acuity	 (BCVA)	 was	 unaffected.	 The	 Macular	Edema:	 Assessment	 of	 Implantable	 Dexamethasone	 in	 Diabetes	 (MEAD)	 study	subsequently	demonstrated	anatomical	and	BCVA	 improvement	 in	0.35mg	and	0.7mg	 dexamethasone	 implants	 compared	 with	 a	 sham	 procedure	 in	 a	 larger	study	of	1048	eyes.	[218]			Fluocinolone	implants,	which	contain	0.59	mg	of	fluocinolone	acetonide,	release	approximately	0.5	μg	of	drug	per	day	for	approximately	3	years.	The	surgically	inserted	 Retisert	 implant	 was	 compared	 with	 sham	 injections	 combined	 with	standard	of	care	laser	in	a	prospective	randomised	trial	of	196	eyes.	While	this	study	 showed	 improved	 visual	 outcomes	 for	 the	 fluocinolone	 arm,	 there	were	notable	complications	with	surgical	intervention	required	for	cataract	in	91%	of	phakic	 participants	 and	 ocular	 hypertension	 in	 33.8%	 participants.	 [219]	 The	Fluocinolone	Acetonide	for	Macular	Edema	(FAME)	study	was	a	randomised	trial	of	953	eyes,	which	compared	0.2-	or	0.5-μg/day	Iluvien	implants	delivered	via	an	intravitreal	 injection	to	sham	injections.	 [220]	After	24	months,	eyes	gained	an	average	 of	 4.4	 and	 5.4	 letters	 in	 the	 low	 and	 high	 dose	 fluocinolone	 groups	respectively	 compared	 with	 1.7	 letters	 in	 the	 sham	 group.	 Additionally,	 this	
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preparation	had	lower	rates	of	intervention	for	ocular	hypertension	and	cataract	than	the	trial	of	Retisert.	Currently,	Iluvien	is	the	only	preparation	approved	for	use	in	DMO.		Corticosteroids	have	been	compared	to	anti-VEGF	drugs	for	the	management	of	DMO	 as	 summarised	 in	 Chapter	 1	 in	 the	 DRCR.net	 Protocol	 I	 and	 BEVORDEX	studies.	[47,	48]		Given	side	effects	of	steroids,	they	are	generally	reserved	as	second	line	therapy	after	anti-VEGF	drugs.	Indeed,	this	is	why	switching	therapy	from	steroid	to	anti-VEGF	 is	 scantly	 reported.	 [165,	 171,	 174]	 However,	 with	 the	 need	 for	 regular	injections	reduced,	 there	can	be	an	argument	made	 for	 the	use	of	 these	agents	earlier	 in	 a	 treatment	 algorithm,	 especially	 in	 pseudophakic	 eyes.	 Caution	 and	close	monitoring	are	required	to	assess	for	elevated	and	uncontrolled	IOP,	which	can	lead	to	rapid	visual	loss.		
Non-steroidal	anti-inflammatory	drugs	Despite	 the	 efficacy	 of	 steroid	 therapy	 for	 DMO,	 the	 response	 to	 topical	 non-steroidal	 anti-inflammatory	 drugs	 (NSAIDs)	 has	 not	 been	 demonstrated	 in	clinical	 trials.	 [221]	 The	 DRCR.net	 Protocol	 R	 compared	 0.1%	 nepafenac	 with	placebo	 and	 demonstrated	 no	 anatomical	 or	 visual	 benefit	 after	 12	months	 of	therapy	for	non-centre	involving	DMO.	[222]		
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An	animal	model	has	demonstrated	the	benefit	of	high	dose	systemic	aspirin	in	the	 suppression	 of	 BRB	 breakdown	 but	 the	 translational	 dose	 in	 humans	 of	50mg/kg	would	result	in	severe	side	effects.	[223]			
Switching	from	anti-VEGF	to	Steroid	Higher	 intravitreal	 levels	 of	 inflammatory	 cytokines	 are	 associated	 with	more	severe	DMO,	suggesting	that	inflammation	may	play	a	greater	role	in	treatment-resistant	 disease.	 [224]	 Chronic	DMO	may	 also	 be	more	 likely	 to	 be	 driven	 by	inflammatory	cytokines.	In	the	long-term	follow	up	of	the	FAME	study,	eyes	with	DMO	 for	 longer	 than	 3	 years	 had	 superior	 visual	 outcomes	 to	 those	 with	 a	shorter	history.	 [220]	Switching	 therapy	 from	anti-VEGF	agents,	which	may	be	more	efficacious	earlier	in	the	natural	history	of	DMO,	to	steroid	therapy,	follows	this	rationale.		Several	 studies	 have	 assessed	 the	 utility	 of	 a	 dexamethasone	 implant	 for	DMO	resistant	 to	 anti-VEGF	 therapy,	 as	 summarised	 in	 Table	 2.1.	 These	 are	mostly	retrospective	 case	 series	 or	 prospective	 cohort	 studies,	 most	 of	 which	demonstrated	both	anatomical	and	visual	improvement	at	the	end	of	follow	up.	[160-164,	 169,	 170,	 172,	 175]	 The	 only	 randomised	 controlled	 trial	 assessing	dexamethasone	 for	 anti-VEGF	 resistant	 DMO	 found	 an	 anatomical	 benefit	 in	combination	 with	 bevacizumab	 but	 demonstrated	 no	 change	 in	 BCVA	 at	 12	months.	 [170]	 Switching	 therapy	 to	 intravitreal	 triamcinolone	 is	 also	 effective	but	 the	 duration	 of	 action	 of	 this	 is	 limited	 compared	 to	 dexamethasone	implants.	[166,	168]	 	
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Anti-VEGF	THERAPY	The	identification	of	VEGF-A	as	a	key	growth	factor	in	the	pathogenesis	of	DMO	has	revolutionised	the	management	and	treatment	outcomes	of	this	condition	as	described	in	Chapter	1.		
Switching	between	anti-VEGF	agents	Though	 all	 anti-VEGF	 drugs	 block	 the	 action	 of	 VEGF,	 differences	 in	 size,	structure,	mechanism	of	action	and	half-lives	result	in	different	clinical	effects	as	demonstrated	in	Protocol	T.			Previous	 studies	 of	 treatment-resistant	 neovascular	 age-related	 macular	degeneration	 (nAMD)	 have	 shown	 benefit	 in	 switching	 therapy	 from	one	 anti-VEGF	 drug	 to	 another,	 prompting	 others	 to	 investigate	 this	 approach	 in	 DMO.	[225]	These	studies,	summarised	in	Table	2.1,	are	heterogeneous	in	their	design,	inclusion	 and	 exclusion	 criteria	 and	 follow	 up,	 making	 comparison	 difficult.	However,	 there	 seems	 to	 be	 a	 universal	 anatomical	 improvement	 in	 switching	from	 bevacizumab	 to	 ranibizumab	 [80-82]	 and	 there	 may	 be	 a	 benefit	 in	switching	 from	 either	 of	 these	 drugs	 to	 aflibercept.	 [84-86]	 The	 benefits	 of	switching	most	likely	have	to	do	with	improved	binding	affinity	with	VEGF	and	blockade	of	PlGF	with	aflibercept	and	will	be	explored	further	in	Chapter	3.	[226]		
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Dose	response	Compared	 to	 nAMD,	 the	 intravitreal	 concentration	 of	 VEGF	 in	 DMO	 may	 be	higher,	 suggesting	 there	 may	 be	 a	 role	 for	 increased	 blockade	 of	 the	 VEGF	pathway	for	treatment-resistant	disease.	[227]		In	 addition	 to	 the	 aforementioned	REEF	 study	 in	Chapter	1,	 the	READ-3	 study	randomised	 participants	 with	 DMO	 to	 receive	 either	 0.5mg	 or	 2.0mg	 of	ranibizumab.	The	six-month	results	demonstrated	no	benefit	to	the	higher	dose	of	therapy.	[228]	It	is	likely	that	the	effects	of	higher	doses	of	ranibizumab	may	be	 equivocal.	 Similarly,	 a	 head	 to	 head	 study	 of	 1.25mg	 and	 2.5mg	 doses	 of	bevacizumab	showed	no	differences	in	BCVA	or	CMT	after	six	months	of	therapy.	[76]		 	
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COMBINATION	THERAPY	The	combination	of	anti-VEGF	agents	and	coritcosteroids	may	be	more	effective	in	certain	patients	with	DMO	who	are	difficult	to	control	with	anti-VEGF	agents	alone.	 In	 a	 three	 arm	 randomised	 trial,	 bevacizumab	 was	 compared	 with	combination	 bevacizumab/triamcinolone	 and	 macular	 laser	 photocoagulation.	After	16	weeks	of	follow-up,	combination	therapy	for	these	patients	provided	a	longer	period	of	BCVA	and	CMT	improvement.	[229]			Several	 studies	 have	 explored	 the	 efficacy	 of	 combined	 laser	 and	 anti-VEGF	therapy,	with	rescue	laser	forming	part	of	the	DRCR.net	Protocol	T	study	design.	[77]	 Over	 the	 2-year	 follow	 up	 of	 this	 study,	 41%	 of	 aflibercept,	 64%	 of	bevacizumab	and	52%	of	ranibizumab	eyes	received	macula	grid/focal	 laser	 in	addition	to	intravitreal	injection.	[78]	Though	some	smaller	prospective	studies	have	 shown	 reduced	 need	 for	 intravitreal	 injections	 with	 combined	 laser	therapy,	 larger	trials	such	as	RESTORE	showed	no	benefit	 to	combination	 laser	and	 ranibizumab.	 [121,	 230]	 A	 three-arm	 trial	 compared	 intravitreal	bevacizumab,	macular	laser	photocoagulation	and	a	combination	of	the	two.	This	demonstrated	significant	improvements	in	visual	acuity	and	reduction	in	CMT	in	both	bevacizumab	treatment	arms	at	one	month	though	this	was	not	maintained	in	 the	bevacizumab	monotherapy	arm	at	 three	and	six	months.	This	study	was	limited	by	only	a	single	treatment	being	given	and	a	six-month	follow	up.	[230]			 	
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SUMMARY	Incomplete	response	to	treatment	for	DMO	has	been	described	since	the	ETDRS	report	number	1	 in	1985.	Focal/grid	macular	 laser	as	defined	 in	this	study	has	limitations	 for	 treating	DMO	 and	may	 result	 in	 poorer	 visual	 outcomes	 due	 to	photoreceptor	 damage	 and	 other	 complications.	 OCT,	 ultra-widefield	 FA,	 new	laser	technology,	vitrectomy	and	a	range	of	pharmacotherapies	are	available	as	diagnostic	 and	 treatment	 tools	 for	 treating	 clinicians.	 Although	 corticosteroid	and	anti-VEGF	drugs	have	been	shown	to	be	more	effective	than	argon	laser	 in	clinical	 trials,	 suboptimal	 response	 continues	 to	 be	 observed	 in	 a	 subgroup	 of	these	patients.	Resistance	 to	pharmacotherapy	may	 represent	 abnormalities	 in	the	vitreoretinal	interface.	Anti-VEGF	resistance	may	represent	a	progression	in	the	natural	history	of	DMO	with	 inflammation	or	 alternative	 growth	 factors	or	cytokines	 increasingly	 contributing	 to	 the	 pathophysiology	 with	 time.	 The	dynamic	 nature	 of	 DMO	 means	 that	 treatment	 modalities	 may	 need	 to	 be	individualised	throughout	the	course	of	treatment.	Efficacy	for	therapies	must	be	balanced	 with	 their	 risks.	 Trials	 evaluating	 treatment-resistant	 DMO	 are	heterogeneous	 in	 design,	 follow-up,	 eligibility	 criteria	 and	 intervention.	Therefore,	formulating	recommendations	becomes	challenging	given	the	scarcity	of	strong	scientific	data.	Nevertheless,	from	the	current	studies	reviewed	in	this	paper,	patients	who	are	refractory	to	one	treatment	may	benefit	from	switching	to	a	different	agent	or	a	combination	therapy.			 	
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Chapter	3:	Aflibercept	for	the	management	of	persistent	diabetic	macular	oedema			As	highlighted	in	the	systematic	review	of	the	literature	in	the	previous	chapter,	there	is	a	relative	paucity	of	prospective	data	regarding	the	management	of	persistent	diabetic	macular	oedema.			This	chapter	presents	the	primary	visual	and	anatomical	outcomes	from	a	clinical	trial	undertaken	to	assess	the	effect	in	a	switch	in	therapy	from	bevacizumab	to	aflibercept	for	the	management	of	persistent	diabetic	macular	oedema.		The	material	presented	in	this	chapter	has	been	published	or	is	under	peer-review	and	is	reproduced	from:		
• Bahrami	B,	Hong	T,	Zhu	M,	Schlub	TE,	Chang	A.	Switching	therapy	from	bevacizumab	to	aflibercept	for	the	management	of	persistent	diabetic	macular	edema.	Graefes	Arch	Clin	Exp	Ophthalmol.	2017	Jun;255(6):1133-1140.		
• Bahrami	B,	Hong	T,	Schlub	TE,	Chang	A.	Aflibercept	for	persistent	diabetic	macular	edema:	48	week	outcomes.	Retina.	Under	review	Feb	21	2018.		
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	Furthermore,	the	data	presented	in	this	chapter	has	been	published	and	presented	at	the	following	conferences	and	meetings:		RANZCO	47th	Annual	Scientific	Conference:	Wellington,	New	Zealand,	2015	
Bahrami	B,	Ewe	S,	Hong	T,	et	al.	The	Efficacy	of	Aflibercept	in	the	Management	of	Treatment-Resistant	Diabetic	Macular	Oedema.	Clin	Exp	Ophthalmol.	2015	Oct;	43:16-33.		RANZCO	48th	Annual	Scientific	Conference:	Melbourne,	Australia	2016	
Bahrami	B,	Nair	R,	Hong	T,	Chang	A.	Effect	of	aflibercept	on	diabetic	retinopathy	severity	in	patients	with	treatment-resistant	diabetic	macular	oedema:	12	month	outcomes.	Clin	Exp	Ophthalmol.	2016	Nov;	44:80-140.		Association	for	Research	in	Vision	and	Ophthalmology	Annual	Meeting:	Seattle,	USA	2016	
Bahrami	B,	Hong	T,	Zhu	M,	Chang	A.	The	efficacy	of	aflibercept	in	the	management	of	treatment-resistant	diabetic	macular	edema:	a	12-month	prospective	study.	Invest.	Ophthalmol.	Vis.	Sci.	2016;	57(12):2070.		Association	for	Research	in	Vision	and	Ophthalmology	Annual	Meeting:	Baltimore,	USA	2017	
Bahrami	B,	Hong	T,	Zhu	M,	Chang	A.	Aflibercept	for	treatment-resistant	DME:	48-week	outcomes.	Invest.	Ophthalmol.	Vis.	Sci.	2017;	58(8):65.		 	
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ABSTRACT		
Purpose:	To	evaluate	functional	and	anatomical	outcomes	following	a	switch	from	intravitreal	bevacizumab	to	aflibercept	in	patients	with	persistent	diabetic	macular	oedema	(DMO).		
Methods:	Prospective,	single-arm,	open-label	clinical	trial	of	patients	with	persistent	DMO	despite	prior	treatment	with	bevacizumab.	Five	loading	doses	of	intravitreal	aflibercept	were	administered	every	4	weeks	with	subsequent	injections	administered	every	8	weeks.	Patients	were	reviewed	every	4	weeks	and	best-corrected	visual	acuity	(BCVA)	and	central	macular	thickness	(CMT)	were	recorded.	Primary	outcome	measures	included	change	in	CMT	and	BCVA	at	week	48	compared	with	baseline.	Paired	t-tests	were	used	to	assess	change	between	baseline	and	follow-up	visits.		
Results:	At	baseline,	43	eyes	from	43	patients	were	recruited	with	a	median	(interquartile	range)	of	12	(7-24)	previous	intravitreal	anti-VEGF	injections	over	a	period	of	18	(8-34)	months.	Mean	±	standard	deviation	CMT	reduced	by	59	±	114μm	(p=0.002)	and	BCVA	improved	by	3.9	±	7.0	letters	(p=0.001)	after	48	weeks	in	the	41	patients	who	completed	the	trial.	BCVA	improvements	were	more	marked	in	patients	who	gained	≥	5	letters	following	the	first	injection	(8.9	±	5.7	vs.	1.8	±	6.5	letter	gain	at	48	weeks,	p=0.002),	a	difference	which	remained	significant	following	regression	analysis	with	baseline	BCVA.	Vision	gains	and	CMT	reduction	were	similar	in	9	fellow	eyes	eligible	for	inclusion	being	concurrently	treated	for	DMO	with	bevacizumab.	
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Conclusion:	Intravitreal	aflibercept	was	effective	in	improving	anatomical	and	visual	outcomes	among	patients	with	an	incomplete	response	to	intravitreal	bevacizumab	with	48-weeks	of	follow-up.	Patients	with	a	good	early	response	subsequent	to	switching	had	a	better	improvement	in	vision	at	48-weeks.		 	
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BACKGROUND	Intravitreal	anti-vascular	endothelial	growth	factor	(VEGF)	drugs	have	revolutionised	the	management	of	diabetic	macular	oedema	(DMO).	Long-term	clinical	trial	data	has	shown	visual	gain	and	anatomical	improvements	are	maintained	with	use	of	these	drugs.	[63-65,	71,	78]	Furthermore,	the	use	of	anti-VEGF	drugs	for	DMO	demonstrates	a	disease	modifying	effect	and	regression	of	diabetic	retinopathy	severity.	[64,	71,	79]			Despite	their	marked	benefit,	a	proportion	of	patients	have	persistent	edema	even	with	repeated	anti-VEGF	therapy.	In	the	Protocol	T	study,	41%	of	patients	in	the	bevacizumab	arm	met	criteria	for	rescue	laser	after	24	weeks	of	treatment.	[77]	In	a	post-hoc	analysis	of	the	Protocol	I	study,	39.7%	of	eyes	had	a	visual	gain	of	less	than	5	letters	after	12	weeks	of	treatment.	At	the	end	of	156	weeks,	this	rate	of	suboptimal	response	was	similar	at	34.2%.	[231]		Clinical	trial	data	supporting	the	long-term	use	of	anti-VEGF	drugs	rely	mostly	on	treatment	naïve	patients	or	those	who	have	had	lengthy	washout	periods	where	treatment	is	ceased	for	a	period	of	months	prior	to	enrolment.	[63-65,	71,	78,	232]	Thus,	those	patients	who	have	an	incomplete	response	to	therapy	pose	a	management	challenge.	There	is	an	increasing	body	of	research	evaluating	strategies	in	managing	patients	with	persistent	DMO.	These	include	higher	doses	of	drug,	switching	between	anti-VEGF	agents	as	well	as	intravitreal	steroids.		
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In	this	48-week	prospective	cohort	study,	we	evaluate	the	visual	and	anatomical	outcomes	in	switching	therapy	from	bevacizumab	to	aflibercept	in	patients	with	persistent	DMO.	
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METHODS	
Study	Design	This	study	was	a	prospective,	open	label,	single-armed,	clinical	trial	of	patients	referred	to	a	tertiary	referral	retinal	clinic	in	Sydney,	Australia.	The	trial	was	listed	on	the	Australian	and	New	Zealand	Clinical	Trials	Registry	(ACTRN12614001307695).	Informed	consent	was	obtained	from	all	individual	participants	and	the	study	was	performed	in	accordance	with	the	1964	Declaration	of	Helsinki.		
Study	Participants	One	eye	from	each	patient	was	included	in	the	study.	Eligible	participants	were	aged	18	or	older,	with	DMO	secondary	to	type	1	or	type	2	diabetes	mellitus,	best	corrected	visual	acuity	(BCVA)	between	34	and	85	ETDRS	letters,	retinal	thickness	greater	than	300µm	in	the	central	1mm	ETDRS	field	on	spectral	domain	OCT	(SD-OCT)	and	at	least	4	previous	intravitreal	injections	of	bevacizumab	(2.5mg/0.1mL)	in	the	6	months	prior	to	baseline	examination.	Exclusion	criteria	included	prior	intravitreal	steroid	therapy	or	vitrectomy	surgery	in	the	study	eye	within	3	months	of	baseline,	cataract	surgery	or	macular	laser	within	2	months	of	baseline,	pregnancy,	active	proliferative	diabetic	retinopathy	and	uncontrolled	diabetes	mellitus	(HbA1c≥12%).	When	both	eyes	were	eligible	for	inclusion,	the	study	eye	was	selected	at	the	discretion	of	the	primary	investigator.		
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Study	Protocol		All	participants	received	5	loading	doses	of	intravitreal	aflibercept	(2.0mg/0.1mL)	administered	at	4-week	intervals	(week	0,	week	4,	week	8,	week	12	and	week	16).	Further	intravitreal	aflibercept	injections	were	then	given	at	8-week	intervals	(week	24,	week	32	and	week	40),	as	per	product	label	indication,	with	a	total	follow-up	of	48	weeks.	Participants	were	reviewed	at	baseline,	1	week	after	the	initial	injection,	and	then	every	4	weeks.	At	each	visit	ophthalmic	examination	was	undertaken	including	BCVA	assessed	on	an	ETDRS	chart,	intraocular	pressure	(IOP)	measured	using	Goldman	applanation	tonometry,	and	central	macular	thickness	(CMT)	measured	with	SD-OCT	(Spectralis;	Heidelberg	Engineering,	Heidelberg,	Germany).	In	phakic	eyes,	nuclear,	cortical	and	posterior	subcapsular	lens	opacities	were	graded	according	to	the	Age	Related	Eye	Diseases	Study	(AREDS)	protocol.	Fundus	fluorescein	angiography	was	performed	at	baseline	to	confirm	the	diagnosis	of	DMO	and	to	exclude	other	causes	of	macular	edema.		Retinal	thickness	was	defined	on	OCT	as	the	distance	between	the	inner	limiting	membrane	and	Bruch’s	membrane.	This	distance	was	measured	automatically	with	the	inbuilt	Heidelberg	HRA/OCT	software	and	checked	manually	to	ensure	correct	segmentation.	Segmentation	lines	were	redefined	manually	if	required.	CMT	values	were	calculated	as	the	average	retinal	thickness	in	the	central	1mm	circle	of	the	ETDRS	grid.	Progression	scans	utilising	eye	and	landmark	tracking	were	undertaken	to	ensure	accurate	measurement	of	the	same	anatomical	location.			
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The	morphology	of	DMO	was	analysed	and	classified	on	OCT	as	the	presence	of	intraretinal	fluid,	subretinal	fluid	or	both.	The	presence	or	absence	of	vitreomacular	adhesion	(VMA),	defined	as	an	elevation	of	the	cortical	vitreous	above	the	retina	surface	in	the	perifoveal	area	without	any	changes	in	foveal	contour	or	retinal	morphology,	was	graded.	The	inner	segment	ellipsoid	(ISe)	band	integrity	was	assessed	in	the	central	1mm	circle	of	the	ETDRS	grid	with	disruption	as	present	or	absent.	The	presence	or	absence	of	external	limiting	membrane	(ELM)	disruption	within	the	central	1mm	circle	of	the	ETDRS	grid	was	also	graded.	Disorganisation	of	the	retinal	inner	layers	(DRIL)	affecting	≥50%	of	the	1-mm	central	retinal	zone	was	graded	as	previously	described	[15].		All	intravitreal	injections	were	given	according	to	a	standardised	procedure	with	strict	aseptic	technique.	The	eye	was	anesthetised	using	topical	oxybuprocaine	hydrochloride	0.4%	and	the	conjunctiva	was	prepared	with	an	antiseptic	agent	(povidone	iodine	5%	or	chlorhexidine	0.1%).	The	intravitreal	injection	was	delivered	using	a	30-gauge	needle	through	the	pars	plana.	Post-procedure	topical	antibiotic	drops	were	not	routinely	administered.		Ocular	and	systemic	adverse	events	were	recorded.	An	increase	in	lens	opacity	grading	of	2	or	more	AREDS	levels	in	either	nuclear,	cortical,	or	posterior	subcapsular	cataract,	IOP	of	25	mmHg	or	more	or	a	rise	in	IOP	of	10	mmHg	or	more	compared	with	baseline	were	considered	an	adverse	event.		
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Additional	examinations	at	baseline,	24	weeks	and	48	weeks	were	lens	status	graded	according	to	the	Age	Related	Eye	Diseases	Study	(AREDS)	protocol	and	ultra-widefield	(UWF)	retinal	imaging	(Optos	PLC,	Dunfermline,	UK).		An	ETDRS	7	standard	fields	(7SF)	template	was	overlaid	on	UWF	imaging	obtained	and	DR	lesions	were	graded	for	severity	and	as	predominantly	peripheral	or	within	the	7SF	as	previously	described.	[233,	234]		
Statistical	Analyses	All	statistical	tests	were	performed	using	IBM	SPSS	software	(version	22;	SPSS	Inc,	Chicago,	Illinois,	USA).	Complete	case	analysis	was	performed	with	missing	data	excluded.	Data	was	confirmed	to	be	distributed	normally	using	Shapiro-Wilk	tests.	Paired	t-tests	were	used	to	compare	differences	in	means	of	BCVA	and	CMT.	Homogeneity	of	data	was	confirmed	using	Levene’s	test	for	all	independent	samples’	t-tests,	which	were	used	to	group	patients	by	baseline	vision	less	than	or	greater	than	or	equal	to	69	letters,	baseline	CMT	less	than	or	greater	than	or	equal	to	400μm	and	vision	gain	greater	or	equal	to	five	letters	at	4-weeks.	In	cases	where	variances	were	deemed	unequal,	adjustment	was	made	to	the	analysis	using	the	Welch-Satterthwaite	method.	Intrapatient	BCVA	and	CMT	variability	was	assessed	using	vision	data	from	the	fellow	eye.	Post-hoc	analyses	were	performed	comparing	changes	in	BCVA	and	CMT	in	patients	receiving	bevacizumab	treatment	for	DMO	in	their	fellow	eye	with	the	study	eye.		
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Multiple	regression	was	performed	to	assess	for	an	effect	of	outcomes	with	baseline	vision,	gender,	age,	duration	and	type	of	diabetes	mellitus,	glycated	haemoglobin,	duration	and	number	of	previous	treatments	for	DMO,	previous	panretinal	photocoagulation,	morphology	of	DMO	and	lens	status.		For	all	analyses,	a	p-value	of	less	than	0.05	was	considered	to	be	statistically	significant.		
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RESULTS	
Baseline	Characteristics	Baseline	characteristics	of	the	patients	are	summarised	in	Table	3.1.	Of	patients	screened,	9	had	both	eyes	eligible	as	per	inclusion	criteria.	There	was	no	significant	difference	in	the	CMT	(428 ± 84μm	vs.	405 ± 91μm,	p=0.42)	or	BCVA	(70.0 ± 7.7	vs.	74.8 ± 8.2	letters,	p=0.06)	in	the	study	eye	compared	to	the	fellow	eye.	Among	the	43	patients	recruited,	41	patients	were	included	in	the	final	analysis.	One	patient	experienced	a	retinal	detachment	following	the	second	injection	and	was	withdrawn	from	the	study.	One	other	withdrew	consent	after	the	baseline	visit	and	injection.	Baseline	mean ± standard	deviation	BCVA	was	67.8 ± 10.3	letters,	and	baseline	CMT	was	417 ± 91μm.	Completion	of	study	visits	is	summarised	in	Table	3.2.		 	
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Table	3.1:	Baseline	characteristics	of	patient	cohort	
Characteristic	 Data	Number	of	patients	 43	Age	(years),	mean	±	SD	 62.9	±	9.7	Male,	n	(%)	 27	(62.7)	Right	eyes,	n	(%)	 21	(48.8)	Baseline	BCVA	(letters),	mean	±	SD	 67.8 ± 10.3	Baseline	CMT	(μm),	mean	±	SD	 417 ± 91	Pseudophakic	eyes,	n	(%)	 13	(30.2)	Type	1	Diabetics,	n	(%)	 5	(11.6)	Duration	of	diabetes	(years),	mean	±	SD	 17.4	±	10.6	HbA1c	(%),	mean	±	SD	 8.0	±	1.7	Duration	of	anti-VEGF	treatment	(months),	median	(interquartile	range)	 18	(8-34)	Total	number	of	anti-VEGF	injections,	median	(interquartile	range)	 12	(7-24)	Interval	between	last	bevacizumab	and	baseline	aflibercept	injection	(days),	mean	±	SD	 42.4	±	13.1	Prior	treatments	in	study	eye	Focal/grid	macular	photocoagulation,	n	(%)	Panretinal	photocoagulation,	n	(%)	Vitrectomy,	n	(%)	Triamcinolone,	n	(%)	
	18	(41.9)	17	(39.5)	5	(11.6)	2	(4.6)	SD	=	standard	deviation,	BCVA=	best	corrected	visual	acuity,	CMT=	central	macular	thickness	VEGF=vascular	endothelial	growth	factor			
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Table	3.2:	Summary	of	study	visits	and	missed	appointments	
		 Visit	Week	
Patient	ID	 Week	1	 Week	4	 Week	8	 Week	12	 Week	16	 Week	20	 Week	24	 Week	28	 Week	32	 Week	36	 Week	40	 Week	44	 Week	48	
001	 	 	 	 	 	 	 	 	 	 X	 	 	 	
002	 	 	 	 	 	 	 	 	 	 	 	 	 	
003	 	 	 	 	 	 	 	 	 	 	 	 	 	
004	 	 	 	 	 	 	 	 	 	 	 	 	 	
005	 	 	 	 	 	 	 	 	 	 	 	 	 	
006	 	 	 	 X		 	 	 	 	 	 	 	 	 	
007	 	 	 	 	 	 	 	 	 	 	 	 X	 	
008	 X	 	 	 	 	 	 	 	 	 	 	 X	 	
009	 	 Withdrawn	from	study	
010	 	 	 	 	 	 	 	 	 	 	 	 	 	
011	 	 	 	 	 	 	 	 	 	 	 	 	 	
012	 	 	 	 	 	 	 	 	 	 	 	 	 	
013	 	 	 	 	 	 	 	 	 	 	 	 	 	
014	 	 	 	 	 	 X	 	 X	 	 X	 X	 X	 	
015	 	 	 	 	 	 	 	 	 	 	 	 	 	
016	 	 	 	 	 	 	 	 	 	 	 	 	 	
017	 	 	 	 	 	 	 	 	 	 	 	 	 	
018	 	 	 	 	 	 X	 	 	 	 	 	 X		 	
019	 	 	 	 	 	 	 	 	 	 	 	 	 	
020	 	 	 	 	 	 	 	 	 	 	 	 	 	
021	 	 	 	 Withdrawn	from	study	
022	 	 	 	 	 	 	 	 	 	 	 	 	 	
023	 	 	 	 	 	 	 	 	 	 	 	 	 	
024	 	 	 	 	 	 	 	 	 	 	 	 	 	
025	 	 	 	 	 	 	 	 	 	 	 	 	 	
026	 	 	 	 	 	 	 	 	 	 	 	 	 	
027	 	 	 	 	 	 	 	 	 	 	 	 X	 	
028	 	 	 	 	 	 	 	 	 	 X	 X	 X	 X	
	 -108-	
029	 	 	 	 	 	 	 	 	 	 	 	 	 	
030	 	 	 	 	 	 X	 	 	 	 	 	 	 	
031	 	 	 	 	 	 	 	 	 	 	 	 	 	
032	 	 	 	 	 	 	 	 	 	 	 	 	 	
033	 	 	 	 	 	 	 	 	 	 	 	 	 	
034	 	 	 	 	 	 	 	 	 	 	 	 	 	
035	 	 	 	 	 	 	 	 	 	 	 	 	 	
036	 	 	 	 	 	 	 	 	 	 	 	 	 	
037	 	 	 	 	 	 	 	 	 	 	 	 	 	
038	 	 	 	 	 	 X	 	 	 	 	 	 	 	
039	 X	 	 	 	 	 	 	 X	 	 X	 	 	 	
040	 	 	 	 	 	 	 	 	 	 	 	 	 	
041	 	 	 	 	 	 	 	 X	 	 X	 	 X	 	
042	 	 	 	 	 	 	 	 X	 	 	 	 	 	
043	 X	 	 	 	 	 	 	 	 	 	 	 	 		X	=missed	visit	
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Visual	outcomes	post	switch	to	aflibercept	The	changes	in	vision	are	summarised	in	Figure	3.1	with	rates	of	changes	further	categorised	by	magnitude	in	Table	3.3.	Mean	 ± standard	deviation	BCVA	improved	from	67.8 ± 10.3	letters	to	71.7 ± 9.6	letters	at	48	weeks	(3.9	±	7.0	letter	gain,	p=0.001).	Vision	gain	was	greater	in	patients	with	a	poorer	BCVA	(less	than	69	letters)	at	baseline	(6.9	±	7.4	vs.	1.7	±	5.9	letter	gain,	p=0.02).	Simple	linear	regression	found	a	significant	association	between	baseline	BCVA	and	48-week	vision	gain	(standardised	coefficient	-0.44,	p=0.004)	with	an	R2	=	0.19.	Patients	who	gained	5	or	more	letters	compared	to	those	who	gained	less	than	5	letters	after	the	first	injection	at	4	weeks	had	superior	vision	gain	at	48	weeks	(8.9	±	5.7	vs.	1.8	±	6.5	letter	gain,	p=0.002).	Multiple	regression	was	performed	to	assess	the	effect	of	both	baseline	BCVA	(standardised	coefficient	-0.31,	p=0.04)	and	a	5	or	greater	letter	gain	at	4	weeks	(standardised	coefficient	0.37,	p=0.01)	on	vision	gain	at	48-weeks	with	an	R2	=	0.31.	Multiple	regression	did	not	identify	a	statistically	significant	effect	of	other	variables	on	BCVA	change	at	48-weeks	(Table	3.4).		 	
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Table	3.3:	Vision	and	macular	thickness	changes	48	weeks	after	switching	from	bevacizumab	to	aflibercept	
	
Characteristic	 Data	BCVA	change	at	48	weeks	≥10	letter	gain,	n	(%)	5-9	letter	gain,	n	(%)	<5	letters	lost	or	gained,	n	(%)	5-9	letter	loss,	n	(%)	≥10	letter	loss,	n	(%)	
	10	(24)	7	(17)	19	(46)	4	(10)	1	(3)	CMT	change	at	48	weeks	≥50µm	reduction,	n	(%)	<50µm	reduction	or	gain,	n	(%)	≥50µm	gain,	n	(%)	
	21	(51)	15	(37)	5	(12)	BCVA=best	corrected	visual	acuity,	CMT=central	macular	thickness			
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Figure	3.1:	Graph	demonstrating	the	change	in	mean	best-corrected	visual	acuity	(in	letters)	over	48	weeks	compared	with	baseline	values.		Error	bars	correspond	to	standard	error	of	the	mean.			
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Table	3.4:	Multiple	regression	to	assess	effect	of	different	factors	on	change	in	visual	acuity		
	
Parameter	 Unstandardised	
coefficient	
Standardised	
coefficient	
P-	value	Baseline	vision	 -0.453	 -0.681	 0.01	Age	 -0.212	 -0.277	 0.24	Gender	 -0.875	 -0.055	 0.78	Type	of	diabetes	 0.388	 0.200	 0.927	Duration	of	diabetes	 0.131	 0.173	 0.446	HbA1c	 -1.526	 -0.366	 0.169	Previous	PRP	 -1.083	 -0.075	 0.733	Previous	focal/grid	macular	photocoagulation	 -2.396	 -0.161	 0.465	Number	of	prior	intravitreal	anti-VEGF	injections	 -0.216	 -0.334	 0.172	Duration	of	prior	anti-VEGF	therapy	 0.043	 0.151	 0.543	Presence	of	subretinal	fluid	 -1.185	 -0.060	 0.763	Pseudophakia	 -2.212	 -0.148	 0.504	PRP=panretinal	photocoagulation,	HbA1c=glycated	haemoglobin	
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Anatomical	and	morphological	outcomes	post	switch	to	aflibercept	Change	in	CMT	is	summarised	in	Figure	3.2	with	further	categorisation	of	change	summarised	in	Table	3.3.	Overall,	mean	CMT	improved	from	415 ± 92μm	to	357 ± 108μm	(-59	±	114μm	difference,	p=0.002)	at	week	48.	There	was	no	difference	in	change	in	CMT	for	patients	with	a	CMT	less	than	or	greater	than	or	equal	to	400μm	at	baseline	(-87	±	154μm	vs.	-35	±	60μm,	p = 0.19).		Morphological	OCT	findings	at	baseline	and	at	the	conclusion	of	the	study	are	summarised	in	Table	3.4.	Nine	eyes	had	no	SRF	or	intraretinal	fluid	present	at	48	weeks	of	follow-up.	There	was	a	significantly	greater	reduction	in	CMT	among	these	“dry”	eyes	(-135	±	168μm	vs.	-36	±	82μm,	p = 0.02)	but	not	a	significant	difference	in	vision	gain	(5.1 ± 6.5	vs.	3.3 ± 7.4	letter	gain,	p=0.50).	Patients	with	SRF,	ELM	and	ISe	disruption	and	DRIL	had	worse	BCVA	at	baseline	and	48-weeks	(Table	3.4).	Multiple	regression	did	not	identify	any	a	statistically	significant	effect	of	other	variables	on	CMT	change	at	48-weeks	(Table	3.5).		 	
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Figure	3.2:	Graph	demonstrating	the	change	in	mean	central	macular	thickness	(in	micrometers)	over	48	weeks	compared	with	baseline.		Error	bars	correspond	to	standard	error	of	the	mean.			
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Table	3.4.	Baseline	anatomical	features	prior	to	switch	from	bevacizumab	to	aflibercept	for	diabetic	macular	oedema	(DMO)	
	
Characteristic	 Baseline	 Baseline	
BCVA	with	
characteristic	
Baseline	
BCVA	without	
characteristic	
Difference	
(p-value)	*	
48	weeks	 48-week	
BCVA	with	
characteristic	
48-week	
BCVA	without	
characteristic	
Difference	
(p-value)	*	DMO	pattern	Intraretinal	fluid,	n	(%)		Subretinal	fluid,	n	(%)	
	41	(100)		7	(17)	
	67.8 ± 10.3		60.0	±	8.1	
	N/A		69.4	±	10.1	
	N/A		
9.4	±4.1	
(p=0.03)	
	32	(78)		0	(0)	
	69.7	±	9.4		N/A	
	77.9	±	8.1		71.5 ± 9.7	
	
8.2	±	3.5	
(p=0.02)		N/A	VMA,	n	(%)	 9	(22)	 67.3	±	10.9	 70.1	±	7.2	 2.8	±4.3	(p=0.52)	 6	(15)	 70.3	±	9.9	 71.7	±	9.8		 1.3	±	4.3	(p=0.77)		ELM	disruption,	n	(%)	 29	(71)	 59.7	±	9.5	 71.2	±	8.8	 11.5	±	3.1	
(p<0.01)	
27	(66)	 68.2	±	8.6	 77.8	±	8.6	 9.6	±	2.8	
(p<0.01)		ISe	band	disruption,	n	(%)	 33	(80)	 65.8	±	10.2	 75.1	±	7.5	 9.4	±	3.7	
(p=0.01)	
38	(93)	 71.2	±	10.0	 75.3	±	1.5	 4.2	±	1.8	
(p=0.03)		DRIL	≥50%	in	central	1mm,	n	(%)	 33	(80)	 66.2	±	10.5	 74.3	±	6.7	 8.0	±	3.0	(p=0.02)	 32	(78)	 69.2	±	9.0	 79.7	±	7.5	 10.5	±	3.3	(p<0.01)		VMA=vitreomacular	adhesion,	ELM=external	limiting	membrane,	ISe=inner	segment	ellipsoid,	DRIL=	disorganisation	of	the	inner	retinal	layers,	BCVA=best-corrected	visual	acuity,	*independent	samples	t-test	
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Table	3.5:	Multiple	regression	to	assess	effect	of	different	factors	on	change	in	central	macular	thickness			
Parameter	 Unstandardised	
coefficient	
Standardised	
coefficient	
P-	value	Baseline	CMT	 -0.548	 -0.428	 0.063	Age	 3.635	 0.278	 0.183	Gender	 -89.553	 -0.328	 0.070	Type	of	diabetes	 22.849	 0.068	 0.721	Duration	of	diabetes	 -1.679	 -0.130	 0.526	HbA1c	 13.582	 0.191	 0.349	Previous	PRP	 58.965	 0.238	 0.235	Previous	focal/grid	macular	photocoagulation	 0.067	 0.000	 0.999	Number	of	prior	intravitreal	anti-VEGF	injections	 2.340	 0.212	 0.411	Duration	of	prior	anti-VEGF	therapy	 -2.475	 -0.510	 0.079	Presence	of	subretinal	fluid	 -21.938	 -0.065	 0.693	Pseudophakia	 -41.851	 -0.164	 0.409	CMT=central	macular	thickness,	PRP=panretinal	photocoagulation,	HbA1c=glycated	haemoglobin				 	
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Fellow	Eye	Outcomes	Overall,	BCVA	remained	stable	over	the	study	period	(0.3	±	6.1	letter	change,	p=0.73)	in	the	fellow	eye	of	the	41	patients	in	the	final	analysis.	There	was	a	small	but	statistically	significant	reduction	in	the	CMT	of	the	fellow	eye	from	baseline	to	week	48	(-25	±	46μm,	p = 0.001).			Of	the	41	patients,	16	were	receiving	concomitant	treatment	with	monthly	as	needed	bevacizumab	for	DMO	in	the	fellow	eye.	When	these	patients	were	excluded	from	analysis,	there	was	no	significant	difference	in	vision	(0.1	±	7.2	letter	change,	p=0.93)	or	CMT	(-19	±	45μm	p=0.052)	for	the	remaining	25	patients	from	baseline	to	week	48.		For	the	9	patients	whom	initially	had	both	eyes	eligible	for	inclusion	in	the	trial,	there	were	similar	vision	(1.9 ± 5.4	vs.	1.0 ± 4.0	letter	gain,	p=0.70)	and	CMT	(-57	±	65μm	vs.	-55	±	63μm,	p = 0.95)	outcomes	between	the	eye	that	was	switched	to	aflibercept	and	the	fellow	eye	that	remained	on	bevacizumab	(paired	t-tests).	For	treated	fellow	eyes,	there	were	a	greater	number	of	injections	administered	(median	12	vs.	8	injections).		
Diabetic	Retinopathy	Severity	Of	the	41	patients	who	completed	the	trial,	20	had	scatter	panretinal	photocoagulation	(PRP)	for	proliferative	DR	(PDR).	For	the	patients	who	did	not	have	quiescent	PDR,	1	had	moderately	severe	non-proliferative	DR	(NDPR),	12	had	moderate	NPDR	and	8	had	mild	NPDR.	Of	these	patients,	Diabetic	
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Retinopathy	Severity	Score	(DRSS)	improved	by	1-step	in	6	(28%),	worsened	by	1-step	in	1	(5%)	and	remained	unchanged	in	14	(67%).	An	illustration	of	this	is	shown	in	Figure	3.3.	Lesions	were	predominantly	peripheral	in	6	(28%)	of	these	21	eyes.	BCVA	(6.8 ± 6.2	vs.	3.7 ± 7.2	letter	gain,	p = 0.33)	and	CMT	(-64	±	99μm	vs.	-62	±	119μm,	p = 0.96)	outcomes	were	similar	in	patients	with	regression	of	disease	compared	to	those	who	remained	stable	or	worsened.		 	
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Figure	3.3:	Ultra-widefield	imaging	at	(A)	baseline	and	(B)	48-weeks	post	switch	to	aflibercept	therapy	in	a	sample	patient.		Standard	ETDRS	7-field	area	is	superimposed	for	reference.	Arrows	identify	microaneurysms	and	hemorrhages.			 	
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Initial	response	to	bevacizumab	Median	duration	(interquartile	range)	of	treatment	with	bevacizumab	prior	to	starting	trial	was	12	(7-24)	injections	over	18	(8-34)	months.	Vision	data	and	CMT	measurements	were	available	for	39	and	30	patients	respectively	from	referring	practitioners.	There	was	no	significant	improvement	in	vision	(-1.0	±	8.4	letters,	p=0.48)	or	CMT	(-22	±	97	um,	p=0.002)	in	these	patients	during	this	period.		Visual	outcomes	at	48	months	were	similar	among	eyes	demonstrating	a	good	initial	response	to	bevacizumab	prior	to	switch	(5	or	more	letter	gain)	compared	to	eyes	with	a	poorer	initial	response	(1.2	±	4.9	vs.	4.1	±	7.0	letter	gain	at	48	weeks,	p=0.25).		
Safety	data	Adverse	events	encountered	during	the	study	are	summarised	in	Table	3.6.	Notable	ocular	adverse	events	included	a	rhegmatogenous	retinal	detachment.	There	was	no	progression	of	cataract	severity	or	raised	IOP	in	any	of	the	study	eyes	and	no	patients	required	medical	or	surgical	intervention	for	cataract	or	raised	IOP.		 	
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Table	3.6.	Ocular	and	systemic	adverse	events	
	
Event	 Frequency	Pneumonia	 2	(4%)	Hypoglycemia	 2	(4%)	Myocardial	Infarction	 1	(2%)	Transient	Ischemic	Attack	 1	(2%)	Retinal	detachment	 1	(2%)	Spinal	Fusion	 1	(2%)	Bronchitis	 1	(2%)	Cellulitis	in	leg	 1	(2%)	Renal	failure	requiring	dialysis	 1	(2%)	Prostatitis	 1	(2%)	Diabetic	Ketoacidosis	 1	(2%)				
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DISCUSSION	Persistent	DMO	following	treatment	with	bevacizumab	is	a	clinical	management	challenge.	This	trial	provides	prospective	evidence	that	aflibercept	may	be	effective	in	improving	anatomical	and	vision	outcomes	in	these	patients	over	a	48-week	period.	Approximately	40%	of	patients	gained	one	or	more	lines	of	vision	and	vision	loss	was	rare.			There	is	limited	data	from	prospective	studies	investigating	a	switch	from	bevacizumab	to	aflibercept.	One	prospective	study	of	14	eyes	reported	improvements	in	CMT	but	not	in	visual	acuity	when	switching	from	bevacizumab	or	ranibizumab	to	aflibercept	over	a	period	of	one-month.	[86]	Additionally,	several	retrospective	studies	have	evaluated	the	effect	of	a	switch	in	therapy	from	bevacizumab	to	aflibercept	for	persistent	DMO	with	follow	up	periods	ranging	from	one	to	five	months.	[83-85,	235]	All	of	these	have	consistently	demonstrated	statistically	significant	reductions	in	CMT	ranging	from	60-124um.	Significant	improvement	in	visual	acuity	was	observed	in	two	of	these	studies	with	a	mean	gain	of	0.05	and	0.06	logMAR,	a	similar	gain	to	what	was	measured	in	this	trial.	[84,	235]		The	effects	seen	in	switching	studies	may	relate	to	the	differing	structure	and	function	of	aflibercept	compared	with	the	monoclonal	antibody	bevacizumab.	Aflibercept	is	a	protein	formed	by	the	fusion	of	the	binding	domains	from	both	VEGF	receptor	(VEGFR)-1	and	VEGFR-2.	The	binding	affinity	of	this	drug	to	VEGF-A,	the	main	member	of	the	VEGF	family	responsible	for	the	major	pathological	effects	in	DMO,	is	greater	than	that	of	bevacizumab.	[226]	Due	to	its	
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structure	it	additionally	binds	other	members	of	the	VEGF	family,	VEGF-B	and	placental	growth	factor	(PlGF).	[226]	There	are	in	vitro	and	in	vivo	evidence	implicating	elevated	levels	of	PlGF	in	the	pathogenesis	of	DR	as	well	as	DMO.	[23]	Aflibercept	has	also	been	shown	to	interact	with	galectin-1,	a	factor	implicated	in	anti-VEGF-A	refractory	neoplasms.	[56,	57]	This	protein	may	also	play	a	role	in	the	pathogenesis	of	DR.	[56]			Response	to	anti-VEGF	drugs	may	also	be	related	to	genetic	variation	in	the	VEGF-A	gene.	The	CC	genotype	of	the	C-634G	polymorphism	of	this	gene	has	been	associated	with	improved	response	to	bevacizumab	in	the	management	of	DMO,	with	patients	significantly	more	likely	to	gain	three	or	more	lines	in	vision	and	have	a	greater	than	50%	reduction	in	their	CMT.	[236]	It	is	possible	that	DMO	in	patients	with	certain	polymorphisms	in	the	VEGF-A	gene	may	have	disease	increasingly	driven	by	VEGF	and	will	respond	better	to	increased	blockade	of	VEGF	signaling	pathways.		Both	good	and	poor	early	response	within	the	first	12	weeks	of	treatment	has	been	correlated	with	12-month	to	3-year	outcomes	in	other	retrospective	series	and	randomised	trials	treating	DMO	with	bevacizumab,	ranibizumab	and	the	dexamethasone	implant.	[231,	237,	238]	The	data	from	this	trial	adds	to	this	evidence	and	may	aid	clinicians	in	individualizing	a	management	strategy.		Vision	gains	overall	may	have	been	limited	due	to	a	ceiling	effect	in	some	of	these	patients.	This	is	reflected	in	patients	with	a	worse	baseline	BCVA	having	greater	gains	at	48-weeks.	Interestingly,	the	reduction	in	CMT	in	patients	was	not	
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different	for	those	with	a	thicker	CMT	≥400μm.	This	may	suggest,	an	anatomical	ceiling	effect	may	not	be	as	significant	in	patients	with	persistent	DMO.	Analyses	based	on	baseline	BCVA	are	also	subject	to	confounding	by	regression	to	the	mean,	where	those	with	a	poorer	baseline	measurement	would	on	average	have	a	greater	improvement	in	subsequent	measurements	and	should	be	interpreted	with	this	in	mind.			Chronic	macular	edema	may	lead	to	irreversible	damage	to	the	neural	retina,	limiting	visual	gain	as	seen	in	the	delayed	anti-VEGF	treatment	arms	of	RISE/RIDE	and	VISTA/VIVID.	[64,	71]	The	chronic	nature	of	DMO	in	these	patients	may	also	explain	why	other	commonly	identified	biomarkers	for	vision	improvement,	such	as	SRF,	young	age	and	duration	of	diabetes,	may	not	be	applicable	as	prognostic	markers.	[239]	This	includes	OCT	markers,	such	as	SRF,	DRIL,	ISe	band	and	ELM	integrity.	These	markers	have	all	been	correlated	with	visual	acuity,	as	was	demonstrated	in	our	study	at	baseline	and	at	48-weeks.	[178-181]	Presence	of	these	factors	at	baseline	was	not	associated	with	a	worse	outcome	at	48-weeks,	as	other	studies	have	shown.	[240,	241]	Additionally,	we	did	not	find	a	restoration	of	ISe	band	integrity,	as	others	have	suggested	following	treatment	in	treatment	naïve	patients	treated	with	bevacizumab	and	ranibizumab.	[139,	241]			Anatomically,	the	mean	CMT	reduction	began	to	fluctuate	at	the	point	of	treatment	extension	to	8	weeks.	This	finding	is	consistent	with	that	of	the	VISTA/VIVID	studies	of	mostly	treatment	naïve	eyes.	[71]	These	fluctuations	are	likely	due	to	re-accumulation	of	fluid	in	a	proportion	of	patients	who	may	
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require	more	frequent	treatment	to	prevent	the	re-accumulation	of	DMO.	Despite	this,	a	significant	reduction	in	CMT	was	maintained	throughout	all	follow-up	points	and	was	maximal	at	44	weeks.		These	data	also	support	previous	reports	of	aflibercept	promoting	the	regression	of	DR.	[71,	79]	This	disease	modifying	effect	in	patients	with	prior	anti-VEGF	treatment	was	also	observed	in	a	post-hoc	analysis	of	the	VISTA/VIVID	studies.	[232]	In	that	study,	the	effect	of	DR	regression	was	similar	in	patients	with	DMO	who	were	treatment	naïve	compared	with	those	previously	treated	with	anti-VEGF	drugs.		Furthermore,	the	use	of	ultra-widefield	imaging	helped	to	accurately	quantify	the	DRSS,	28%	of	which	would	have	been	otherwise	missed	by	ETDRS	7SF	imaging.	This	finding	is	consistent	with	a	comparative	study	of	where	the	number	of	hemorrhages	and	microaneurysms	identified	increased	by	50%	when	using	UWF	images.	[242]	Whilst	improvement	in	DRSS	did	not	correlate	with	vision	or	CMT	outcomes	in	our	trial,	peripheral	retinal	examination	has	important	prognostic	implications	for	progression	of	DR	with	peripheral	lesions	predicting	risk	of	progression	of	DR.	[233]		This	study’s	strengths	are	the	prospective	design,	standardised	examinations	inclusion	criteria	and	treatment	regime.	Patients	were	treated	intensively	with	bevacizumab	prior	to	switch	with	no	washout	period	to	allow	for	re-accumulation	of	edema	and	exaggerate	any	treatment	effect.	This	may	be	why	no	difference	was	seen	in	VISTA/VIVID	patients	with	and	without	prior	anti-VEGF	
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therapy,	who	had	a	washout	period	of	three	months	prior	to	enrollment.	[232]	There	was	no	additional	macular	laser	administered,	as	was	mandated	in	Protocol	T,	also	removing	another	potential	confounder	for	treatment	effect.	[77].	Finally,	the	dose	of	bevacizumab	used	prior	to	switch	was	higher	than	other	trials	for	DMO	(2.5mg	vs.	1.25mg),	which	may	be	more	effective	for	persistent	DMO.	[80]		This	study	is	limited	by	the	lack	of	a	control	group	and	a	small	sample	size.	There	was	no	significant	change	in	vision	or	CMT	in	a	post-hoc	analysis	of	untreated	fellow	eyes	suggesting	a	treatment	effect.	Protocol	I	data	suggests	that	patients	with	persistent	DMO	at	3	or	6	months	post	initiation	of	therapy	would	continue	to	improve	if	kept	on	the	same	therapy.	[243]	Supporting	this,	for	fellow	eyes	continuing	treatment	with	bevacizumab,	there	were	similar	vision	and	CMT	outcomes	in	our	trial.	There	was,	however,	a	larger	treatment	burden	in	these	fellow	eyes,	requiring	a	median	of	12	injections	compared	to	8	in	the	eye	receiving	treatment	with	aflibercept.			Switching	therapy	from	bevacizumab	to	aflibercept	may	be	an	effective	strategy	in	the	management	of	persistent,	chronic	DMO.	The	data	from	this	prospective	study	shows	that	an	early	response	to	a	switch	in	therapy	may	predict	longer-term	outcomes	in	this	cohort	of	patients.		 	
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Chapter	4:	The	influence	of	retinal	pathology	on	the	reliability	of	macular	thickness	measurement:	a	comparison	between	optical	coherence	tomography	devices				Optical	coherence	tomography	has	revolutionised	the	diagnosis	and	management	of	macular	pathology.	So	ubiquitous	have	these	devices	become	that	outcomes	from	clinical	trials	use	automated	measurements	generated	by	these	devices	as	a	reference	standard.			The	purpose	of	this	chapter	is	to	highlight	the	differences	in	measurements	and	readings	provided	by	different	OCT	machines	and	to	demonstrate	the	effect	pathology	has	on	repeatability	and	reliability.	Patients	enrolled	in	the	clinical	trial	from	this	section	of	the	thesis	are	compared	with	that	of	patients	enrolled	in	a	study	of	age-related	macular	degeneration	as	well	as	a	sample	of	normal	controls.		The	results	of	this	Chapter	have	important	implications	for	the	interpretation	of	anatomical	outcomes	from	clinical	trials.				
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The	material	presented	in	this	chapter	has	been	published	and	is	reproduced	from:		
Bahrami	B,	Ewe	S,	Hong	T,	Zhu	M,	Ong	G,	Luo	K,	Chang	A.	Influence	of	retinal	pathology	on	the	reliability	of	macular	thickness	measurement:	a	comparison	between	optical	coherence	tomography	devices.	Ophthalmic	Surg	Lasers	Imaging	Retina.	2017	Apr	1;48(4):319-325			Furthermore,	the	data	presented	in	this	chapter	has	been	published	and	presented	at	the	following	conference:		RANZCO	47th	Annual	Scientific	Conference:	Wellington,	New	Zealand,	2015	Ewe	SYP,	Bahrami	B,	Zhu	M,	Hong	T,	Ong	GJM,	Chang	A.	A	Comparison	of	Macular	Thickness	Measurements	Across	Three	Different	Spectral-Domain	Optical	Coherence	Tomography	(SD-OCT)	Machines.	Clin	Exp	Ophthalmol.	2015	Oct;	43	(S1):79-123.		 	
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ABSTRACT		
	
Purpose:	To	evaluate	the	repeatability,	reliability	and	comparability	of	macular	thickness	 measurements	 between	 three	 optical	 coherence	 tomography	 (OCT)	machines	 in	healthy	 eyes,	 eyes	with	diabetic	macular	 oedema	 (DMO)	and	eyes	with	neovascular	age-related	macular	degeneration	(nAMD).		
Methods:	Twenty-three	eyes	with	DMO,	26	eyes	with	nAMD,	and	24	healthy	eyes	as	 controls	were	 evaluated.	 Scans	were	performed	on	 the	 swept-source	Triton	(Topcon)	 as	 well	 as	 the	 spectral-domain	 Cirrus	 (Zeiss)	 and	 Spectralis	(Heidelberg)	 machines.	 Scans	 were	 evaluated	 for	 central	 macular	 thickness	(CMT),	 presence	 of	 segmentation	 and	 fixation	 imaging	 artifacts	 (IA),	 re-scan	reliability	and	agreement	between	machines	and	groups.		
Results:	Mean	CMT	was	significantly	different	between	all	OCT	machines	 in	all	groups	(p<0.01	for	all	comparisons).	Manually	correcting	IA	did	not	alter	these	results.	There	was	good	scan	repeatability	among	healthy	and	DMO	eyes	for	each	machine,	 but	 poor	 repeatability	 among	 the	 nAMD	 group	 with	 the	 Spectralis	(p=0.038).	IA	was	significantly	increased	in	the	presence	of	pathology.		
Conclusion:	 There	 is	 poor	 agreement	 of	 CMT	 measurement	 between	 OCT	machines	in	healthy	eyes	and	those	with	DMO	and	nAMD.	DMO	and	nAMD	have	a	significant	 effect	on	 the	 rate	of	 IA	 in	 scans.	Care	 is	 required	when	 interpreting	measurements	 from	 different	 OCT	 devices	 in	 clinical	 practice	 and	 research	settings.		 	
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BACKGROUND	The	development	of	optical	coherence	tomography	(OCT)	has	revolutionised	the	diagnosis	 and	 management	 of	 retinal	 pathology.	 OCT	 is	 an	 increasingly	accessible	 technology,	with	 over	 35	 device	manufacturers	 producing	machines	for	commercial	and	research	use.	[244]	These	machines	utilise	different	software	and	hardware	to	analyse	obtained	images.	As	a	consequence	of	these	variations,	retinal	 thickness	measurements	obtained	 from	different	OCT	machines	are	not	comparable.	Additionally,	readings	from	individual	machines	may	be	unreliable	due	to	 image	segmentation	errors	and	artifacts.	These	differences	are	apparent	in	both	healthy	eyes	as	well	as	those	with	pathology.	[150,	206,	245-254]		Reliable	 measurements	 of	 central	 macular	 thickness	 (CMT)	 are	 important	 in	common	vision	threatening	conditions	such	as	neovascular	age-related	macular	degeneration	(nAMD)	and	diabetic	macular	oedema	(DMO).	This	information	can	be	indicative	of	disease	activity	and	is	an	outcome	measure	in	many	clinical	trials	of	these	conditions.	[122,	255-259]	With	the	ubiquity	of	OCT,	it	is	not	uncommon	for	a	patient	to	have	multiple	retinal	scans	performed	by	different	practitioners	on	 different	 machines	 at	 different	 times.	 Thus,	 interpreting	 quantitative	 data	obtained	from	different	machines	poses	a	challenge.		In	 this	 study,	 we	 evaluate	 the	 reliability	 and	 comparability	 of	 CMT	measurements	 and	 rates	 of	 imaging	 artifacts	 on	 two	 commonly	 used	 spectral-domain	(SD)	and	a	newer	swept-source	(SS)-OCT	machine.	We	also	evaluate	the	influence	of	DMO	and	nAMD	on	the	OCT	scan	performance.		 	
	 -131-	
METHODS	Patients	and	volunteers	from	a	single	tertiary	referral	center	were	recruited	for	this	cross-sectional	study.	Participants	were	divided	into	three	groups:	eyes	with	no	previous	ocular	history	used	as	control,	eyes	diagnosed	with	DMO	and	eyes	diagnosed	 with	 nAMD.	 All	 study	 assessments	 were	 performed	 after	 obtaining	informed	consent	 from	all	participants	and	were	conducted	 in	accordance	with	the	tenets	of	the	Declaration	of	Helsinki.		Recruited	 patients	 had	 a	 best-corrected	 visual	 acuity	 (BCVA)	 greater	 than	 or	equal	to	55	ETDRS	letters	(Snellen	equivalent	20/80)	in	the	study	eye	and	were	able	 to	 fixate	 on	 machine-generated	 targets.	 Tropicamide	 1%	 was	 used	 for	pupillary	dilation	prior	to	posterior	segment	examination	and	scanning.			All	 OCT	 scans	 were	 performed	 by	 four	 technicians	 with	 previous	 clinical	 trial	scanning	 experience.	 Scans	 were	 performed	 using	 the	 swept-source	 SS	 Triton	DRI-OCT	(Figure	4.1A,	Topcon	Corporation,	Tokyo,	Japan,	software	version	10.0),	Spectralis	 SD-OCT	 (Figure	 4.1B,	 Heidelberg	 Engineering,	 Heidelberg,	 Germany,	software	version	6.4.8.0)	and	Cirrus	SD-OCT	(Figure	4.1C,	Carl	Zeiss	Meditec	Inc.,	Dublin,	California,	USA,	software	version	6.0.2.81).	For	each	participant,	the	same	OCT	operator	performed	all	OCT	scans	on	each	of	the	machines	on	the	same	day.	Two	replicate	scans	were	performed	for	each	equivalent	scanning	protocol	on	all	three	OCT	machines	 (Triton:	 3D	Macular	 Scan;	Cirrus:	Macular	 Cube	 512x128;	Spectralis:	Dense	Scan	(49	lines)).			 	
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Figure	4.1:	The	three	optical	coherence	tomography	devices	used	in	this	study.		A)	Topcon	Triton	DRI	OCT	(image	reproduced	from	https://bit.ly/2Hqlfty)	 ,	B)	Heidelberg	Spectralis	OCT	(image	reproduced	from	https://bit.ly/2qTxRPE)	and	C)	Zeiss	Cirrus	OCT	(image	reproduced	from	https://bit.ly/2FeBQuh)	 	
A B 
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Outcome	 measures	 were	 CMT,	 defined	 as	 the	 mean	 thickness	 from	 Bruch’s	membrane	 to	 the	 inner	 retinal	 border	 within	 the	 central	 1	 mm	 circle	 of	 the	ETDRS	 grid,	 presence	 of	 imaging	 artifacts	 (IA),	 re-scan	 repeatability	 and	agreement	between	machines	and	groups.		IA	 were	 classified	 as	 related	 to	 segmentation	 or	 fixation	 errors.	 Segmentation	artifacts	 were	 due	 to	 inappropriate	 automated	 segmentation	 of	 retinal	 layers	resulting	 in	 inaccurate	 retinal	 thickness	 measurements	 (Figure	 4.2).	 Fixation	artifacts	were	 associated	with	 inappropriate	 identification	of	 the	 fovea	 (Figure	4.3).	IA	were	subsequently	corrected	manually	and	analyses	were	redone.		Results	were	 analyzed	 using	 IBM	 SPSS	 (version	 21;	 SPSS	 Inc,	 Chicago,	 Illinois,	USA).	Paired	t-tests	were	used	to	 investigate	differences	between	two	repeated	scans	 for	 reliability	 on	 each	 OCT	 machine,	 and	 between	 each	 pair	 of	 OCT	machines	for	comparability.	Mean	measurements	of	the	two	replicate	scans	were	used	 when	 evaluating	 the	 comparability	 between	 each	 pair	 of	 the	 three	 OCT	machines.	 For	 the	 analyses	 presented,	 all	 eyes	 studied	 were	 considered	independent	 from	 one	 another.	 A	 p	 value	 <0.05	 was	 considered	 to	 be	 a	significant	difference.			
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Figure	4.2:	(A)	Segmentation	error	with	the	Triton	device	due	to	retinal	hard	exudate	in	an	eye	with	diabetic	macular	oedema.	(B)	Segmentation	error	with	the	Cirrus	device	due	to	pigment	epithelium	detachment	in	an	eye	with	neovascular	age-related	macular	degeneration	(nAMD).	(C)	Segmentation	error	with	the	Spectralis	device	due	to	geographic	atrophy	in	an	eye	with	nAMD.	
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Figure	4.3:	Fixation	error	on	the	Triton	device	resulting	in	incorrect	ETDRS	grid	placement	and	calculation	of	central	macular	thickness.		
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RESULTS	
Subjects	A	 total	 of	 73	 eyes	 from	45	participants	were	 enrolled	during	 the	 study	period	between	June	and	August	2015.	The	control	group	consisted	of	24	healthy	eyes	of	12	participants	with	no	history	of	ocular	disease,	the	nAMD	group	consisted	of	26	 eyes	 of	 17	 participants	 and	 the	 DMO	 group	 consisted	 of	 23	 eyes	 of	 16	participants.	Both	the	nAMD	and	DMO	groups	were	undergoing	treatment	with	anti-vascular	 endothelial	 growth	 factor	 (anti-VEGF)	 drugs.	 Baseline	characteristics	of	the	entire	cohort	are	summarised	in	Table	4.1.		 	
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Table	4.1:	Baseline	characteristics	of	study	participants	
Characteristic	 Control	group	 DMO	group	 nAMD	group	Participants	(n)	 12	 16	 17	Eyes	(n)	 24	 23	 26	Female	(n)	 9	 8	 11	Age,	mean	years	(SD)	 42	(14.1)	 62.1	(8.3)	 83.5	(6.0)	BCVA,	mean	letters	(SD)	 55.8	(1.9)	 47.4	(9.3)	 42.2	(11.2)	Phakic	(n)	 24	 20	 11	
Spectralis	OCT	 	 	 	CMT	(µm),	mean	(SD)	 265.0	(14.5)	 337.7	(65.9)	 286.3	(72.9)	
Cirrus	OCT	 	 	 	CMT	(µm),	mean	(SD)	 245.9	(14.1)	 319.8	(66.5)	 229.6	(70.6)	
Triton	OCT	 	 	 	CMT	(µm),	mean	(SD)	 231.5	(11.8)	 287.4	(69.9)	 213.2	(66.7)	DMO=	diabetic	macular	oedema,	nAMD=	neovascular	age-related	macular	degeneration,	n	=	number,	SD	=	standard	deviation,	OCT	=	optical	coherence	tomography,	CMT	=	central	macular	thickness		
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Repeatability	of	Macular	Scans	All	 test-retest	 repeated	 CMT	 measurements	 performed	 for	 the	 entire	 cohort	demonstrated	reliability	in	each	machine	with	no	significant	differences	between	the	 first	 and	 second	 scans	 (Spectralis	 3.0µm	 (95%	 CI	 -1.1	 to	 7.2µm,	 p=0.15),	Cirrus	 -0.4µm	 (95%	 CI	 -2.8	 to	 2.0µm,	 p=0.74),	 Triton	 -0.4µm	 (95%	 CI	 -3.3	 to	2.4µm,	p=0.77)).			Subgroup	 analysis	 showed	 that	 the	 control	 and	 DMO	 groups	 maintained	repeatability	of	scans	across	all	3	machines.	The	nAMD	group,	however,	showed	relatively	 poor	 repeatability,	 with	 a	 significant	 difference	 identified	 on	 CMT	measurements	obtained	 from	the	Spectralis	 (p=0.038),	but	not	 from	the	Triton	or	the	Cirrus	(Table	4.2).		
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Table	4.2:	Mean	difference	between	two	consecutive	scans	stratified	by	subgroup	before	and	after	re-segmentation	to	correct	for	imaging	artifacts.	
	DMO=	diabetic	macular	oedema,	nAMD=	neovascular	age-related	macular	degeneration,	n	=	number,	OCT	=	optical	coherence	tomography,	CMT	=	central	macular	thickness,	CI=confidence	interval	
	 Before	re-segmentation	 After	re-segmentation	
Subgroup	 OCT	machine	 Mean	CMT		
(µm)	
95%	CI	 P	value	 Mean	CMT	
(µm)	
95%	CI	 P	value	
Control	 Spectralis	 -0.88	 -4.7	to	2.9	 0.64	 0.79	 -0.6	to	2.2	 0.26	
	 Triton	 -0.17	 -1.1	to	0.8	 0.72	 -0.17	 -1.1	to	0.8	 0.72	
	 Cirrus	 -2.38	 -5.7	to	0.9	 0.15	 -1.29	 -4.1	to	1.5	 0.36	
DMO	 Spectralis	 -1.83	 -5.9	to	2.2	 0.36	 -3.26	 -7.7	to	1.1	 0.14	
	 Triton	 -1.65	 -6.6	to	3.3	 0.49	 0.61	 -4.3	to	5.5	 0.80	
	 Cirrus	 0.13	 -5.2	to	5.5	 0.96	 -0.74	 -7.1	to	5.7	 0.81	
nAMD	 Spectralis	 10.96	 0.7	to	21.2	 0.04	 -2.54	 -7.8	to	2.7	 0.33		 Triton	 0.50	 -4.9	to	5.9	 0.85	 3.65	 -1.9	to	9.2	 0.19		 Cirrus	 0.88	 -5.3	to	7.0	 0.77	 0.73	 -2.2	to	3.7	 0.62	
Overall	 Spectralis	 3.04	 -1.0	to7.1		 0.15	 -1.67	 -3.9	to	0.6	 0.15		 Triton	 -0.39	 -2.7	to	1.9		 0.74	 -0.40	 -2.7	to	1.9	 0.74		 Cirrus	 -0.42	 -3.2	to	2.3		 0.77	 1.41	 -1.7	to	4.5	 0.77	
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Imaging	Artifacts	(IA)	There	was	a	low	occurrence	of	IA	in	the	control	group	(4.2%,	8.3%	and	8.3%	in	Spectralis,	Triton,	Cirrus	 respectively).	Higher	 rates	of	artifacts	occurred	 in	 the	DMO	 group	 (47.8%,	 52.2%	 and	 34.8%	 in	 Spectralis,	 Triton,	 Cirrus;	 p<0.05	compared	to	controls)	and	in	the	nAMD	group	(84.6%,	50%,	42.3%	in	Spectralis,	Triton,	 Cirrus;	 p<0.05	 compared	 to	 controls).	 When	 comparing	 machines,	 the	incidence	of	IA	in	nAMD	eyes	was	significantly	higher	on	the	Spectralis	compared	to	 Triton	 (p=0.02)	 and	 Cirrus	 (p<0.01).	 The	 prevalence	 of	 IA	 was	 otherwise	similar	in	the	control	group	and	the	DMO	group	across	all	3	machines.			Poor	 reliability	 of	 repeated	 measures	 were	 associated	 with	 IA.	 This	 was	supported	 by	 the	 overall	 scan-rescan	 reliability	when	manual	 re-segmentation	corrected	 these	 errors	 (Table	 4.2).	 The	 incidence	 of	 IA	 and	 the	 breakdown	 of	pathological	lesions	found	in	the	groups	are	summarised	in	Table	4.3.		
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Table	4.3:	Incidence	of	artifacts	by	optical	coherence	tomography	machine	and	subgroup.		
	 	 Total	artifact,	n	(%)	 Artifact	type	 P	value*	
OCT	
machine	
Subgroup	 	 Segmentation	 Fixation	 	
Spectralis	 Control	 1/24	(4.2%)	 0	 1	 	
	 DMO	 11/23	(47.8%)	 5	 6	 <0.01	
	 nAMD	 22/26	(84.6%)	 19	 12	 <0.01	
Triton	 Control	 2/24	(8.3%	 2	 0	 	
	 DMO	 12/23	(52.2%)	 5	 7	 <0.01	
	 nAMD	 13/26	(50%)	 10	 3	 <0.01	
Cirrus	 Control	 2/24	(8.3%)	 2	 0	 	
	 DMO	 8/23	(34.8%)	 3	 2	 0.04	
	 nAMD	 11/26	(42.3%)	 11	 1	 0.01		*P-value	compared	to	control	group	within	OCT	machine	type	DMO=	 diabetic	 macular	 oedema,	 nAMD=	 neovascular	 age-related	 macular	 degeneration,	 n	 =	 number,	 OCT	 =	 optical	 coherence	tomography	
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Comparability	between	OCT	Machines	Significant	differences	were	seen	in	CMT	across	all	three	machines	amongst	the	whole	 cohort	 as	 well	 as	 in	 each	 subgroup.	 The	 CMT	 mean	 measurements	consistently	measured	highest	in	Spectralis,	followed	by	the	Triton	and	then	the	Cirrus,	 showing	 low	 agreement	 between	 machines	 (p<0.05	 in	 all	 group	comparisons)	 (Figure	 4.4).	 These	 differences	 remained	 evident	 even	 after	manual	re-segmentation	of	scans	to	correct	for	IA.	 	
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Figure	4.4:	Average	central	macular	thickness	(CMT)	for	different	groups	and	machines	following	manual	resegmentation.		A	 consistent	 difference	 in	 measurements	 was	 found	 across	 all	 three	 optical	coherence	 tomography	 machines,	 with	 the	 Spectralis	 device	 consistently	recording	the	highest	CMT	values,	followed	by	the	Cirrus	and	the	Triton	devices,	respectively,	in	all	three	groups.	 	
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DISCUSSION	In	this	study,	there	was	good	repeatability	of	OCT	scans	in	both	healthy	eyes	as	well	 as	 those	with	 nAMD	 and	DMO.	However,	 there	was	 a	 significantly	 higher	rate	 of	 IA	 in	 eyes	 with	 pathology,	 reducing	 the	 reliability	 of	 scans	 in	 these	settings.	Additionally,	CMT	measurements	were	not	comparable	between	 these	three	machines,	with	poor	agreement	of	 values	 in	healthy	eyes	and	 those	with	pathology.	Recorded	CMT	was	highest	 in	 the	 Spectralis,	 followed	by	 the	Cirrus	and	then	the	Triton	in	all	groups.		Similarly,	 previous	 studies	 have	 demonstrated	 good	 reliability	 and	reproducibility	of	 a	number	of	 SD-OCT	machines	 in	 calculating	CMT	 in	healthy	eyes,	including	the	Spectralis	and	Cirrus.	[150,	246,	247,	250,	252]	Additionally,	differences	have	been	demonstrated	between	OCT	machines	in	both	healthy	eyes	as	 well	 as	 those	 with	 pathology.	 [150,	 206,	 245-247,	 249-252,	 254]	 However,	these	studies	included	eyes	with	only	one	form	of	pathology	or	mixed	pathology	with	small	sample	sizes	and	no	subgroups	analyses.	Only	one	study	by	Ho	et	al	performed	a	subgroup	analysis	across	differing	pathology,	corrected	 for	 IA	and	re-performed	analyses	finding	a	similar	effect	of	pathology	on	IA.	[245]			Outer	 retinal	 pathology	 such	 as	 subretinal	 fibrosis,	 drusen	 and	 geographic	atrophy	 encountered	 in	 nAMD	were	more	 likely	 to	 result	 in	 segmentation	 IA.	This	 was	 most	 evident	 in	 the	 Spectralis	 which	 generated	 differing	 automated	segmentation	on	repeated	scans	 in	 this	group.	Eyes	with	gross	central	macular	thickening	were	more	likely	to	have	fixation	IA,	likely	due	to	loss	of	detection	of	the	normal	foveal	contour.		
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	Variances	in	CMT	measured	may	be	partly	explained	by	different	hardware.	The	Triton	utilizes	SS-OCT	to	obtain	images,	compared	with	the	Cirrus	and	Spectralis	which	 both	 use	 SD-OCT.	 The	 differences	 in	 technology	 between	 these	 systems	are	reviewed	elsewhere.	[260]		Additionally,	 each	 of	 these	 machines	 utilizes	 different	 software	 to	 analyze	obtained	 images.	 Identification	 of	 the	 outer	 retinal	 border	 differs	 between	machines	 as	 a	 line	 above,	 through,	 or	 below	 the	 retinal	 pigment	 epithelium	(RPE)	thus	affecting	the	CMT	measurement.	[252]	This	can	also	lead	to	differing	rates	 of	 IA,	 especially	 in	 nAMD,	 which	 affects	 the	 Bruch’s-RPE	 complex.	 [261]	Scale	calibration	may	also	be	an	issue	with	differing	standards	for	what	defines	1µm	 on	 a	 scan.	 This	 can	 be	 critical	 as	 prognosis,	 classification	 and	 treatment	guidelines	 for	 a	 wide	 range	 of	 retinal	 pathology	 may	 depend	 on	 these	measurements.	 [255,	 262]	 Fovea	 finding	 algorithms,	 as	 well	 as	 eye	 tracking	software	also	differs,	affecting	rates	of	fixation	IA.	[263]			Updates	 in	 software	 may	 reduce	 IA	 but	 make	 comparisons	 between	 different	versions	 unreliable.	 An	 industry	 standard	 for	 measurement	 formulas	 and	calibrated	segmentation	algorithms	across	all	available	OCT	devices	would	help	address	these	issues.	[245]		There	may	be	a	role	for	a	conversion	formula	to	allow	for	better	comparability	of	macular	thickness	measurements	across	different	OCT	for	different	pathologies,	as	has	been	described	by	others.	[264]	Indeed,	a	conversion	formula	was	utilised	
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in	 the	 Diabetic	 Retinopathy	 Clinical	 Research	 network	 Protocol	 T	 study	 to	compare	the	time	domain	and	SD-OCT	devices	used	in	the	study.	[255]	However,	these	formulae	would	need	to	be	verified	with	each	update	in	imaging	software	to	ensure	accuracy	and	validity.		The	strengths	of	this	study	are	that	all	scans	for	each	patient	were	formed	on	the	same	 day,	 eliminating	 the	 effects	 of	 temporal	 changes	 on	 pathology.	 The	 data	was	collected	prospectively	with	a	defined	protocol	and	evaluates	the	new	Triton	SS-OCT,	which	has	not	been	studied	for	these	purposes.			The	pathologies	evaluated	 in	 this	study	are	 limited	 to	nAMD	and	DMO.	A	more	complete	comparison,	including	vitreomacular	interface	pathology,	high	myopia,	retinal	degenerations	as	well	as	segmentation	of	individual	retinal	layers,	would	be	 valuable.	Whilst	 including	 patients	 able	 to	 fixate	 on	 a	 target	minimised	 the	effects	 of	 fixation	 errors,	 this	 may	 be	 a	 source	 of	 selection	 bias,	 limiting	 the	application	of	 these	 findings.	Furthermore,	 controls	were	not	age-matched	and	there	was	no	sample	size	calculated	for	this	study.		These	 study	 findings	 validate	 the	 presence	 of	 inter-device	 measurement	variability	 and	 how	 reliability	 can	 be	 further	 affected	 by	 retinal	 pathology.	Consequently,	 care	 should	be	exercised	when	 interpreting	measurements	 from	different	 OCT	 devices	 in	 clinical	 practice	 and	 research	 settings.	 Investigators	should	 be	 aware	 of	 the	 high	 rates	 of	 IA	 that	 occur	 in	 DMO	 and	 nAMD	 and	consider	 manual	 correction	 of	 these	 errors	 in	 order	 to	 accurately	 report	quantitative	 measurements.	 Further	 in-depth	 studies	 are	 required	 to	 evaluate	
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the	 reliability	 of	 OCT	 machines	 when	 performing	 scans	 in	 participants	 with	poorer	vision	and	other	ocular	and	retinal	pathology.	 	
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Chapter	5:	Ultrawidefield	fluorescein	angiography	predictors	of	response	to	switch	to	aflibercept	in	persistent	diabetic	macular	oedema		Identification	of	morphological	biomarkers	are	important	for	prognosis	and	can	guide	management	of	DMO.	As	discussed	in	Chapter	3,	OCT	biomarkers	correlate	well	with	vision	and	ultrawidefield	imaging	of	the	retina	allows	for	more	accurate	grading	of	severity	of	diabetic	retinopathy.		This	chapter	explores	the	utility	and	significance	of	ultrawidefield	fluorescein	angiography	in	these	patients	with	persistent	DMO.	Peripheral	ischaemia	is	thought	to	be	an	important	pathological	process	in	the	development	and	progression	of	DMO	and	may	be	associated	with	persistent	DMO.			 	
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ABSTRACT	
Purpose	To	explore	the	effect	of	peripheral	ischaemia	identified	on	ultrawidefield	fluorescein	angiography	(UWFA)	as	a	biomarker	of	response	to	switch	in	therapy	from	bevacizumab	to	aflibercept	in	persistent	diabetic	macular	oedema	(DMO).			
Methods	Prospective,	non-controlled	clinical	trial	of	38	eyes	from	38	patients	with	persistent	DMO	despite	previous	treatment	with	bevacizumab.	All	patients	were	switched	to	therapy	with	aflibercept	following	a	loading	dose	protocol	and	followed	up	for	48	weeks.	UWFA	images	were	obtained	on	all	patients	at	baseline	and	at	conclusion	of	the	trial.	UWFA	images	were	graded	for	non-perfusion	and	used	to	calculate	an	overall	ischemic	index	(II)	and	a	macular	ischaemic	index	(MII).	II	was	compared	with	the	primary	visual	and	central	macular	thickness	(CMT)	outcomes	as	well	as	OCT	biomarkers	including	inner	segment	ellipsoid	band	disruption,	external	limiting	membrane	disruption,	morphology	of	DMO	and	disoragnisation	of	the	inner	retinal	layers.	Paired	and	independent	samples	t-tests	and	Fisher’s	exact	tests	were	used	to	assess	change	and	associations.		
Results	There	was	a	significant	overall	improvement	in	vision	(4.0	±	7.2	letter	gain,	p=0.002)	and	CMT	(-60	±	111μm	difference,	p=0.002)	in	the	38	patients	with	UWFA	data.	Patients	with	an	II	greater	than	or	equal	to	50%	at	baseline	had	a	poorer	baseline	visual	acuity	(60.1	±	10.2	vs.	70.7	±	9.0	letters,	p=0.005)	and	a	
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worse	MII	(6.9	±	25	vs	56	±	52%,	p<0.001).	These	patients	gained	significantly	more	letters	of	vision	at	48	weeks	(8.3	±	9.3	vs.	2.6	±	5.9	letters,	p=0.03).	At	48	weeks,	there	was	no	significant	difference	in	absolute	visual	acuity	in	patients	with	an	II	greater	than	or	equal	to	50%	compared	to	those	with	an	index	less	than	50%	(68.4	±	6.0	vs.	73.3	±	9.6	letters,	p=0.16).	There	was	no	correlation	between	II	with	CMT	or	any	OCT	biomarker.		
Conclusion	Patients	with	persistent	DMO	previously	treated	with	bevacizumab	with	a	worse	ischemic	index	had	poorer	baseline	visual	acuity,	potentially	due	to	worse	macular	ischaemia.	Despite	this,	these	patients	had	a	greater	visual	gain	with	similar	final	visual	outcomes	compared	to	those	without	marked	peripheral	ischaemia	subsequent	to	switching	to	aflibercept.		 	
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BACKGROUND	Ocular	imaging	is	a	cornerstone	of	diagnosis	and	management	of	diabetic	macular	oedema	(DMO).	Historically,	fluorescein	angiography	(FA)	has	played	a	pivotal	role	in	qualifying	vascular	leakage	and	guiding	therapy	for	DMO.	[35]	In	the	past	two	decades,	optical	coherence	tomography	(OCT)	has	revolutionised	diagnosis	of	DMO,	as	well	as	led	to	the	identification	of	prognostic	biomarkers	such	as	distribution	of	oedema,	disruption	to	the	inner	segment	ellipsoid	(ISe)	band	and	external	limiting	membrane	(ELM),	and	disorganisation	of	the	inner	retinal	layers	(DRIL).	[178-181]		More	recently,	ultrawidefield	(UW)	imaging	enabled	documentation	of	peripheral	lesions,	leading	to	more	detailed	description	of	disease	severity	and	prognosis	of	progression.	[233,	242]	When	combined	with	FA,	ultrawidefield	fluorescein	angiography	(UWFA)	has	been	shown	to	identify	3.9	times	more	nonperfusion,	1.9	times	more	neovascularization,	and	1.1	times	more	retinal	pathology	as	compared	with	standard	7-fields	photography.	[234]			Peripheral	ischaemia	may	be	quantified	through	the	calculation	of	an	ischaemic	index	(II).	[265]	Such	an	index	gives	a	ratio	of	non-perfused	to	perfused	retina	and	has	been	shown	to	be	associated	with	the	prevalence	of	DMO	in	a	retrospective	study	of	122	eyes	(OR	3.75,	95%CI	1.26-11.13,	p<0.02).	[191]	Furthermore,	DMO	that	is	recalcitrant	to	macular	photocoagulation	was	found	to	be	associated	with	a	worse	II	in	a	retrospective	study	of	148	eyes	with	persistent	DMO.	[176]	These	patients	also	required	a	greater	number	of	treatments	with	macular	laser	photocoagulation	and	had	a	lesser	reduction	in	the	CMT.	
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	It	is	unclear	what	prognostic	information	can	be	gained	from	UWFA	for	patients	with	DMO	being	treated	with	anti-VEGF	drugs.	Herein	we	report	the	prognostic	value	of	UWFA	from	a	prospective	clinical	trial	where	patients	with	persistent	DMO	were	switched	from	bevacizumab	to	aflibercept.			 	
	 -153-	
METHODS	
Participants	Full	inclusion	and	exclusion	criteria	for	the	patients	enrolled	in	this	trial	were	reported	in	Chapter	3.			
Image	Acquisition	UWFA	images	were	acquired	using	the	Optos	200TX	(Optos	Plc,	Dunfermline,	Scotland).	An	intravenous	bolus	of	5mL	of	10%w/v	fluorescein	was	given	and	images	were	obtained	in	the	transit	phase	(up	to	45	seconds)	arteriovenous	phase	(1	to	2	minutes)	and	during	recirculation	(up	to	10	minutes).	A	single	best	image	from	the	arteriovenous	phase	of	the	study	eye	was	selected	for	grading.			
Calculation	of	ischaemic	index	The	ischaemic	index	was	calculated	using	the	concentric	rings	method	previously	described.	[266]	Briefly,	UWFA	images	for	each	patient	at	baseline	and	48	weeks	were	overlaid	with	the	template	of	seven	concentric	rings	(Figure	5.1)	as	supplied	in	the	supplement	to	the	publication	by	Nicholson	et	al.	[266]	Using	ImageJ	software	(NIH,	Bethesda,	Maryland),	the	template	was	resized	and	repositioned	for	each	image	such	that	the	innermost	ring	was	equal	in	size	to	the	optic	disc	and	the	central	point	of	the	template	was	placed	at	the	fovea.	Each	of	these	seven	rings	was	divided	into	12	equal	segments	subtending	an	angle	of	30	degrees	at	the	fovea.	Each	segment	was	graded	as	perfused,	non-perfused	or	non-gradable	if	more	than	half	of	the	segment	consisted	of	one	of	the	three.	Grading	was	validated	by	an	independent	external	grader.	Areas	with	scatter	
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laser	were	deemed	not	gradable	and	were	excluded	from	the	calculation	of	the	index.		The	II	was	calculated	from	the	grading	by	multiplying	each	segment	by	the	total	disc	area	represented	and	then	dividing	non-perfused	retina	by	the	total	gradable	area.	The	macular	ischaemic	index	(MII)	was	calculated	from	the	12	sectors	comprising	the	innermost	ring	of	the	template.	
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Figure	5.1:	Ultrawidefield	fluoresecein	angiography	with	concentric	rings	overlay.		The	size	of	the	centre-most	ring	is	calibrated	to	the	size	of	the	optic	nerve	and	repositioned	at	the	fovea.	Each	sector	is	then	graded	and	calculated	in	relation	to	disc	area.	
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Optical	Coherence	Tomography	Grading	Images	were	graded	for	morphology	of	DMO	(intraretinal	fluid	and/or	subretinal	fluid),	presence	or	absence	of	disorganization	of	the	inner	retinal	layers	(DRIL),	inner	segment	ellipsoid	(ISe)	band	disruption,	external	limiting	membrane	(ELM)	disruption	in	a	1mm	area	centred	around	the	fovea	as	described	in	Chapter	3.			
Statistical	Analysis	All	statistical	tests	were	performed	and	figures	produced	using	IBM	SPSS	software	(version	22;	SPSS	Inc,	Chicago,	Illinois,	USA).	Patients	were	grouped	by	baseline	II	greater	than	or	less	than	or	equal	to	50%.	Data	was	confirmed	to	be	distributed	normally	using	Shapiro-Wilk	tests.	Homogeneity	of	data	was	confirmed	using	Levene’s	test	for	all	independent	samples’	t-tests.	Adjustment	was	made	to	the	analysis	using	the	Welch-Satterthwaite	method	for	data	that	was	not	homogenous.	Fisher’s	exact	test	was	used	to	analyse	categorical	data	when	sample	sizes	in	groups	were	small.	Pearson’s	correlation	coefficient	was	calculated	for	correlation	analyses.	For	all	analyses,	a	p-value	of	less	than	0.05	was	considered	to	be	statistically	significant.			 	
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RESULTS	Of	the	43	patients	recruited,	one	withdrew	consent	after	the	baseline	visit,	one	was	withdrawn	due	to	a	retinal	detachment	in	the	study	eye	after	the	second	injection,	three	did	not	have	UWFA	performed	at	baseline	and	six	did	not	have	UWFA	performed	at	48-weeks.			BCVA	improved	by	a	mean	±	standard	deviation	of	4.0	±	7.2	letters	(p=0.002)	and	CMT	reduced	by	60	±	111μm	(p=0.002)	in	the	38	patients	with	UWFA	data	at	baseline	over	the	48-week	study	period.			There	was	no	significant	change	in	mean	II	(24.9	±	32.5%	to	22.7	±	29.7%,	p=0.36)	or	MII	(8.1	±	23.5%	to	7.9	±	19.7%,	p=0.88)	from	baseline	to	48-weeks.	There	was	correlation	between	II	and	MII	at	baseline	(r=0.66,	p<0.001)	and	at	48-weeks	(r=0.57,	p<0.001).		Patients	with	an	II	greater	than	50%	(n=9)	at	baseline	had	a	poorer	baseline	visual	acuity	(60.1	±	10.2	vs.	70.7	±	9.0	letters,	p=0.005;	Figure	5.2a)	and	a	worse	MII	(6.9	±	25%	vs	56	±	52%,	p<0.001).	These	patients	gained	significantly	more	letters	of	vision	at	48	weeks	(8.3	±	9.3	vs.	2.6	±	5.9	letters,	p=0.03).	At	48	weeks,	there	was	no	significant	difference	in	absolute	visual	acuity	in	patients	with	an	II	greater	than	50%	compared	to	those	with	an	index	less	than	or	equal	to	50%	(68.4	±	6.0	vs.	73.3	±	9.6	letters,	p=0.16;	Figure	5.2b).		 	
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Figure	5.2.	Boxplot	showing	(a)	baseline	and	(b)	48-week	visual	acuities	grouped	by	baseline	ischaemic	index	 	
A 
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There	was	no	difference	in	CMT	at	baseline	or	48-weeks	for	patients	with	an	II	greater	than	50%	at	baseline	compared	with	those	less	than	or	equal	to	50%	(429	±	61μm	vs.	412	±	101μm,	p=0.63	and	395	±	112μm	vs.	343	±	107μm	p=0.22,	respectively;	Figure	5.3).	There	was	no	difference	in	change	in	CMT	for	patients	with	an	II	greater	than	50%	(-34	±	73μm	vs.	-68	±	120μm,	p=0.42).			There	was	no	significant	correlation	between	II	and	HbA1c	(r=0.16,	p=0.40),	duration	of	diabetes	(r=0.25,	p=0.13),	or	number	of	previous	anti-VEGF	injections	for	DMO	(r=-0.31,	p=0.06).		There	was	no	correlation	between	II	or	MII	and	presence	of	subretinal	fluid,	disorganization	of	the	inner	retinal	layers,	external	limiting	membrane	or	inner	segment	ellipsoid	band	disruption	(data	not	shown).		 	
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Figure	5.3.	Boxplot	showing	(a)	baseline	and	(b)	48-week	central	macular	thickness	grouped	by	baseline	ischaemic	index		 	
A 
B 
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DISCUSSION	Among	patients	with	persistent	DMO	and	significant	prior	treatment	with	bevacizumab,	a	worse	baseline	II	was	associated	with	a	poorer	baseline	visual	acuity.	However,	these	patients	gained	more	vision	and	had	a	similar	final	visual	acuity	to	those	with	a	lower	II	when	therapy	was	switched	to	aflibercept.			Visual	acuity	is	dependent	on	the	health	of	the	macula,	both	in	the	available	blood	supply	as	well	as	the	integrity	of	the	various	cells	involved	in	phototransduction.	In	this	study,	visual	acuity	was	not	associated	with	a	thicker	CMT	but	with	worse	macular	ischaemia.	Recent	studies	utilising	OCT	angiography	have	identified	a	negative	correlation	between	macular	capillary	density	and	visual	acuity.	[267]	OCT	biomarkers	such	as	ISe	band	and	ELM	disruption,	DRIL	and	presence	of	subretinal	fluid	are	all	associated	with	a	poorer	visual	acuity.	[178-181]	Whilst	ischaemia	may	be	postulated	to	explain	these	structural	abnormalities,	presence	of	these	factors	did	not	correlate	with	macular	ischaemia	in	this	study.			There	are	several	potential	explanations	for	a	greater	gain	in	vision	for	the	patients	with	a	higher	baseline	II.	Firstly,	the	starting	visual	acuity	was	significantly	lower,	meaning	that	there	was	more	potential	for	vision	gain.	Secondly,	there	may	be	a	“ceiling	effect”,	to	the	amount	of	vision	that	can	be	gained	in	this	cohort	of	patients	with	persistent	DMO.	Finally,	ischaemia	and	hypoxia	are	strongly	implicated	in	the	pathogenesis	of	DMO.	Thus	areas	of	untreated	retinal	non-perfusion	may	stimulate	the	production	of	mediators	such	as	VEGF-A	and	placental	growth	factor	(PlGF)	that	contribute	to	the	formation	
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and	persistence	of	DMO.	These	factors	may	be	more	effectively	inhibited	by	aflibercept,	leading	to	improved	outcomes	in	these	patients.	[226]		It	has	been	hypothesised	that	scatter	photocoagulation	to	areas	of	peripheral	ischaemia	may	help	in	the	management	of	DMO.	Complete	resolution	of	macular	edema	following	panretinal	photocoagulation	was	demonstrated	in	a	case	series	of	17	eyes	with	florid	proliferative	DR	and	DMO.	[268]	Worsening	of	DMO	was	reduced	over	a	period	of	six	months	in	a	clinical	trial	of	52	patients	randomised	to	a	single	dose	of	bevacizumab	either	with	or	without	targeted	photocoagulation.	[269]	Reduced	levels	of	VEGF	in	the	eye	following	panretinal	photocoagulation	(PRP)	may	be	responsible	for	this	effect.	[2]	However,	PRP	is	also	known	to	exacerbate	macular	oedema	likely	through	transient	increases	in	inflammatory	cytokines	and	VEGF.	[270,	271]		Most	recently,	monotherapy	with	ranibizumab	was	shown	to	have	similar	outcomes	to	combination	therapy	with	ranibizumab	and	targeted	laser	photocoagulation	in	a	three	year,	randomised	trial	of	40	eyes	from	29	patients	with	DMO	and	significant	peripheral	ischaemia.	[272]	There	were	no	differences	in	treatment	burden	or	visual	or	anatomical	outcomes.	The	authors	suggested	areas	of	non-perfusion	may	represent	dead	rather	than	stressed	tissue	and	thus	do	not	contribute	to	increased	production	of	factors	driving	DMO.	This	is	similar	to	the	outcomes	presented	in	the	RELATE	study,	where	patients	with	branch	and	central	retinal	vein	occlusion	who	were	randomised	to	intravitreal	ranibizumab	therapy	with	targeted	scatter	laser	had	similar	vision	and	anatomical	outcomes	to	those	treated	with	ranibizumab	monotherapy.	[273]		
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	Contrary	to	Wessel	et	al,	we	did	not	find	any	correlation	between	diabetes	control	and	II,	nor	did	we	find	a	relationship	between	duration	of	diabetes	and	II.	[191]	However,	there	was	borderline	significant	negative	correlation	between	number	of	previous	injections	and	II.	This	may	be	due	to	a	disease	modifying	effect	of	anti-VEGF	drugs	slowing	the	progression	of	retinal	non-perfusion	as	was	demonstrated	in	patients	treated	with	ranibizumab	in	a	retrospective	analysis	of	the	RISE/RIDE	studies.	[274]	Whilst	UWFA	was	not	used	in	the	quantification	of	this,	it	may	explain	the	lack	of	change	in	II	from	baseline	to	48	weeks	in	the	participants	of	our	study	who	were	treated	with	8	injections	of	aflibercept	during	the	study	period.	Other	authors	have	presented	data	suggesting	a	reversal	of	areas	of	non-perfusion.	[275]	Ischaemic	index	was	reduced	in	a	pilot	study	of	nine	eyes	with	DMO	treated	with	the	dexamethasone	implant	over	a	12-week	period.	[276]		The	strengths	of	this	study	are	in	the	prospective	and	standardised	nature	of	data	collection	in	a	clinical	trial	setting.	The	trial	participants	received	the	per	protocol	treatment	during	the	study	period	and	had	retinal	imaging	performed	at	standardised	time	points.	The	methodology	for	grading	ischaemia	has	been	previously	validated.			There	are	inherent	limitations	in	the	data	and	analyses	performed	due	to	lack	of	a	control	arm	as	well	as	a	relatively	small	sample	size	from	a	single	centre.	Furthermore,	correction	for	peripheral	distortion	and	introducing	validated,	
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reliable	computer	based	segmentation	for	the	calculation	of	peripheral	ischaemia	may	yield	more	accurate	results	in	the	future.	[277,	278]		The	exploratory	analyses	from	this	study	demonstrate	that	significant	peripheral	ischaemia	may	correlate	with	poorer	visual	acuity	and	a	greater	capacity	for	vision	improvement	in	patients	with	persistent	DMO	switched	to	aflibercept.	Additionally,	there	appears	to	be	no	clear	association	between	degree	of	peripheral	ischaemia	and	severity	of	macular	oedema,	suggesting	that	other	factors	may	be	involved	in	macular	thickening	in	DMO.	Future	directions	for	these	findings	are	to	assess	the	effect	of	peripheral	ischaemia	as	a	biomarker	of	treatment	response	to	anti-VEGF	drugs	in	treatment	naïve	eyes	as	well	as	those	treated	with	other	modalities	such	as	corticosteroids	that	target	different	pathological	pathways.		 	
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Chapter	6:	Correlation	of	functional	and	morphological	retinal	impairment	in	patients	with	persistent	diabetic	macular	oedema			In	previous	chapters,	objective	anatomical	and	visual	outcomes	of	a	switch	in	therapy	from	bevacizumab	to	aflibercept	have	been	analysed	and	discussed.	One	of	the	challenges	and	limitations	of	clinical	trials	in	ocular	pathology	is	the	quantification	of	functional	outcomes	following	interventions.			The	purpose	of	this	chapter	is	to	explore	both	subjective	and	objective	functional	outcomes	from	these	patients	and	to	explore	associations	with	morphological	findings.			The	material	presented	in	this	chapter	is	under	peer-review	for	publication	and	is	reproduced	from:		
Bahrami	B,	Nair	R,	Spooner	K,	Hong	T,	Chang	A.	Correlation	of	functional	and	morphological	retinal	impairment	in	patients	with	persistent	diabetic	macular	edema.	Graefe’s	Archive	for	Clinical	and	Experimental	Ophthalmology	Under	
review	April	29th	2018		
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Additionally,	preliminary	data	from	this	chapter	was	presented	at	the	RANZCO	48th	Annual	Scientific	Conference:	Melbourne,	Australia,	2016	as:		Nair	R,	Bahrami	B,	Spooner	K,	Hong	T,	Chang	A.	Assessing	changes	in	macula	microperimetry	among	patients	with	treatment	resistant	diabetic	macular	oedema	switched	to	intravitreal	aflibercept	over	12	months.	Clin	Exp	Ophthalmol.	2016	Nov;	44	(S1):80-140.		 	
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ABSTRACT	
Purpose	To	evaluate	subjective	and	objective	functional	outcomes	in	patients	with	persistent	diabetic	macular	oedema	(DMO)	switched	from	bevacizumab	to	aflibercept	and	to	correlate	these	with	retinal	morphological	abnormalities.		
Methods	Prospective	clinical	trial	of	43	eyes	from	43	patients	with	persistent	DMO.	All	patients	were	switched	from	bevacizumab	to	aflibercept	with	a	loading	dose	protocol	and	were	followed	up	for	48	weeks.	Microperimetry	(MAIA,	Centervue,	Padova,	Italy)	was	performed	at	baseline	and	48	weeks	using	a	4-2-1	strategy	for	the	central	10	degrees	of	vision.	Bivariate	correlation	analyses	were	calculated	using	Pearson’s	correlation	coefficient	for	vision	and	central	macular	thickness	(CMT).	Independent	samples	t-tests	were	used	to	compare	OCT	biomarkers	to	macular	sensitivity.	The	National	Eye	Institute	Visual	Functioning	Questionnaire	25	(VFQ-25)	was	used	to	assess	vision-related	quality	of	life	at	baseline,	24-	and	48	weeks.	Changes	in	composite	and	subscale	score	were	assessed	using	paired	t-tests.	The	relationship	between	composite	questionnaire	scores	and	BCVA,	CMT	and	macular	sensitivity	were	assessed	using	Pearson’s	correlation	coefficient.		
Results	There	was	an	improvement	in	BCVA	(3.7	±	7.2	letters,	p=0.002)	and	CMT	(58	±	112μm	reduction,	p=0.002)	in	these	patients	over	the	48-week	study	period.	Average	threshold	sensitivity	and	BCVA	correlated	at	baseline	and	48-weeks	
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(r=0.72,	p<0.001	and	r=0.62,	p<0.001	respectively).	There	was	negative	correlation	between	average	threshold	and	CMT	at	baseline	and	48-weeks	(r=-0.35,	p=0.02	and	r=-0.37,	p=0.03	respectively).	Average	threshold	was	poorer	in	the	presence	of	subretinal	fluid,	inner	segment	ellipsoid	band	and	external	limiting	membrane	disruption	at	baseline	and	48-weeks	and	for	disorganization	of	the	inner	retinal	layers	at	48-weeks.	There	was	no	significant	difference	between	baseline	and	24-week	and	48-week	VFQ	composite	scores	(0.7	±	11.0,	p=0.72	and	-0.2	±	9.1,	p=0.94	respectively).	VFQ	composite	scores	did	not	correlate	with	BCVA	or	CMT.	VFQ	composite	score	correlated	with	average	6-degree	macular	sensitivity	threshold	at	baseline	(r=0.36,	p=0.05)	and	48	weeks	(r=0.56,	p=0.006).		
Conclusion	There	is	good	correlation	between	macular	sensitivity	and	visual	acuity	in	patients	with	persistent	DMO.	Sensitivity	thresholds	correlated	with	the	presence	of	OCT	biomarkers	and	negatively	with	CMT.	Microperimetry	may	correlate	with	vision	related	quality	of	life	and	function	in	patients	with	persistent	DMO.		 	
	 -169-	
BACKGROUND	There	has	been	a	paradigm	shift	in	the	management	of	diabetic	macular	edema	(DMO)	through	the	introduction	of	intravitreal	anti-vascular	endothelial	growth	factor-A	(VEGF)	drugs.	As	with	most	studies	in	ophthalmic	research,	assessment	of	functional	change	in	these	trials	is	largely	limited	to	the	measurement	of	visual	acuity.	Whilst	this	is	an	easily	measured	and	useful	objective	outcome,	other	functional	aspects	of	vision	may	be	of	value	when	assessing	response	to	treatments.		Vision	related	quality	of	life	assessments	are	one	subjective	measure	of	functional	change	and	have	been	reported	in	landmark	trials	of	anti-VEGF	for	the	management	of	DMO	such	as	RISE/RIDE	and	VISTA/VIVID.	[259,	279]	Other	objective	measurements	generally	not	reported	in	these	larger	trials	include	contrast	sensitivity,	electroretinography,	reading	speed	and	microperimetry.	[280]	Such	objective	functional	measures	may	be	of	increasing	importance	in	diabetic	retinopathy	where	neuronal	and	retinal	sensitivity	changes	can	predate	vascular	changes	such	as	microaneurysms	and	haemorrhages	that	can	be	detected	on	clinical	examination.	[281,	282]	However,	these	may	be	limited	by	access	to	devices,	expense,	and	the	time	consuming	and	invasive	nature	of	some	of	these	tests.		Microperimetry	allows	the	retinal	sensitivity	of	a	patient	to	be	mapped	onto	an	image	of	the	fundus	using	a	scanning	laser	ophthalmoscope.	Thus,	it	allows	for	topographical	correlation	between	function	of	the	central	retina	and	pathology	present.	Macular	sensitivity	quantified	with	microperimetry	has	been	shown	to	
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correlate	with	visual	acuity	as	well	as	macular	thickness	measurements	in	DMO.	[283]	Furthermore,	OCT	biomarkers	such	as	inner	segment	ellipsoid	band	disruption	have	been	shown	to	overlap	with	focal	scotomas	and	impaired	macular	sensitivity	in	DMO	as	well	as	other	conditions	such	as	age-related	macular	degeneration	(AMD)	and	retinitis	pigmentosa.	[284-286]	Whilst	data	correlating	microperimetry	findings	and	vision	related	quality	of	life	in	DMO	are	lacking,	a	relationship	has	been	found	in	patients	with	retinitis	pigmentosa.	[287]	This	suggests	information	gained	from	microperimetry	may	explain	subjectively	reported	visual	function	that	is	discordant	with	DMO	observed	on	clinical	examination.		In	this	study	we	present	secondary	functional	outcomes	from	a	cohort	of	patients	prospectively	switched	from	bevacizumab	to	aflibercept	for	the	management	of	persistent	DMO	and	correlate	these	with	primary	visual	and	structural	outcomes.			 	
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METHODS	
Study	Design	The	methods,	inclusion	and	exclusion	criteria	for	this	open-label,	non-randomised	clinical	trial	have	been	previously	described	in	Chapter	3.			
Microperimetry	Microperimetry	was	performed	at	baseline	and	48-weeks	using	the	MAcular	Integrity	Assessment	(Figure	6.1,	MAIA;	Centervue,	Padova,	Italy)	microperimeter.	This	device	uses	a	scanning	laser	ophthalmoscope	(SLO)	to	obtain	a	retinal	image	and	track	eye	movements	during	measurement.	A	pre-programmed	method	was	used	to	obtain	sensitivity	measures	(“Expert	Examination”),	which	used	a	4-2-1	staircase	strategy	on	a	grid	consisting	of	three	concentric	circles	of	2,	6	and	10	degrees	in	diameter.	Background	luminance	was	4	asb,	the	size	of	the	stimulus	used	was	Goldman	III,	presentation	time	was	200ms	and	the	dynamic	range	of	stimuli	ranged	from	0	to	36	decibels	(dB).	A	total	of	37	points	were	assessed	using	this	method	and	the	output	of	the	examination	reports	the	sensitivity	of	each	of	these	points	with	the	image	obtained	by	the	SLO	(Figure	6.2).	The	follow-up	examinations	were	tracked	such	that	the	same	anatomical	points	were	assessed	at	the	baseline	visit	and	the	48-week	time	point.		Outcomes	analysed	included	the	threshold	of	the	central	foveal	point,	average	threshold	of	all	37	points	tested	and	the	average	threshold	of	the	central	13	points	corresponding	with	the	central	two-degree	field	of	vision.	This	area	
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corresponds	to	the	central	ETDRS	ring	which	CMT	and	OCT	biomarkers	were	assessed.		 	
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Figure	6.1:	The	MAIA	microperimeter		(CenterVue,	Padova,	Italy;	image	reproduced	from	https://bit.ly/2Hs8COA)			 	
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Figure	6.2:	Tracked	microperimetry	output	from	the	MAIA	for	a	sample	patient	at	baseline	(left)	and	48-weeks	(right).		The	numbers	represent	the	threshold	sensitivity	for	each	point	in	decibels.	A	topographical	map	is	made	ranging	from	colours	red	to	green	to	corresponds	with	the	sensitivity	in	different	areas	within	the	macula.	The	three	concentric	rings	represent	an	angle	of	2,	6	and	10	degrees	from	fixation. 	 	
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Self-reported	Vision	Function	and	Quality	of	Life	The	National	Eye	Institute	Visual	Functioning	Questionnaire-25	(VFQ-25)	was	distributed	and	collected	from	patients	at	baseline,	24-	and	48-week	time	points.	This	vision	related	quality	of	life	questionnaire	assesses	general	health,	general	vision,	ocular	pain,	near	vision	activities,	distance	vision	activities,	social	functioning,	vision-specific	role	difficulties,	vision-specific	mental	health,	dependency	due	to	vision,	driving,	peripheral	vision	and	color	vision.	The	results	from	this	questionnaire	were	converted	to	a	composite	score,	which	includes	all	subscales	except	general	health,	and	analysed	in	accordance	with	published	guidelines.	[288]			
Statistical	Analyses	Statistical	analyses	were	performed	and	figures	created	using	IBM	SPSS	software	(version	22;	SPSS	Inc,	Chicago,	Illinois,	USA).	Normal	distribution	of	data	was	confirmed	using	Shapiro-Wilk	tests.	Paired	t-tests	were	used	to	compare	differences	in	means	of	BCVA,	CMT,	composite	and	subscale	scores	in	the	VFQ-25,	and	change	in	sensitivity	measurements	obtained	with	microperimetry.	Independent	samples’	t-tests	were	used	to	analyse	microperimetry	outcomes	grouping	by	presence	of	OCT	biomarkers	and	grouping	patients	as	good	responders	(gain	of	1	line	of	vision	or	greater)	in	analysis	of	VFQ-25	data.	Data	was	tested	for	homogeneity	using	Levene’s	test	and	if	variances	were	unequal,	adjustment	was	made	to	the	analysis	using	the	Welch-Satterthwaite	method.	Bivariate	Pearson’s	correlation	coefficient	was	calculated	to	assess	relationships	
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between	continuous	variables.	For	all	analyses,	a	p-value	of	less	than	0.05	was	considered	to	be	statistically	significant.			 	
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RESULTS	
Microperimetry	Outcomes	MAIA	microperimetry	was	completed	by	43	patients	at	baseline	and	36	patients	at	48-weeks.	Baseline	values,	change	and	correlation	with	BCVA	and	CMT	are	summarised	in	Table	6.1.	Average	threshold	values	were	lower	for	those	patients	who	had	received	grid/focal	laser	in	the	past	at	baseline	(19.6	±	4.3	vs.	22.3	±	3.2,	p=0.02)	but	not	at	48-weeks	(20.6	±	3.1	vs.	22.6	±	3.8,	p=0.11).	There	was	no	correlation	between	average	threshold	at	baseline	and	duration	of	diabetes	(r=0.09,	p=0.58),	HbA1c	(r=-0.20,	p=0.27)	or	number	of	previous	anti-VEGF	injections	(r=-0.04,	p=0.80).	The	associations	between	OCT	biomarkers	with	VA	and	central	six-degree	threshold	are	summarised	in	Table	6.2.			
	 -178-	
Table	6.1:	Microperimetry	outcomes	and	correlation	with	best-corrected	visual	acuity	and	central	macular	thickness	at	baseline	and	48-weeks		
Microperimetry	
Characteristic		
Baseline	value	
(dB),	mean	±	
SD	(n=43)	
Correlation	of	
baseline	value	with	
BCVA	at	baseline	
Change	at	48-weeks	
(dB)	(n=36)	
Correlation	of	48-
week	value	with	BCVA	
at	48-weeks	
Correlation	of	change	
in	value	with	change	in	
BCVA	at	48-weeks		 Mean	± SD	 Pearson’s	correlation	coefficient	 p-value	 Mean	± SD	 p-value	 Pearson’s	correlation	coefficient	 p-value	 Perason’s	correlation	coefficient	 p-value	Average	threshold	 21.2	±	3.9	 0.61	 <0.001	 0.08	±	1.9	 0.79	 0.62	 <0.001	 -0.02	 0.90	Centre	2	degree	threshold	 20.2	±	4.2	 0.63	 <0.001	 0.62	±	2.7	 0.18	 0.59	 <0.001	 -0.16	 0.35	Centre	point	threshold	 19.5	±	6.3	 0.41	 0.01	 0.81	±	4.2	 0.26	 0.40	 0.02	 -0.004	 0.98			
Microperimetry	
Characteristic		
Correlation	of	baseline	
value	with	CMT	at	
baseline	
Correlation	of	48-week	
value	with	CMT	at	48-
weeks	
Correlation	of	change	in	
value	with	change	in	
CMT	at	48-weeks		 Pearson’s	correlation	coefficient	 p-value	 Pearson’s	correlation	coefficient	 p-value	 Pearson’s	correlation	coefficient	 p-value	Average	threshold		 -0.35	 0.02	 -0.37	 0.03	 0.05	 0.76	Centre	2	degree	threshold	 -0.16	 0.35	 -0.43	 0.01	 0.07	 0.67	Centre	point	threshold	 -0.24	 0.17	 -0.42	 0.01	 -0.17	 0.34			 	
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Table	6.2:	Differences	in	visual	acuity	and	central	two-degree	average	threshold	in	the	presence	of	OCT	biomarkers	
Characteristic	 Number	of	
patients	at	
baseline	(n=43)	
Baseline	BCVA	
(letters)	with	
characteristic	
Baseline	BCVA	
(letters)	without	
characteristic	
Difference	(p-
value)	*	
Centre	two-
degree	
threshold	(dB)	
with	
characteristic	
Centre	two-
degree	
threshold	(dB)	
without	
characteristic	
Difference	(p-
value)	*	
Intraretinal	fluid,	n	(%)	 43	(100)	 67.8	 ±	10.1 	 N/A	 N/A	 20.2 ± 4.2	 N/A	 N/A	Subretinal	fluid,	n	(%)	 7	(16)	 60.0	±	8.1	 69.2	±	9.8	 9.2	±	4.0	(p=0.02)	 15.0	±	4.4	 21.0	±	3.6	 6.0	±	1.8	(p=0.002)	ELM	disruption,	n	(%)	 29	(66)	 60.7	±	9.2	 71.2	±	8.8	 10.5	±	2.9	(p=0.001)	 17.7	±	4.2	 21.1	±	3.9	 3.4	±	1.5	(p=0.03)	ISe	band	disruption,	n	(%)	 35	(81)	 65.8	±9.9		 76.3	±	6.0	 10.4	±	3.7	(p=0.007)	 19.2	±	4.1	 23.7	±	2.6	 4.5	±	1.5	(p=0.006)	DRIL,	n	(%)	 35	(81)	 66.3	±	10.2	 74.3	±	6.7	 8.0	±	3.8	
(p=0.04)	
19.8	±	4.1	 21.6	±	4.6	 1.8	±	1.7	(p=0.30)	
	
Characteristic	 Number	of	
patients	at	48-
weeks	(n=41)		
48-week	BCVA	
(letters)	with	
characteristic	
48-week	BCVA	
(letters)	without	
characteristic	
Difference	(p-
value)	*	
Centre	two-
degree	
threshold	(dB)	
with	
characteristic	
Centre	two-
degree	
threshold	(dB)	
without	
characteristic	
Difference	(p-
value)	*	
Intraretinal	fluid,	n	(%)	 32	(78)	 69.7	 ± 9.4	 77.9	± 8.1	 8.2	±	3.5	(p=0.02)	 19.9 ± 4.2	 24.1	±	5.3	 4.2	±	1.8	(p=0.03)	Subretinal	fluid,	n	(%)	 0	(0)	 N/A	 71.5	±	9.7	 N/A	 N/A	 20.8	±	4.7	 N/A	ELM	disruption,	n	(%)	 27	(66)	 68.2	±	8.6	 77.8	±8.6		 9.6	±	2.8	(p=0.002)	 19.3	±	4.4	 23.9	±	3.9	 4.6	±	1.5	(p=0.005)	ISe	band	disruption,	n	(%)	 38	(93)	 71.2	±	10.0	 75.3	±	1.5	 4.2	±	5.8	(p=0.03)	 20.3	±	4.6	 26.3	±	2.5	 6.0	±	2.7	(p=0.04)	DRIL,	n	(%)	 32	(78)	 69.2	±	9.0	 79.7	±	7.5	 10.5	±	3.3	
(p=0.003)	
19.6	±	4.7	 25.2	±	1.1	 5.6	±	1.0	
(p<0.001)	
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CMT=central	macular	thickness,	VMA=vitreomacular	adhesion,	ELM=external	limiting	membrane,	BCVA=best-corrected	visual	acuity,	DRIL=disorganization	of	inner	retinal	layers	*independent	samples	t-test			
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Vision	Function	Questionnaire	Outcomes	The	VFQ-25	was	completed	by	37,	33	and	24	patients	at	baseline,	24-	and	48-weeks	respectively.	Changes	in	composite	and	subscale	scores	at	24-	and	48-weeks	are	summarised	in	Table	6.3	for	patients	with	complete	data	at	these	time	points.	There	was	no	significant	difference	in	any	subscale	or	composite	score	at	any	time	point.	Patients	classified	as	good	responders	(gain	of	greater	than	or	equal	to	five	letters)	did	not	have	a	greater	change	in	composite	score	at	24-	(3.5	±	12.4	vs.	-3.9	±	8.8,	p=0.07)	or	48-weeks	(2.1	±	8.2	vs.	-0.9	±	9.7,	p=0.48).	Patients	in	whom	the	study	eye	was	the	better-seeing	eye	had	similar	composite	scores	to	those	in	which	the	study	eye	was	the	worse-seeing	eye	at	24-	(-0.5	±	10.6	vs.	-1.6	±	13.3,	p=0.82)	and	48-weeks	(-0.7	±	8.7	vs.	8.6	±	11.9,	p=0.18).	There	was	correlation	between	visual	acuity	change	and	change	in	mental	health	(r=0.48,	p=0.007)	and	dependence	(r=0.54,	p=0.002)	subscales	at	24-weeks	and	dependence	(r=0.57,	p=0.005)	and	driving	subscales	(r=0.73,	p=0.001)	at	48-weeks.	No	other	significant	correlations	between	change	in	BCVA	and	composite	score	or	subscales	were	noted.		 	
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Table	6.3:	Changes	in	Visual	Function	Questionnaire-25	scores	during	the	study	period		
VFQ-25	Subscale		 Baseline	
score,	
mean	±	SD	
(n=37)	
Change	at	24-
weeks	(n=33)	
Change	at	48-weeks	
(n=24)	
	 	 Mean	± SD	 p-value	 Mean	± SD	 p-value	Composite	Score	  86.1	±	12.9 	  0.7	± 11.0	 0.729	 -0.2	±	9.1 	 0.935	
Subscales	  	 	 	General	Health	  53.4	±	25.8 	 -1.3	± 16.6	 0.662	 0.9	± 11.5	 0.715	General	Vision	  71.9	±	12.9 	 -3.3	± 21.5	 0.403	 -4.6	± 21.3	 0.329	Ocular	Pain	  88.9	±	16.3 	 1.7	± 18.8	 0.631	 -1.1	± 14.4	 0.715	Near	Activities	  79.7	± 	19.2	 1.7	± 19.0	 0.635	 0.8	± 16.8	 0.835	Distance	Activities	  86.0	± 16.8	 2.2	± 22.7	 0.596	 -0.4	± 16.6	 0.916	Social	Functioning	  92.9	± 14.3	 -1.3	± 12.0	 0.573	 2.3	± 16.2	 0.518	Mental	Health	  82.4	± 18.0	 -0.8	± 17.8	 0.800	 1.1	± 14.9	 0.724	Role	Difficulties	  82.4	± 22.9	 2.5	± 28.1	 0.630	 -2.8	± 17.6	 0.459	Dependence	  95.0	± 13.7	 0.6	± 22.1	 0.891	 0.4	± 13.5	 0.896	Driving	  82.8	± 30.1	 -2.9	± 9.1	 0.119	 -0.9	± 7.8	 0.630	Color	Vision	  88.4	± 30.7	 -4.7	± 25.7	 0.311	 -7.3	± 29.0	 0.231	Peripheral	Vision	  79.3	± 32.5	 -4.7	± 30.7	 0.395	 -8.0	± 37.3	 0.294	VFQ-25=Visual	Function	Questionnaire-25,	SD=standard	deviation.	P-values	reflect	paired	t-test	results.		 	
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Relationship	between	Microperimetry	and	VFQ-25	Average	threshold	correlated	with	VFQ-25	composite	score	at	baseline	(r=0.38,	p=0.02)	but	did	not	reach	statistical	significance	at	48-weeks	(r=0.40,	p=0.06).	Centre	six-degree	threshold	correlated	with	VFQ-25	composite	score	at	baseline	(r=0.36,	p=0.046)	and	48-weeks	(r=0.56,	p=0.01).	Foveal	threshold	correlated	at	baseline	(r=0.37,	p=0.04)	but	not	48-weeks	(r=0.28,	p=0.21).			 	
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DISCUSSION	Functional	vision	is	only	partially	represented	through	visual	acuity	measurements.	Consequently,	patients	with	a	similar	clinical	examination	and	morphology	of	disease	may	report	different	degrees	of	visual	impairment.	Reporting	functional	outcomes	other	than	visual	acuity	that	are	quantifiable	are	important	in	assessing	the	effects	of	treatments	we	administer.			In	this	clinical	trial,	patients	with	recalcitrant	DMO	who	had	received	significant	prior	treatment	were	switched	in	therapy	to	aflibercept.	Whilst	we	demonstrated	statistically	significant	visual	acuity	gains,	these	did	not	correlate	with	a	subjective	overall	improvement	in	reported	vision-related	quality	of	life	(VR-QoL).		This	lack	of	improvement	may	reflect	the	chronic	nature	of	the	disease	in	these	patients	and	is	concordant	with	other	studies	reporting	VR-QoL	in	DMO.	There	was	no	significant	change	in	any	of	the	VFQ-25	subscales	or	composite	score	following	12	months	of	therapy	in	a	study	of	100	patients	with	persistent	DMO	who	were	randomised	to	either	fixed	or	as	needed	dexamethasone	implant.	[289]	Similarly,	a	study	of	20	consecutive	patients	receiving	bevacizumab	for	persistent	DMO	following	vitrectomy	showed	no	change	in	VFQ-25	scores	at	three	months,	althought	this	did	show	a	brief	improvement	in	the	mental	health	subscale	following	the	1-month	review.	[290]			Subscale	correlations	between	change	in	vision	and	mental	health	and	dependency	subscales	at	24-weeks	and	dependency	and	driving	subscales	at	48-
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weeks	reported	in	our	data	may	be	disproportionately	affected	by	an	outlier	which	was	evident	when	data	was	plotted	(data	not	shown).		Whilst	there	was	no	significant	correlation	between	vision	outcome	and	VR-QoL,	there	was	significant	correlation	between	threshold	sensitivities	and	VFQ-25	composite	scores	at	baseline	and	48	weeks.	These	results	suggest	microperimetry	may	help	to	quantify	functional	vision	that	impacts	VR-QoL	not	well	assessed	with	visual	acuity	in	DMO.			Microperimetry	average	threshold	directly	correlated	with	absolute	values	of	BCVA	and	inversely	with	CMT.	This	has	been	consistently	documented	in	DMO.	[283,	291]	However,	despite	an	overall	significant	improvement	in	BCVA	and	CMT,	there	was	no	significant	change	in	overall	average	threshold,	central	six-degree	threshold	or	foveal	point	threshold	from	baseline	to	48-weeks.	These	findings	are	consistent	with	a	study	of	28	patients	with	DMO	who	were	treated	with	micropulse	laser	and	had	microperimetry	performed	at	baseline	and	three	months.	The	investigators	reported	a	significant	improvement	in	both	BCVA	and	CMT	over	this	time	period	but	no	significant	change	in	threshold	sensitivity.	[292]			There	were	further	structural	correlations	with	the	average	threshold	in	the	central	six	degrees	of	vision,	an	area	corresponding	to	the	central	1mm	area	graded	on	OCT.	All	of	the	parameters	evaluated	(presence	of	SRF,	ISe	band	disruption,	ELM	disruption	and	DRIL)	had	a	significant	effect	on	visual	acuity.		
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Subretinal	fluid,	or	neurosensory	detachment	of	the	retina,	had	the	largest	impact	on	threshold	sensitivity.	Accumulation	of	fluid	in	this	space	may	effect	both	the	oxygenation	of	the	photoreceptor	layer	as	well	as	impairing	the	elimination	of	metabolites,	thus	decreasing	sensitivity.	This	was	also	shown	to	have	a	significant	impact	on	retinal	sensitivity	in	DMO	in	a	cross	sectional	study	of	26	eyes.	[293]			The	ISe	band	is	thought	to	correspond	to	the	junction	of	the	inner	and	outer	segments	of	the	photoreceptors.	Disruption	of	this	layer	has	been	strongly	associated	with	poorer	visual	acuity	in	DMO.	[181]	Furthermore,	a	study	utilizing	a	device	capable	of	combined	perimetry	and	OCT	demonstrated	point	disruptions	in	the	ISe	band	corresponded	with	areas	of	lower	retinal	sensitivity	in	DMO.	[284]	The	ELM	has	a	close	relationship	with	the	ISe	band	and	may	correspond	to	the	cell	bodies	of	photoreceptors	and	similar	disruptions	in	this	layer	have	been	associated	with	poorer	sensitivity	in	DMO.	[294]		DRIL	has	shown	strong	association	with	visual	acuity	in	DMO.	[295,	296]	This	biomarker	is	thought	to	correspond	to	anatomical	disruption	in	inner	retinal	cells	such	as	bipolar,	amacrine	or	horizontal	cells,	thus	affecting	phototransduction.	[178]	Whilst	DRIL	was	not	associated	with	poorer	retinal	sensitivity	at	baseline,	there	were	strong	associations	at	the	48-week	follow	up.	Data	regarding	DRIL	and	microperimetry	is	lacking	and	the	associations	observed	here	warrant	further	investigation	in	future	studies.		
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Patients	who	had	received	prior	grid	or	focal	laser	for	DMO	had	a	poorer	average	threshold	that	was	significant	at	baseline	but	not	48-weeks.	The	effect	may	not	have	been	statistically	significant	at	48-weeks	due	to	the	sample	size.		Whilst	grid	laser	has	consistently	been	shown	to	preserve	vision	in	DMO,	this	therapy	may	come	at	the	expense	of	loss	of	central	visual	function.	Grid	laser	has	been	shown	to	impair	central	ten-degree	thresholds	with	both	argon	green	and	krypton	red	laser	in	64	eyes	of	32	patients	with	DMO.	[297]	Furthermore,	whilst	this	effect	was	again	confirmed	with	green	laser,	micropulse	laser	was	shown	to	improve	overall	average	thresholds	in	a	randomised	clinical	study	of	patients	with	DMO.	[298]			The	strengths	of	this	study	are	prospectively	collected	data	from	a	homogenous	group	of	patients	in	a	standardised	manner.	No	other	studies	have	evaluated	correlation	between	subjective	and	objective	functional	outcomes	in	DMO.			This	study	is	limited	by	the	small	sample	size	and	poor	response	rate	in	the	VFQ-25.	Only	25	patients	completed	the	VFQ-25	upon	completing	the	trial	and	a	more	complete	data	set	would	have	added	weight	to	the	results,	especially	changes	in	composite	and	subscale	scores.	The	lack	of	a	control	group	means	conclusions	regarding	functional	effects	of	a	switch	in	therapy	are	limited.	Furthermore,	this	analysis	is	limited	as	structure	and	function	were	assessed	on	separate	devices	and	anatomical	correlation	was	estimated	manually.	Devices	that	can	reliably	correlate	retinal	structure	and	function	may	be	able	to	validate	the	findings	in	this	study.	[284]		
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Future	clinical	studies	should	aim	to	incorporate	other	functional	measures	such	as	microperimetry	to	assess	the	effects	of	treatment.	This	test	is	a	relatively	quick,	non-invasive	and	objective	way	to	measure	functional	outcome	that	may	correlate	with	VR-QoL	as	we	have	shown	here.		 	
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																 Section	3:	In	vitro	effects	of	anti-VEGF	drugs	on	human	retinal	pigment	epithelium				 	
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Chapter	7:	Effects	of	anti-VEGF	drugs	on	human	retinal	pigment	epithelium	under	high	glucose	and	oxidative	stress		The	findings	reported	in	Chapter	3	demonstrated	the	effect	that	anti-VEGF	drugs	have	on	the	regression	of	vascular	lesions	typical	of	DR.	However,	as	highlighted	in	Chapter	1,	neurodegeneration	is	a	feature	of	DR	and	may	be	influenced	by	blockade	of	VEGF.	Clinical	data	regarding	the	effect	of	anti-VEGF	drugs	on	neurodegeneration	in	the	retina	is	conflicting.		The	retinal	pigment	epithelium	is	known	to	secrete	a	large	range	of	neurotrophic	factors	important	to	the	survival	of	neurons	and	potentially	affecting	neurodegeneration.	The	purpose	of	this	chapter	is	to	investigate	the	effects	of	glucose,	hypoxia	and	anti-VEGF	drugs	on	the	production	of	neurotrophic	factors	by	the	retinal	pigment	epithelium	in	an	in	vitro	model	of	DR.			Preliminary	findings	from	this	chapter	are	to	be	presented	at	the	Association	for	Research	in	Vision	and	Ophthalmology	Annual	Meeting	in	Honolulu,	USA,	April-May	2018	as:	
	
Bahrami	B,	Zhu	L,	Zhang	T,	Zhu	M,	Chang	A,	Gillies	MC,	Shen	W.	Effects	of	anti-VEGF	drugs	on	human	retinal	pigment	epithelium	under	oxidative	stress.		 	
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ABSTRACT	
Background:	Retinal	pigment	epithelium	(RPE)	is	known	to	secrete	factors	important	in	retinal	homeostasis.	How	this	secretome	changes	in	diabetic	eyes	treated	with	anti-vascular	endothelial	growth	factor	(VEGF)	drugs	is	unclear.			
Methods:	Diabetic	conditions	were	simulated	in	vitro	using	ARPE-19	cell-line	culture,	with	high	glucose	(25mM)	culture	media	and	chemically	induced	oxidative	stress	using	cobalt	chloride.	Stress	was	assessed	using	cell	viability	assays	as	well	as	Western	blots	and	enzyme-linked	immunosorbent	assay	(ELISA)	for	production	of	HIF-1a	and	VEGF-A.	Once	conditions	were	established,	production	of	neurotrophic	factors	was	quantified	using	ELISA	under	stress	with	and	without	the	addition	of	anti-VEGF	drugs.	Changes	were	analysed	with	one-way	ANOVA.		
Results:	Hypoxia	induced	downregulation	of	pigment	epithelium	derived	factor	(PEDF)	expression.	Under	normoxia,	the	addition	of	bevacizumab,	ranibizumab	and	aflibercept	all	led	to	a	significant	downregulation	of	PEDF.	Glucose	concentration	had	no	effect	on	secretion	of	PEDF.	Brain	derived	neurotrophic	factor	(BDNF)	secretion	was	downregulated	in	high	glucose	states	and	was	upregulated	in	hypoxia.	Placental	growth	factor	(PlGF)	secretion	by	ARPE-19	was	undetectable	by	ELISA.		
Conclusions:	Neurotrophic	factor	secretion	may	be	effected	by	hypoxia,	high	glucose	or	anti-VEGF	drugs.	This	variation	under	different	conditions	may	influence	neuron	and	photoreceptor	survival	in	the	diabetic	state	and	has	
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potential	clinical	implications	for	preservation	of	vision	in	patients	receiving	anti-VEGF	therapy.	Further	studies	are	warranted	to	determine	the	impacts	of	a	diabetic	state	and	these	drugs	on	multiple	neuroprotective	pathways	in	diabetes.		 	
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BACKGROUND	The	identification	of	vascular	endothelial	growth	factor-A	(VEGF)	as	a	key	factor	in	the	pathogenesis	of	diabetic	retinopathy	(DR)	has	revolutionised	the	approach	to	managing	this	blinding	disease.	There	is	now	a	large	body	of	evidence	to	support	the	use	of	these	drugs	for	the	management	of	diabetic	macular	oedema	(DMO)	as	well	as	a	growing	body	of	evidence	for	their	use	in	other	ocular	diabetic	complications	such	as	proliferative	DR	and	neovascular	glaucoma.	[299]		DR	is	characterised,	and	graded	in	clinical	severity,	by	the	presence	of	vascular	lesions	on	clinical	examination.	[300]	Anti-VEGF	drugs	have	been	shown	to	have	a	disease	modifying	effect	on	DR	severity	by	clearing	these	lesions	when	used	for	longer	periods.	[299]			In	addition	to	these	vascular	changes,	there	is	increasing	evidence	to	suggest	that	neurodegeneration	occurs	in	parallel	to	and	may	precede	vascular	damage	in	the	pathogenesis	of	DR.	[301]	Reduced	thickness	of	the	retinal	ganglion	cell	(RGC)	layer	in	vivo	as	well	as	a	reduced	ganglion	cell	density	post	mortem	was	reported	in	a	study	of	streptozotocin-induced	diabetic	mice.	[281]	Patients	with	diabetes	had	a	thinner	ganglion	cell	layer	as	measured	on	optical	coherence	tomography	(OCT)	in	a	case-control	study.	[302]	Furthermore,	ganglion	cell	layer	thickness	had	a	negative	correlation	with	the	duration	of	diabetes	(r=-0.53,	p<0.01)	in	these	patients.			The	effect	of	anti-VEGF	drugs	on	modulation	of	this	neurodegeneration	is	unclear.	It	is	established	that	VEGF-A	has	important	developmental	and	
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physiological	roles	in	the	retina.	[109]	Inhibition	of	VEGF-A	increased	both	inner	nuclear	layer	and	RGC	apoptosis	in	a	study	of	streptozotocin-induced	diabetic	rats.	Anti-VEGF	therapy	reduced	signaling	through	the	phosphorylated	Akt	pathway,	which	is	key	for	the	neurotrophic	effects	of	this	growth	factor.	[303]		Clinical	evidence	has	shown	that	retinal	nerve	fibre	layer	thickness	may	be	reduced	in	eyes	treated	with	anti-VEGF	from	a	meta-analysis	of	trials	of	patients	with	neovascular	age	related	macular	degeneration	(nAMD)	though	the	strength	of	the	evidence	and	findings	from	included	trials	was	variable.	[304]			In	contrast	to	these	findings,	ranibizumab	has	been	shown	to	be	protective	in	an	ischaemia-reperfusion	model	of	rats.	[305]	Restoration	of	the	inner	segment	ellipsoid	band	and	external	limiting	membrane	has	been	observed	in	a	clinical	study	of	DMO	treated	with	ranibizumab,	suggesting	that	anti-VEGF	therapy	may	actually	protect	or	restore	photoreceptors.	[139]	The	mechanisms	for	this	are	unclear	and	are	yet	to	be	validated	in	other	studies.			The	retinal	pigment	epithelium	(RPE)	is	known	to	secrete	a	large	range	of	neurotrophic	factors	important	in	the	survival	of	neurons.	[306]	In	this	study,	we	assess	the	effects	of	high	glucose	and	hypoxia,	both	of	which	are	critical	for	the	development	of	DR,	on	key	factors	that	may	be	secreted	by	the	RPE.	Additionally,	we	assess	the	effect	of	clinical	doses	of	bevacizumab,	ranibizumab	and	aflibercept	on	the	secretion	of	these	factors.		 	
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METHODS	
ARPE-19	Cell	Culture	Human	ARPE-19	cells	were	cultured	in	Dulbecco's	Modified	Eagle	Medium	(DMEM;	Gibco,	Grand	Island,	NY,	USA,	cat	#11885-084)	media	containing	1g/L	glucose	in	T25	cell	culture	flasks	until	confluent.	Supplementation	to	this	media	included	10%	fetal	bovine	serum	(FBS),	100	U/mL	penicillin	and	100	U/mL	streptomycin.	Cells	were	incubated	at	37oC,	5%	CO2.		Once	confluent,	cells	were	seeded	at	a	density	of	7.5	x	103	cells	per	well	in	96-well	plates	for	cell	viability	and	ELISA-based	supernatant	experiments	or	at	a	density	of	3	x	104	cells	per	well	in	24-well	plates	for	Western	blot	experiments.			
Stress	Media	Culture	media	was	replaced	with	stress	media	once	cells	had	reached	85-90%	confluence	in	either	24-	or	96-well	plates.	To	reduce	the	background	levels	of	factors	detected	in	the	supernatant,	a	lower	concentration	of	FBS	was	utilised.	All	stress	media	was	supplemented	with	1%	FBS,	1%	insulin-transferrin-selenium-ethanolamine	(ITS-X,	Gibco,	cat	#51500056),	100	U/mL	penicillin	and	100	U/mL	streptomycin	and	was	prepared	fresh	on	the	day	of	experiments.	Cells	were	cultured	in	stress	media	for	a	treatment	period	of	24	hours	for	all	experiments.		The	concentration	of	control/low	glucose	was	1g/L	and	high	glucose	was	4.5g/L	(Gibco,	cat	#11995-065)	in	DMEM.	Hypoxia	was	induced	chemically	through	the	addition	of	cobalt	chloride	(CoCl2;	Sigma,	St.	Louis,	MO,	USA).	CoCl2	mimics	the	
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hypoxic	state	through	induction	of	hypoxia	inducible	factor	1-	alpha	(HIF-1a)	activity	in	many	mammalian	cell	lines	including	ARPE-19.	[307,	308]	HIF-1a	is	considered	the	master	regulator	of	hypoxia	and	mediates	homeostatic	response	to	low	oxygen	states.	[309]		
AlamarBlue	cell	viability	assay	Conditions	to	establish	cell	viability	were	either	low	glucose	(LG)	or	high	glucose	(HG)	with	the	addition	of	0μM,	50μM,	100μM,	200μM,	400μM	or	600μM	CoCl2	for	a	total	of	12	groups.	LG	without	CoCl2	was	used	as	the	reference	control	group.		Cell	viability	was	measured	using	a	resazurin	assay	(alamarBlue,	Invitrogen,	Frederick,	MD,	USA).	In	this	assay,	mitochondria	of	viable	cells	are	able	to	reduce	resazurin,	which	is	blue	and	non-fluorescent,	to	resorufin,	which	is	pink	and	highly	fluorescent.	[310]	Following	24	hours	of	treatment	in	96-well	plates,	15μL	of	alamarBlue	was	added	to	each	well.	Fluorescence	measurements	were	performed	following	120	minutes	of	incubation	using	a	Tecan	Safire2	fluorescence	multi-well	plate	reader	(Tecan,	Männedorf,	Switzerland).		
Western	blot	analysis	for	HIF-1α	Treatment	groups	to	quantify	changes	in	HIF-1α	were	either	low	glucose	(LG)	or	high	glucose	(HG)	with	the	addition	of	0μM,	100μM,	200μM	or	400μM	CoCl2	for	a	total	of	8	groups.	LG	without	CoCl2	was	used	as	the	reference	control	group.			
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Following	24	hours	of	treatment	in	24-well	plates,	culture	media	was	removed	and	cells	rinsed	three	times	with	phosphate	buffered	saline.	Cells	were	lysed	and	protein	extracted	with	the	addition	of	RIPA	buffer	(Sigma;	cat	#R0278)	combined	with	protease	inhibitor	(Roche,	Mannheim,	Germany;	cat	#04	693	124	001).	The	lysed	cells	were	centrifuged	at	12,000	rpm	at	4°C	for	10	minutes.	The	supernatant	was	collected	and	protein	concentration	was	determined	using	a	bicinchoninic	acid	(BCA)	assay	(QuantiPro	BCA	assay	kit,	Sigma;	cat	#QPBCA).	A	standard	amount	of	protein	was	mixed	with	NuPAGE	loading	dye	and	reducing	buffer	(Invitrogen;	cat	#NP0007)	and	heated	for	10	min	at	70°C.	This	was	subjected	to	sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	then	transferred	to	a	polyvinylidene	difluoride	membrane	(Millipore,	Bedford,	MA,	USA).		After	blocking	with	5%	bovine	serum	albumin	for	one	hour,	the	membrane	was	incubated	with	HIF-1α	antibody	(1:500,	Novus	Biologicals,	Littleton,	CO,	USA;	cat	#NB-100-449)	overnight	at	4°C	followed	by	incubation	with	secondary	antibodies	conjugated	with	horseradish	peroxidise	for	two	hours	at	room	temperature.		Protein	bands	were	visualised	after	extensive	washing	with	enhanced	chemiluminescence	substrate	(Bio-Rad,	Hercules,	CA,	USA;	cat	#1705060)	using	the	G:Box	BioImaging	system	(Syngene,	Cambridge,	UK).	Results	were	quantified	using	the	GeneTools	image	analysis	package	(Syngene,	software	version	3.07).	Protein	expression	was	normalised	to	α/β	tubulin	(1:2000;	Cell	Signaling	#2148).		
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Measurement	of	VEGF-A	using	Enzyme	Linked	Immunosorbent	Assay	Treatment	groups	to	quantify	VEGF-A	secretion	were	either	LG	or	HG	with	the	addition	of	0μM,	100μM,	200μM	or	400μM	CoCl2	for	a	total	of	8	groups.	LG	without	CoCl2	was	used	as	the	reference	control	group.		Following	24	hours	of	treatment	in	96-well	plates,	culture	media	was	collected	and	centrifuged	at	1400rpm	for	1	minute.	The	supernatant	was	subsequently	analysed	using	enzyme	linked	immunosorbent	assay	(ELISA)	according	to	the	manufacturer’s	instructions	to	detect	and	quantify	VEGF-A	(Invitrogen;	cat	#KHG0111).		
Anti-VEGF	drug	treatment	and	measurements	of	BDNF,	PEDF	and	PlGF	in	
conditioned	media	using	Enzyme	Linked	Immunosorbent	Assay	Based	on	the	results	of	the	above,	a	concentration	of	CoCl2	was	chosen	that	would	lead	to	the	increased	expression	of	HIF-1a	and	VEGF-A	without	a	major	reduction	in	cell	viability.	Dose	appropriate	concentrations	of	bevacizumab	(1.25mg/4mL),	ranibizumab	(0.5mg/4mL)	and	aflibercept	(2.0mg/4mL)	were	added	to	media	based	on	an	assumed	volume	of	the	human	vitreous	at	4mL	as	previously	described.	[311]	Treatment	conditions	were	media	with	LG	or	HG	with	or	without	CoCl2,	with	or	without	each	of	the	anti-VEGF	drugs	for	a	total	of	12	treatment	groups.			
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ELISAs	were	conducted	to	detect	pigment	epithelium	derived	factor	(PEDF;	R&D	Systems,	Minneapolis,	MN	USA,	cat	#DY1177-05),	brain	derived	neurotrophic	factor	(BDNF;	R&D	Systems,	cat	#DBD00)	and	placental	growth	factor	(PlGF;	R&D	Systems,	cat	#DPG00)	as	per	the	manufacturer’s	instructions	on	the	supernatant	of	treated	cells.		
Statistical	analysis	For	each	ELISA,	a	standard	curve	was	generated	and	concentrations	of	factors	were	interpolated	from	samples	from	this.	All	statistical	analyses	were	performed	and	figures	created	using	GraphPad	Prism	software	(Version	7,	San	Diego,	CA,	USA).	Differences	between	groups	were	calculated	using	a	one-way	ANOVA	with	a	post	hoc	correction	using	Bonferroni’s	multiple	comparisons	test.	Values	presented	in	figures	are	reported	as	the	mean	±	standard	error	of	the	mean.	A	p-value	of	less	than	0.05	was	considered	statistically	significant.		 	
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RESULTS	
Effects	of	hypoxia	and	high	glucose	on	the	viability	of	RPE	The	addition	of	CoCl2	did	not	have	a	quantifiable	effect	on	the	viability	of	RPE	below	concentrations	of	200µM	(Figure	7.1).	Mean	viability	of	cells	reduced	to	90%	of	control	with	both	LG	(p=0.009)	and	HG	(p=0.02)	in	the	presence	of	200µM	CoCl2.	Glucose	concentration	did	not	have	a	significant	effect	on	cell	viability	between	the	LG	and	HG	groups.		 	
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Figure	7.1:	Effects	of	high	glucose	and	hypoxia	on	ARPE-19	cell	viability.		Fluorescence	readings	by	alamarBlue	viability	assays	24	hours	after	incubating	cells	in	stress	media.	Values	expressed	as	a	percentage	of	low	glucose	control.	LG=low	glucose,	HG=high	glucose.	n	=	8	per	group.	*	p	<	0.05,	**	p<0.01,	****	p<0.0001			 	
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Effects	of	hypoxia	and	high	glucose	on	the	expression	of	HIF-1a	and	VEGF	secretion	
in	RPE	There	was	increased	expression	of	HIF-1a	for	all	concentrations	of	CoCl2	in	LG	media	(Figure	7.2A).	Increased	expression	of	HIF-1α	was	not	apparent	until	concentrations	of	CoCl2	were	greater	than	200µM	in	HG	media	(Figure	7.2B).	Expression	of	HIF-1α	was	comparatively	less	in	the	HG	media	compared	to	the	LG	media.	For	example,	there	was	46%	increased	expression	in	HG	media	(p=0.03)	compared	with	a	294%	increase	in	LG	media	(p=0.0002)	at	200µM	CoCl2.		There	was	increased	secretion	of	VEGF-A	for	all	concentrations	of	CoCl2	in	both	LG	and	HG	media	(Figure	7.3).		 	
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B 
					
																														
Figure	7.2:	Effects	of	chemically-induced	hypoxia	on	expression	of	HIF-1α.		(A)	low	glucose	(LG)	groups	and	(B)	high	glucose	(HG)	groups.	All	comparisons	to	control	group.	*	p	<	0.05,	***	p<0.001,	****	p<0.0001.	n	=	3	per	group.		 	
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Figure	7.3:	Effects	of	glucose	and	hypoxia	on	secretion	of	VEGF-A	in	ARPE-19.		Results	expressed	as	a	percentage	of	control	low	glucose	(LG)	group.	HG=	high	glucose,	ns=	not	significant.	*	p	<	0.05,	**	p<0.01,	***	p<0.001,	****	p<0.0001	n	=	5	per	group.		 	
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Effects	of	hypoxia,	high	glucose	and	anti-VEGF	drugs	on	secretion	of	PEDF,	BDNF	
and	PlGF	in	RPE	Based	on	the	results	of	the	viability	assay,	HIF-1α	and	VEGF-A	assays,	a	concentration	of	200µM	of	CoCl2	was	used	for	all	subsequent	experiments.			PEDF	secretion	was	significantly	reduced	with	the	addition	of	all	three	anti-VEGF	drugs	in	the	absence	of	hypoxia	(Figure	7.4).	There	was	no	significant	difference	between	the	three	drugs.	There	was	a	significant	decrease	in	the	secretion	of	PEDF	in	the	presence	of	hypoxia	in	both	LG	and	HG	groups.	There	was	no	significant	difference	in	secretion	of	PEDF	with	the	addition	of	anti-VEGF	drugs	in	the	presence	of	hypoxia.	There	was	no	difference	in	secretion	between	the	LG	and	HG	groups	in	the	presence	or	absence	of	hypoxia.		BDNF	secretion	was	significantly	increased	in	the	presence	of	hypoxia	in	both	the	LG	(Figure	7.5A)	and	HG	(Figure	7.5B)	groups.	There	was	increased	secretion	of	BDNF	detected	with	aflibercept	treatment	in	the	absence	of	hypoxia	in	the	LG	group	only	(Figure	7.5A).	There	was	an	overall	reduced	secretion	of	BDNF	in	HG	compared	to	the	LG	groups	(Figure	7.5C).	Levels	of	secreted	BDNF	were	not	significantly	different	compared	to	the	LG	groups	when	hypoxia	was	introduced	to	the	HG	groups	(Figure	7.5C).			PlGF	was	not	secreted	by	ARPE-19	using	the	ELISA	assay.		 	
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Figure	7.4.	Effects	of	glucose	and	hypoxia	on	secretion	of	PEDF	in	ARPE-19.		Results	expressed	as	a	percentage	of	control	low	glucose	(LG)	group.	HG=	high	glucose,	Bev=bevacizumab,	Ran=ranibizumab,	Afl=aflibercept.	****	p<0.0001	n	=	5	per	group.		
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Figure	7.5.	Effects	of	glucose	and	hypoxia	on	secretion	of	BDNF	in	ARPE-19.		Results	expressed	as	a	percentage	of	control	low	glucose	(LG)	group.	(A)	LG	treatment	groups,	(B)	high	glucose	(HG)	treatment	groups,	(C)	overall	results.	ns=	not	significant,	Bev=bevacizumab,	Ran=ranibizumab,	Afl=aflibercept.		*	p	<	0.05,	**	p<0.01,	****	p<0.0001	n	=	5	per	group.	
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DISCUSSION	Here	we	report	that	hypoxia	and	glucose	affect	the	secretion	of	cytokines	by	the	ARPE-19	in	this	in	vitro	study.	Hypoxia	appears	to	have	a	key	effect	on	the	secretion	of	these	factors;	whether	it	is	upregulation	of	HIF-1α,	VEGF-A	and	BDNF,	or	downregulation	of	PEDF.	Glucose	concentration	appears	to	have	less	effect	on	the	pro/anti-angiogenic	factors	but	may	influence	the	secretion	of	BDNF,	an	important	neurotrophic	factor.	We	also	report	that	anti-VEGF	drugs	may	have	an	influence	on	the	secretion	of	PEDF	in	the	absence	of	hypoxic	stress.		There	was	no	apparent	difference	on	cell	viability	for	different	concentrations	of	glucose	in	the	presence	of	hypoxia.	Glucose	appears	to	have	a	beneficial	effect	on	the	RPE	in	vitro.	High	glucose	has	been	associated	with	increased	proliferation	of	ARPE-19	as	well	as	altering	the	morphology	of	these	cells.	[312]	Additionally,	higher	glucose	concentrations	may	increase	the	expression	of	tight	junction	proteins	and	increase	the	barrier	function	of	these	cells.	[313]		We	did	not	show	a	difference	in	VEGF-A	secretion	with	an	increased	glucose	concentration	in	ARPE-19	as	others	have	shown.	[312]	In	our	study,	the	expression	of	HIF-1α	under	hypoxic	conditions	was	relatively	higher	in	LG	media.	This	may	suggest	that	cells	cultured	in	a	lower	glucose	concentration	are	more	susceptible	to	hypoxic	stress.	However,	this	was	not	associated	with	a	corresponding	difference	in	secretion	of	VEGF-A	between	LG	and	HG	groups.		
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Whilst	the	presence	of	hypoxic	stress	increased	the	secretion	of	BDNF,	higher	glucose	concentration	reduced	secretion	of	this	factor.	BDNF	is	a	neurotrophic	factor	that	has	been	shown	to	have	protective	effects	in	photoreceptors	and	RGCs	in	several	animal	models.	[314]	These	effects	may	be	secondary	to	increasing	glutamate	uptake	and	upregulation	of	glutamine	synthetase	in	Müller	cells	under	hypoxic	conditions.	[315]	BDNF	is	significantly	decreased	systemically	in	the	serum	of	patients	with	proliferative	DR	compared	to	controls	as	well	as	patients	with	diabetes	but	without	retinopathy.	[316]	Furthermore,	BDNF	is	reduced	in	the	serum	and	retina	of	STZ-induced	diabetic	rats.	[316]		High	glucose	states	represent	an	abundance	of	energy	substrate	and	may	consequently	reflect	a	low	stress	environment.	Consequently,	this	may	lead	to	the	secretion	of	lower	levels	of	BDNF.	Indeed,	intraocular	injection	of	glucose	has	been	shown	to	protect	the	retina	from	ischaemic	injury	in	rats	and	administration	of	topical	and	subconjunctival	glucose	has	been	associated	with	an	improvement	in	contrast	sensitivity	in	patients	with	primary	open-angle	glaucoma.	[317,	318]			BDNF	secretion	was	increased	under	hypoxic	stress	with	the	addition	of	aflibercept	in	low	glucose	settings	only.	Aflibercept,	a	fusion	protein	which	combines	the	binding	domains	of	VEGF	receptor-1	and	-2,	differs	in	structure	and	function	to	both	bevacizumab,	a	full-length	monoclonal	antibody	to	VEGF-A,	and	ranibizumab,	an	antibody	fragment	to	VEGF-A.	Aflibercept	subsequently	has	the	ability	to	inhibit	not	only	VEGF-A	but	also	VEGF-B	and	PlGF.	Altered	
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autocrine	signaling	by	the	RPE	as	a	consequence	of	inhibition	of	these	other	factors	may	explain	these	findings.			The	addition	of	anti-VEGF	drugs	led	to	a	reduction	in	secretion	of	PEDF	in	the	absence	of	hypoxia.	PEDF	is	an	anti-angiogenic	glycoprotein	that	is	mainly	produced	by	the	RPE	in	the	retina.	PEDF	appears	to	have	strong	associations	with	DMO.	Vitreous	levels	of	PEDF	were	significantly	lower	in	patients	with	DMO	than	in	diabetic	patients	without	retinopathy	and	quantitatively	were	negatively	correlated	with	retinal	thickness	in	a	case-control	study.	[21]	Conversely,	vitreous	levels	of	VEGF-A	were	higher	in	patients	with	DMO	and	quantitatively	positively	correlated	with	retinal	thickness.	PEDF	has	counter-regulatory	actions	to	that	of	VEGF-A	and	reduced	secretion	in	hypoxic	states	demonstrated	in	our	results	is	consistent	with	this.	[319]	Furthermore	it	has	neuroprotective	effects	on	retinal	ganglion	cells	and	photoreceptors	in	animal	models.	[320,	321]		VEGF-A	is	known	to	stimulate	PEDF	expression	in	RPE	via	VEGF	receptor-1	in	an	autocrine	manner.	[322]	Blocking	this	effect	with	anti-VEGF	drugs	will	thus	reduce	expression	and	secretion	of	PEDF.	The	clinical	significance	of	these	findings	may	be	a	potential	deleterious	effect	of	anti-VEGF	drugs	in	the	absence	of	hypoxia.	It	also	highlights	a	potential	mechanism	for	neurodegeneration	suggested	to	be	a	consequence	of	treatment	with	anti-VEGF	treatment	in	nAMD,	a	condition	not	characterised	by	hypoxia.		There	was	no	difference	in	the	secretion	of	PEDF	in	low	or	high	glucose	groups	in	the	presence	of	hypoxia	with	the	addition	of	anti-VEGF	drug.	This	is	consistent	
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with	a	clinical	study	of	patients	with	neovascular	glaucoma	in	which	aqueous	levels	of	PEDF	were	found	to	remain	constant	following	treatment	with	ranibizumab.	[323]	Our	findings	may	represent	the	minimal	secretion	PEDF	that	has	been	inhibited	by	a	hypoxic	signal.			We	were	not	able	to	demonstrate	secretion	of	PlGF	by	ARPE-19	under	any	of	the	experimental	conditions	tested.	This	is	consistent	with	other	studies	measuring	PlGF	with	ELISA	in	both	ARPE-19	and	human	primary	RPE	constitutively	or	under	stress.	[324,	325]	However,	this	does	contrast	with	a	study	that	demonstrated	that	hypoxia	not	only	increases	expression	of	PlGF	in	ARPE-19	but	alters	RPE	cell	permeability.	[24]		PlGF	may	have	an	important	pathophysiological	role	in	the	development	and	progression	of	DR	and	DMO.	[23]	Additionally,	blockade	of	this	factor	by	aflibercept	is	cited	as	a	key	differentiating	factor	between	the	anti-VEGF	drugs	and	as	a	reason	to	explain	the	differential	results	seen	in	head	to	head	trials	such	as	the	DRCR.net	Protocol	T.	[23,	78]	Clarification	of	the	source	of	this	factor	in	the	retina	would	be	important.		There	are	obvious	limitations	in	using	an	in	vitro	model	and	extrapolating	these	findings	to	a	disease	as	complex	as	diabetes.	The	diabetic	state	consists	of	more	than	just	hypoxia	and	hyperglycaemia.	There	are	other	growth	factors,	cytokines,	and	interactions	between	multiple	cells	types	in	play.	The	RPE	is	only	one	source	of	neurotrophic	factors	in	the	retina	and	microglia	and	Muller	cells	also	secrete	a	range	of	these	factors.	[326]	Nevertheless,	the	findings	here	will	help	generate	
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hypotheses	in	future	animal	and	clinical	studies	and	confirm	their	clinical	significance.		 	
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													 Section	4:	Implications	of	findings	and	future	directions	for	research						 	
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As	with	the	rest	of	the	developed	and	developing	world,	the	prevalence	of	diabetes	in	Australia	is	increasing.	Consequently,	there	will	be	an	increasing	burden	of	care	for	the	complications	of	diabetes	such	as	diabetic	retinopathy	and	diabetic	macular	oedema.			This	thesis	has	addressed	a	number	of	key	issues	relating	to	persistent	diabetic	macular	oedema,	a	management	challenge	with	a	poor	evidence	base.	The	data	presented	and	published	here	has	shown	that	there	may	be	an	overall	anatomical	and	visual	benefit	in	switching	therapy	from	bevacizumab	to	aflibercept	for	these	patients.	This	benefit	is	more	apparent	in	individuals	who	have	a	poorer	baseline	visual	acuity	and	also	those	who	respond	well	after	the	first	injection.	The	reasons	for	this	early	response	warrant	further	research	and	may	be	related	to	the	differences	in	the	anti-VEGF	drugs	or	genetic	variations	in	responses	to	drug.		Further	to	this,	we	have	identified	morphological	biomarkers	in	these	patients	that	correlate	well	with	vision	but	also	may	predict	response	to	a	switch	in	therapy.	The	devices	for	performing	ultrawidefield	imaging	are	becoming	increasingly	accessible	and	the	severity	of	retinopathy	and	peripheral	ischaemia	will	likely	have	increasing	clinical	significance	in	the	management	of	diabetic	retinopathy.		Functional	vision	is	difficult	to	assess	with	visual	acuity	alone.	This	thesis	showed	that	microperimetry	might	be	an	objective	way	to	quantify	this	that	correlates	with	subjectively	reported	outcomes.	There	is	limited	research	
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assessing	a	correlation	between	subjective	and	objective	outcomes	using	microperimetry	and	validation	of	these	findings	in	diabetic	macular	oedema	as	well	in	different	pathologies	is	necessary.		Anatomical	measurements	that	are	generated	automatically	by	OCT	devices	are	used	to	assess	response	to	therapy	clinically	at	an	individual	level	as	well	as	an	outcome	for	clinical	trials.	The	findings	from	this	thesis	shows	that	automatically	generated	readings	are	both	unreliable	and	inconsistent	between	different	devices.	These	may	also	vary	by	different	versions	of	the	software	used.	This	has	important	implications	for	the	conduct	and	reporting	of	results	from	clinical	trials.			The	in	vitro	work	highlighted	signals	which	may	be	affected	by	the	diabetic	state	and	anti-VEGF	drugs.	This	has	important	implications	for	our	understanding	to	the	neurodegeneration	that	is	observed	in	diabetic	retinopathy	as	well	as	how	the	treatments	we	apply	to	this	condition	may	affect	this	process.	These	findings	may	also	have	applications	to	other	retinal	conditions	which	feature	oxidative	stress,	such	as	retinal	vein	occlusions	as	well	as	those	which	are	managed	with	anti-VEGF	drugs	such	as	neovascular	age	related	macular	degeneration.	The	results	presented	here	are	under	further	investigation	analysing	different	neurotrophic	as	well	as	pro-fibrotic	factors	that	may	be	implicated	in	diabetic	retinopathy.	Furthermore,	these	results	are	to	be	validated	in	a	human	primary	cell	culture	model	with	a	potential	for	further	investigation	in	animal	studies.			
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Further	research	is	required	into	the	identification	of	clinical	and	laboratory	biomarkers	to	individualise	pharmacotherapy	and	identify	patients	who	may	be	poor	and	good	responders	to	anti-VEGF	therapy.	 	
	 -218-	
REFERENCES		1.	 Yau	JW,	Rogers	SL,	Kawasaki	R,	Lamoureux	EL,	Kowalski	JW,	Bek	T,	Chen	SJ,	Dekker	JM,	Fletcher	A,	Grauslund	J,	Haffner	S,	Hamman	RF,	Ikram	MK,	Kayama	T,	Klein	BE,	Klein	R,	Krishnaiah	S,	Mayurasakorn	K,	O'Hare	JP,	Orchard	TJ,	Porta	M,	Rema	M,	Roy	MS,	Sharma	T,	Shaw	J,	Taylor	H,	Tielsch	JM,	Varma	R,	Wang	JJ,	Wang	N,	West	S,	Xu	L,	Yasuda	M,	Zhang	X,	Mitchell	P,	Wong	TY,	Meta-Analysis	for	Eye	Disease	Study	G	(2012)	Global	prevalence	and	major	risk	factors	of	diabetic	retinopathy.	Diabetes	care	35:	556-564	DOI	10.2337/dc11-1909	2.	 Aiello	LP,	Avery	RL,	Arrigg	PG,	Keyt	BA,	Jampel	HD,	Shah	ST,	Pasquale	LR,	Thieme	H,	Iwamoto	MA,	Park	JE,	et	al.	(1994)	Vascular	endothelial	growth	factor	in	ocular	fluid	of	patients	with	diabetic	retinopathy	and	other	retinal	disorders.	The	New	England	journal	of	medicine	331:	1480-1487	DOI	10.1056/NEJM199412013312203	3.	 Aiello	LP,	Bursell	SE,	Clermont	A,	Duh	E,	Ishii	H,	Takagi	C,	Mori	F,	Ciulla	TA,	Ways	K,	Jirousek	M,	Smith	LE,	King	GL	(1997)	Vascular	endothelial	growth	factor-induced	retinal	permeability	is	mediated	by	protein	kinase	C	in	vivo	and	suppressed	by	an	orally	effective	beta-isoform-selective	inhibitor.	Diabetes	46:	1473-1480	4.	 Barber	AJ,	Lieth	E,	Khin	SA,	Antonetti	DA,	Buchanan	AG,	Gardner	TW	(1998)	Neural	apoptosis	in	the	retina	during	experimental	and	human	diabetes.	Early	onset	and	effect	of	insulin.	The	Journal	of	clinical	investigation	102:	783-791	DOI	10.1172/JCI2425	5.	 Stem	MS,	Gardner	TW	(2013)	Neurodegeneration	in	the	pathogenesis	of	diabetic	retinopathy:	molecular	mechanisms	and	therapeutic	implications.	Current	medicinal	chemistry	20:	3241-3250	6.	 Antonetti	DA,	Klein	R,	Gardner	TW	(2012)	Diabetic	retinopathy.	The	New	England	journal	of	medicine	366:	1227-1239	DOI	10.1056/NEJMra1005073	7.	 Diabetes	C,	Complications	Trial	/Epidemiology	of	Diabetes	I,	Complications	Research	G,	Lachin	JM,	White	NH,	Hainsworth	DP,	Sun	W,	Cleary	PA,	Nathan	DM	(2015)	Effect	of	intensive	diabetes	therapy	on	the	progression	of	diabetic	retinopathy	in	patients	with	type	1	diabetes:	18	years	of	follow-up	in	the	DCCT/EDIC.	Diabetes	64:	631-642	DOI	10.2337/db14-0930	8.	 Action	to	Control	Cardiovascular	Risk	in	Diabetes	Follow-On	Eye	Study	G,	the	Action	to	Control	Cardiovascular	Risk	in	Diabetes	Follow-On	Study	G	(2016)	Persistent	Effects	of	Intensive	Glycemic	Control	on	Retinopathy	in	Type	2	Diabetes	in	the	Action	to	Control	Cardiovascular	Risk	in	Diabetes	(ACCORD)	Follow-On	Study.	Diabetes	care	39:	1089-1100	DOI	10.2337/dc16-0024	9.	 Brownlee	M	(2005)	The	pathobiology	of	diabetic	complications:	a	unifying	mechanism.	Diabetes	54:	1615-1625	10.	 Geraldes	P,	King	GL	(2010)	Activation	of	protein	kinase	C	isoforms	and	its	impact	on	diabetic	complications.	Circulation	research	106:	1319-1331	DOI	10.1161/CIRCRESAHA.110.217117	11.	 Hammes	HP,	Martin	S,	Federlin	K,	Geisen	K,	Brownlee	M	(1991)	Aminoguanidine	treatment	inhibits	the	development	of	experimental	
	 -219-	
diabetic	retinopathy.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	88:	11555-11558	12.	 Lorenzi	M	(2007)	The	polyol	pathway	as	a	mechanism	for	diabetic	retinopathy:	attractive,	elusive,	and	resilient.	Experimental	diabetes	research	2007:	61038	DOI	10.1155/2007/61038	13.	 Behl	T,	Kaur	I,	Kotwani	A	(2016)	Implication	of	oxidative	stress	in	progression	of	diabetic	retinopathy.	Survey	of	ophthalmology	61:	187-196	DOI	10.1016/j.survophthal.2015.06.001	14.	 Tang	J,	Kern	TS	(2011)	Inflammation	in	diabetic	retinopathy.	Progress	in	retinal	and	eye	research	30:	343-358	DOI	10.1016/j.preteyeres.2011.05.002	15.	 Abcouwer	SF	(2013)	Angiogenic	Factors	and	Cytokines	in	Diabetic	Retinopathy.	Journal	of	clinical	&	cellular	immunology	Suppl	1	DOI	10.4172/2155-9899	16.	 Takahashi	H,	Shibuya	M	(2005)	The	vascular	endothelial	growth	factor	(VEGF)/VEGF	receptor	system	and	its	role	under	physiological	and	pathological	conditions.	Clinical	science	109:	227-241	DOI	10.1042/CS20040370	17.	 Wang	J,	Xu	X,	Elliott	MH,	Zhu	M,	Le	YZ	(2010)	Muller	cell-derived	VEGF	is	essential	for	diabetes-induced	retinal	inflammation	and	vascular	leakage.	Diabetes	59:	2297-2305	DOI	10.2337/db09-1420	18.	 Aiello	LP,	Northrup	JM,	Keyt	BA,	Takagi	H,	Iwamoto	MA	(1995)	Hypoxic	regulation	of	vascular	endothelial	growth	factor	in	retinal	cells.	Archives	of	ophthalmology	113:	1538-1544	19.	 Zhang	X,	Bao	S,	Lai	D,	Rapkins	RW,	Gillies	MC	(2008)	Intravitreal	triamcinolone	acetonide	inhibits	breakdown	of	the	blood-retinal	barrier	through	differential	regulation	of	VEGF-A	and	its	receptors	in	early	diabetic	rat	retinas.	Diabetes	57:	1026-1033	DOI	10.2337/db07-0982	20.	 Witmer	AN,	Blaauwgeers	HG,	Weich	HA,	Alitalo	K,	Vrensen	GF,	Schlingemann	RO	(2002)	Altered	expression	patterns	of	VEGF	receptors	in	human	diabetic	retina	and	in	experimental	VEGF-induced	retinopathy	in	monkey.	Investigative	ophthalmology	&	visual	science	43:	849-857	21.	 Funatsu	H,	Yamashita	H,	Nakamura	S,	Mimura	T,	Eguchi	S,	Noma	H,	Hori	S	(2006)	Vitreous	levels	of	pigment	epithelium-derived	factor	and	vascular	endothelial	growth	factor	are	related	to	diabetic	macular	edema.	Ophthalmology	113:	294-301	DOI	10.1016/j.ophtha.2005.10.030	22.	 Autiero	M,	Waltenberger	J,	Communi	D,	Kranz	A,	Moons	L,	Lambrechts	D,	Kroll	J,	Plaisance	S,	De	Mol	M,	Bono	F,	Kliche	S,	Fellbrich	G,	Ballmer-Hofer	K,	Maglione	D,	Mayr-Beyrle	U,	Dewerchin	M,	Dombrowski	S,	Stanimirovic	D,	Van	Hummelen	P,	Dehio	C,	Hicklin	DJ,	Persico	G,	Herbert	JM,	Communi	D,	Shibuya	M,	Collen	D,	Conway	EM,	Carmeliet	P	(2003)	Role	of	PlGF	in	the	intra-	and	intermolecular	cross	talk	between	the	VEGF	receptors	Flt1	and	Flk1.	Nature	medicine	9:	936-943	DOI	10.1038/nm884	23.	 Nguyen	QD,	De	Falco	S,	Behar-Cohen	F,	Lam	WC,	Li	X,	Reichhart	N,	Ricci	F,	Pluim	J,	Li	WW	(2018)	Placental	growth	factor	and	its	potential	role	in	diabetic	retinopathy	and	other	ocular	neovascular	diseases.	Acta	Ophthalmol	96:	e1-e9	DOI	10.1111/aos.13325	24.	 Miyamoto	N,	de	Kozak	Y,	Jeanny	JC,	Glotin	A,	Mascarelli	F,	Massin	P,	BenEzra	D,	Behar-Cohen	F	(2007)	Placental	growth	factor-1	and	epithelial	
	 -220-	
haemato-retinal	barrier	breakdown:	potential	implication	in	the	pathogenesis	of	diabetic	retinopathy.	Diabetologia	50:	461-470	DOI	10.1007/s00125-006-0539-2	25.	 Huang	H,	He	J,	Johnson	D,	Wei	Y,	Liu	Y,	Wang	S,	Lutty	GA,	Duh	EJ,	Semba	RD	(2015)	Deletion	of	placental	growth	factor	prevents	diabetic	retinopathy	and	is	associated	with	Akt	activation	and	HIF1alpha-VEGF	pathway	inhibition.	Diabetes	64:	200-212	DOI	10.2337/db14-0016	26.	 Kovacs	K,	Marra	KV,	Yu	G,	Wagley	S,	Ma	J,	Teague	GC,	Nandakumar	N,	Lashkari	K,	Arroyo	JG	(2015)	Angiogenic	and	Inflammatory	Vitreous	Biomarkers	Associated	With	Increasing	Levels	of	Retinal	Ischemia.	Investigative	ophthalmology	&	visual	science	56:	6523-6530	DOI	10.1167/iovs.15-16793	27.	 Zhong	X,	Huang	H,	Shen	J,	Zacchigna	S,	Zentilin	L,	Giacca	M,	Vinores	SA	(2011)	Vascular	endothelial	growth	factor-B	gene	transfer	exacerbates	retinal	and	choroidal	neovascularization	and	vasopermeability	without	promoting	inflammation.	Molecular	vision	17:	492-507	28.	 Kinoshita	S,	Noda	K,	Saito	W,	Kanda	A,	Ishida	S	(2016)	Vitreous	levels	of	vascular	endothelial	growth	factor-B	in	proliferative	diabetic	retinopathy.	Acta	Ophthalmol	94:	e521-523	DOI	10.1111/aos.12969	29.	 Huang	D,	Zhao	C,	Ju	R,	Kumar	A,	Tian	G,	Huang	L,	Zheng	L,	Li	X,	Liu	L,	Wang	S,	Ren	X,	Ye	Z,	Chen	W,	Xing	L,	Chen	Q,	Gao	Z,	Mi	J,	Tang	Z,	Wang	B,	Zhang	S,	Lee	C,	Li	X	(2016)	VEGF-B	inhibits	hyperglycemia-	and	Macugen-induced	retinal	apoptosis.	Scientific	reports	6:	26059	DOI	10.1038/srep26059	30.	 Zhao	B,	Smith	G,	Cai	J,	Ma	A,	Boulton	M	(2007)	Vascular	endothelial	growth	factor	C	promotes	survival	of	retinal	vascular	endothelial	cells	via	vascular	endothelial	growth	factor	receptor-2.	The	British	journal	of	ophthalmology	91:	538-545	DOI	10.1136/bjo.2006.101543	31.	 Puddu	A,	Sanguineti	R,	Durante	A,	Nicolo	M,	Viviani	GL	(2012)	Vascular	endothelial	growth	factor-C	secretion	is	increased	by	advanced	glycation	end-products:	possible	implication	in	ocular	neovascularization.	Molecular	vision	18:	2509-2517	32.	 Kaidonis	G,	Burdon	KP,	Gillies	MC,	Abhary	S,	Essex	RW,	Chang	JH,	Pal	B,	Pefkianaki	M,	Daniell	M,	Lake	S,	Petrovsky	N,	Hewitt	AW,	Jenkins	A,	Lamoureux	EL,	Gleadle	JM,	Craig	JE	(2015)	Common	Sequence	Variation	in	the	VEGFC	Gene	Is	Associated	with	Diabetic	Retinopathy	and	Diabetic	Macular	Edema.	Ophthalmology	122:	1828-1836	DOI	10.1016/j.ophtha.2015.05.004	33.	 (1981)	Photocoagulation	treatment	of	proliferative	diabetic	retinopathy.	Clinical	application	of	Diabetic	Retinopathy	Study	(DRS)	findings,	DRS	Report	Number	8.	The	Diabetic	Retinopathy	Study	Research	Group.	Ophthalmology	88:	583-600	34.	 Bressler	NM,	Beck	RW,	Ferris	FL,	3rd	(2011)	Panretinal	photocoagulation	for	proliferative	diabetic	retinopathy.	The	New	England	journal	of	medicine	365:	1520-1526	DOI	10.1056/NEJMct0908432	35.	 Early	Treatment	Diabetic	Retinopathy	Study	research	group	(1985)	Photocoagulation	for	diabetic	macular	edema.	Early	Treatment	Diabetic	Retinopathy	Study	report	number	1.	Archives	of	ophthalmology	103:	1796-1806	
	 -221-	
36.	 Ogata	N,	Wang	L,	Jo	N,	Tombran-Tink	J,	Takahashi	K,	Mrazek	D,	Matsumura	M	(2001)	Pigment	epithelium	derived	factor	as	a	neuroprotective	agent	against	ischemic	retinal	injury.	Current	eye	research	22:	245-252	37.	 Duh	EJ,	Yang	HS,	Suzuma	I,	Miyagi	M,	Youngman	E,	Mori	K,	Katai	M,	Yan	L,	Suzuma	K,	West	K,	Davarya	S,	Tong	P,	Gehlbach	P,	Pearlman	J,	Crabb	JW,	Aiello	LP,	Campochiaro	PA,	Zack	DJ	(2002)	Pigment	epithelium-derived	factor	suppresses	ischemia-induced	retinal	neovascularization	and	VEGF-induced	migration	and	growth.	Investigative	ophthalmology	&	visual	science	43:	821-829	38.	 Hattenbach	LO,	Beck	KF,	Pfeilschifter	J,	Koch	F,	Ohrloff	C,	Schacke	W	(2005)	Pigment-epithelium-derived	factor	is	upregulated	in	photocoagulated	human	retinal	pigment	epithelial	cells.	Ophthalmic	research	37:	341-346	DOI	10.1159/000088263	39.	 Ogata	N,	Ando	A,	Uyama	M,	Matsumura	M	(2001)	Expression	of	cytokines	and	transcription	factors	in	photocoagulated	human	retinal	pigment	epithelial	cells.	Graefe's	archive	for	clinical	and	experimental	ophthalmology	=	Albrecht	von	Graefes	Archiv	fur	klinische	und	experimentelle	Ophthalmologie	239:	87-95	40.	 Sivaprasad	S,	Elagouz	M,	McHugh	D,	Shona	O,	Dorin	G	(2010)	Micropulsed	diode	laser	therapy:	evolution	and	clinical	applications.	Survey	of	ophthalmology	55:	516-530	DOI	10.1016/j.survophthal.2010.02.005	41.	 Jonas	JB,	Sofker	A	(2001)	Intraocular	injection	of	crystalline	cortisone	as	adjunctive	treatment	of	diabetic	macular	edema.	American	journal	of	ophthalmology	132:	425-427	42.	 Gillies	MC,	Sutter	FK,	Simpson	JM,	Larsson	J,	Ali	H,	Zhu	M	(2006)	Intravitreal	triamcinolone	for	refractory	diabetic	macular	edema:	two-year	results	of	a	double-masked,	placebo-controlled,	randomized	clinical	trial.	Ophthalmology	113:	1533-1538	DOI	10.1016/j.ophtha.2006.02.065	43.	 Antonetti	DA,	Wolpert	EB,	DeMaio	L,	Harhaj	NS,	Scaduto	RC,	Jr.	(2002)	Hydrocortisone	decreases	retinal	endothelial	cell	water	and	solute	flux	coincident	with	increased	content	and	decreased	phosphorylation	of	occludin.	Journal	of	neurochemistry	80:	667-677	44.	 Tamura	H,	Miyamoto	K,	Kiryu	J,	Miyahara	S,	Katsuta	H,	Hirose	F,	Musashi	K,	Yoshimura	N	(2005)	Intravitreal	injection	of	corticosteroid	attenuates	leukostasis	and	vascular	leakage	in	experimental	diabetic	retina.	Investigative	ophthalmology	&	visual	science	46:	1440-1444	DOI	10.1167/iovs.04-0905	45.	 Edelman	JL,	Lutz	D,	Castro	MR	(2005)	Corticosteroids	inhibit	VEGF-induced	vascular	leakage	in	a	rabbit	model	of	blood-retinal	and	blood-aqueous	barrier	breakdown.	Experimental	eye	research	80:	249-258	DOI	10.1016/j.exer.2004.09.013	46.	 Nauck	M,	Roth	M,	Tamm	M,	Eickelberg	O,	Wieland	H,	Stulz	P,	Perruchoud	AP	(1997)	Induction	of	vascular	endothelial	growth	factor	by	platelet-activating	factor	and	platelet-derived	growth	factor	is	downregulated	by	corticosteroids.	American	journal	of	respiratory	cell	and	molecular	biology	16:	398-406	DOI	10.1165/ajrcmb.16.4.9115750	47.	 Diabetic	Retinopathy	Clinical	Research	Network,	Elman	MJ,	Aiello	LP,	Beck	RW,	Bressler	NM,	Bressler	SB,	Edwards	AR,	Ferris	FL,	3rd,	Friedman	
	 -222-	
SM,	Glassman	AR,	Miller	KM,	Scott	IU,	Stockdale	CR,	Sun	JK	(2010)	Randomized	trial	evaluating	ranibizumab	plus	prompt	or	deferred	laser	or	triamcinolone	plus	prompt	laser	for	diabetic	macular	edema.	Ophthalmology	117:	1064-1077	e1035	DOI	10.1016/j.ophtha.2010.02.031	48.	 Fraser-Bell	S,	Lim	LL,	Campain	A,	Mehta	H,	Aroney	C,	Bryant	J,	Li	J,	Quin	GJ,	McAllister	IL,	Gillies	MC	(2016)	Bevacizumab	or	Dexamethasone	Implants	for	DME:	2-year	Results	(The	BEVORDEX	Study).	Ophthalmology	123:	1399-1401	DOI	10.1016/j.ophtha.2015.12.012	49.	 Sultan	MB,	Zhou	D,	Loftus	J,	Dombi	T,	Ice	KS,	Macugen	Study	G	(2011)	A	phase	2/3,	multicenter,	randomized,	double-masked,	2-year	trial	of	pegaptanib	sodium	for	the	treatment	of	diabetic	macular	edema.	Ophthalmology	118:	1107-1118	DOI	10.1016/j.ophtha.2011.02.045	50.	 Adamis	AP,	Altaweel	M,	Bressler	NM,	Cunningham	ET,	Jr.,	Davis	MD,	Goldbaum	M,	Gonzales	C,	Guyer	DR,	Barrett	K,	Patel	M,	Macugen	Diabetic	Retinopathy	Study	G	(2006)	Changes	in	retinal	neovascularization	after	pegaptanib	(Macugen)	therapy	in	diabetic	individuals.	Ophthalmology	113:	23-28	DOI	10.1016/j.ophtha.2005.10.012	51.	 Hurwitz	H,	Fehrenbacher	L,	Novotny	W,	Cartwright	T,	Hainsworth	J,	Heim	W,	Berlin	J,	Baron	A,	Griffing	S,	Holmgren	E,	Ferrara	N,	Fyfe	G,	Rogers	B,	Ross	R,	Kabbinavar	F	(2004)	Bevacizumab	plus	irinotecan,	fluorouracil,	and	leucovorin	for	metastatic	colorectal	cancer.	The	New	England	journal	of	medicine	350:	2335-2342	DOI	10.1056/NEJMoa032691	52.	 Mordenti	J,	Cuthbertson	RA,	Ferrara	N,	Thomsen	K,	Berleau	L,	Licko	V,	Allen	PC,	Valverde	CR,	Meng	YG,	Fei	DT,	Fourre	KM,	Ryan	AM	(1999)	Comparisons	of	the	intraocular	tissue	distribution,	pharmacokinetics,	and	safety	of	125I-labeled	full-length	and	Fab	antibodies	in	rhesus	monkeys	following	intravitreal	administration.	Toxicologic	pathology	27:	536-544	DOI	10.1177/019262339902700507	53.	 Raghavan	M,	Bjorkman	PJ	(1996)	Fc	receptors	and	their	interactions	with	immunoglobulins.	Annual	review	of	cell	and	developmental	biology	12:	181-220	DOI	10.1146/annurev.cellbio.12.1.181	54.	 Holash	J,	Davis	S,	Papadopoulos	N,	Croll	SD,	Ho	L,	Russell	M,	Boland	P,	Leidich	R,	Hylton	D,	Burova	E,	Ioffe	E,	Huang	T,	Radziejewski	C,	Bailey	K,	Fandl	JP,	Daly	T,	Wiegand	SJ,	Yancopoulos	GD,	Rudge	JS	(2002)	VEGF-Trap:	a	VEGF	blocker	with	potent	antitumor	effects.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	99:	11393-11398	DOI	10.1073/pnas.172398299	55.	 Uehara	F,	Ohba	N,	Ozawa	M	(2001)	Isolation	and	characterization	of	galectins	in	the	mammalian	retina.	Investigative	ophthalmology	&	visual	science	42:	2164-2172	56.	 Kanda	A,	Noda	K,	Saito	W,	Ishida	S	(2015)	Aflibercept	Traps	Galectin-1,	an	Angiogenic	Factor	Associated	with	Diabetic	Retinopathy.	Scientific	reports	5:	17946	DOI	10.1038/srep17946	57.	 Croci	DO,	Cerliani	JP,	Dalotto-Moreno	T,	Mendez-Huergo	SP,	Mascanfroni	ID,	Dergan-Dylon	S,	Toscano	MA,	Caramelo	JJ,	Garcia-Vallejo	JJ,	Ouyang	J,	Mesri	EA,	Junttila	MR,	Bais	C,	Shipp	MA,	Salatino	M,	Rabinovich	GA	(2014)	Glycosylation-dependent	lectin-receptor	interactions	preserve	
	 -223-	
angiogenesis	in	anti-VEGF	refractory	tumors.	Cell	156:	744-758	DOI	10.1016/j.cell.2014.01.043	58.	 Avery	RL,	Castellarin	AA,	Steinle	NC,	Dhoot	DS,	Pieramici	DJ,	See	R,	Couvillion	S,	Nasir	MA,	Rabena	MD,	Le	K,	Maia	M,	Visich	JE	(2014)	Systemic	pharmacokinetics	following	intravitreal	injections	of	ranibizumab,	bevacizumab	or	aflibercept	in	patients	with	neovascular	AMD.	The	British	journal	of	ophthalmology	98:	1636-1641	DOI	10.1136/bjophthalmol-2014-305252	59.	 Stewart	MW	(2014)	Pharmacokinetics,	pharmacodynamics	and	pre-clinical	characteristics	of	ophthalmic	drugs	that	bind	VEGF.	Expert	review	of	clinical	pharmacology	7:	167-180	DOI	10.1586/17512433.2014.884458	60.	 Stewart	MW,	Rosenfeld	PJ	(2008)	Predicted	biological	activity	of	intravitreal	VEGF	Trap.	The	British	journal	of	ophthalmology	92:	667-668	DOI	10.1136/bjo.2007.134874	61.	 Christoforidis	JB,	Williams	MM,	Kothandaraman	S,	Kumar	K,	Epitropoulos	FJ,	Knopp	MV	(2012)	Pharmacokinetic	properties	of	intravitreal	I-124-aflibercept	in	a	rabbit	model	using	PET/CT.	Current	eye	research	37:	1171-1174	DOI	10.3109/02713683.2012.727521	62.	 Park	SJ,	Oh	J,	Kim	YK,	Park	JH,	Park	JY,	Hong	HK,	Park	KH,	Lee	JE,	Kim	HM,	Chung	JY,	Woo	SJ	(2015)	Intraocular	pharmacokinetics	of	intravitreal	vascular	endothelial	growth	factor-Trap	in	a	rabbit	model.	Eye	29:	561-568	DOI	10.1038/eye.2014.329	63.	 Rajendram	R,	Fraser-Bell	S,	Kaines	A,	Michaelides	M,	Hamilton	RD,	Esposti	SD,	Peto	T,	Egan	C,	Bunce	C,	Leslie	RD,	Hykin	PG	(2012)	A	2-year	prospective	randomized	controlled	trial	of	intravitreal	bevacizumab	or	laser	therapy	(BOLT)	in	the	management	of	diabetic	macular	edema:	24-month	data:	report	3.	Archives	of	ophthalmology	130:	972-979	DOI	10.1001/archophthalmol.2012.393	64.	 Brown	DM,	Nguyen	QD,	Marcus	DM,	Boyer	DS,	Patel	S,	Feiner	L,	Schlottmann	PG,	Rundle	AC,	Zhang	J,	Rubio	RG,	Adamis	AP,	Ehrlich	JS,	Hopkins	JJ,	Ride,	Group	RR	(2013)	Long-term	outcomes	of	ranibizumab	therapy	for	diabetic	macular	edema:	the	36-month	results	from	two	phase	III	trials:	RISE	and	RIDE.	Ophthalmology	120:	2013-2022	DOI	10.1016/j.ophtha.2013.02.034	65.	 Elman	MJ,	Ayala	A,	Bressler	NM,	Browning	D,	Flaxel	CJ,	Glassman	AR,	Jampol	LM,	Stone	TW,	Diabetic	Retinopathy	Clinical	Research	N	(2015)	Intravitreal	Ranibizumab	for	diabetic	macular	edema	with	prompt	versus	deferred	laser	treatment:	5-year	randomized	trial	results.	Ophthalmology	122:	375-381	DOI	10.1016/j.ophtha.2014.08.047	66.	 Schmidt-Erfurth	U,	Lang	GE,	Holz	FG,	Schlingemann	RO,	Lanzetta	P,	Massin	P,	Gerstner	O,	Bouazza	AS,	Shen	H,	Osborne	A,	Mitchell	P,	Group	RES	(2014)	Three-year	outcomes	of	individualized	ranibizumab	treatment	in	patients	with	diabetic	macular	edema:	the	RESTORE	extension	study.	Ophthalmology	121:	1045-1053	DOI	10.1016/j.ophtha.2013.11.041	67.	 Do	DV,	Nguyen	QD,	Khwaja	AA,	Channa	R,	Sepah	YJ,	Sophie	R,	Hafiz	G,	Campochiaro	PA,	Group	R-S	(2013)	Ranibizumab	for	edema	of	the	macula	in	diabetes	study:	3-year	outcomes	and	the	need	for	prolonged	frequent	
	 -224-	
treatment.	JAMA	ophthalmology	131:	139-145	DOI	10.1001/2013.jamaophthalmol.91	68.	 Ishibashi	T,	Li	X,	Koh	A,	Lai	TY,	Lee	FL,	Lee	WK,	Ma	Z,	Ohji	M,	Tan	N,	Cha	SB,	Shamsazar	J,	Yau	CL,	Group	RS	(2015)	The	REVEAL	Study:	Ranibizumab	Monotherapy	or	Combined	with	Laser	versus	Laser	Monotherapy	in	Asian	Patients	with	Diabetic	Macular	Edema.	Ophthalmology	122:	1402-1415	DOI	10.1016/j.ophtha.2015.02.006	69.	 Diabetic	Retinopathy	Clinical	Research	Network,	Elman	MJ,	Qin	H,	Aiello	LP,	Beck	RW,	Bressler	NM,	Ferris	FL,	3rd,	Glassman	AR,	Maturi	RK,	Melia	M	(2012)	Intravitreal	ranibizumab	for	diabetic	macular	edema	with	prompt	versus	deferred	laser	treatment:	three-year	randomized	trial	results.	Ophthalmology	119:	2312-2318	DOI	10.1016/j.ophtha.2012.08.022	70.	 Do	DV,	Nguyen	QD,	Boyer	D,	Schmidt-Erfurth	U,	Brown	DM,	Vitti	R,	Berliner	AJ,	Gao	B,	Zeitz	O,	Ruckert	R,	Schmelter	T,	Sandbrink	R,	Heier	JS,	da	Vinci	Study	G	(2012)	One-year	outcomes	of	the	da	Vinci	Study	of	VEGF	Trap-Eye	in	eyes	with	diabetic	macular	edema.	Ophthalmology	119:	1658-1665	DOI	10.1016/j.ophtha.2012.02.010	71.	 Heier	JS,	Korobelnik	JF,	Brown	DM,	Schmidt-Erfurth	U,	Do	DV,	Midena	E,	Boyer	DS,	Terasaki	H,	Kaiser	PK,	Marcus	DM,	Nguyen	QD,	Jaffe	GJ,	Slakter	JS,	Simader	C,	Soo	Y,	Schmelter	T,	Vitti	R,	Berliner	AJ,	Zeitz	O,	Metzig	C,	Holz	FG	(2016)	Intravitreal	Aflibercept	for	Diabetic	Macular	Edema:	148-Week	Results	from	the	VISTA	and	VIVID	Studies.	Ophthalmology	123:	2376-2385	DOI	10.1016/j.ophtha.2016.07.032	72.	 Bansal	AS,	Khurana	RN,	Wieland	MR,	Wang	PW,	Van	Everen	SA,	Tuomi	L	(2015)	Influence	of	Glycosylated	Hemoglobin	on	the	Efficacy	of	Ranibizumab	for	Diabetic	Macular	Edema:	A	Post	Hoc	Analysis	of	the	RIDE/RISE	Trials.	Ophthalmology	122:	1573-1579	DOI	10.1016/j.ophtha.2015.04.029	73.	 Singh	RP,	Wykoff	CC,	Brown	DM,	Larsen	M,	Terasaki	H,	Silva	FQ,	Saroj	N,	Gibson	A,	Vitti	R,	Kayshap	S,	Berliner	AJ,	Zeitz	O,	Metzig	C,	Thompson	D,	Nguyen	QD	(2017)	Outcomes	of	Diabetic	Macular	Edema	Patients	by	Baseline	Hemoglobin	A1c:	Analyses	from	VISTA	and	VIVID.	Ophthalmology	Retina	1:	382-388	DOI	https://doi.org/10.1016/j.oret.2017.02.003	74.	 Sepah	YJ,	Sadiq	MA,	Boyer	D,	Callanan	D,	Gallemore	R,	Bennett	M,	Marcus	D,	Halperin	L,	Hassan	M,	Campochiaro	PA,	Nguyen	QD,	Do	DV,	Group	R-S	(2016)	Twenty-four-Month	Outcomes	of	the	Ranibizumab	for	Edema	of	the	Macula	in	Diabetes	-	Protocol	3	with	High	Dose	(READ-3)	Study.	Ophthalmology	123:	2581-2587	DOI	10.1016/j.ophtha.2016.08.040	75.	 Diabetic	Retinopathy	Clinical	Research	N,	Scott	IU,	Edwards	AR,	Beck	RW,	Bressler	NM,	Chan	CK,	Elman	MJ,	Friedman	SM,	Greven	CM,	Maturi	RK,	Pieramici	DJ,	Shami	M,	Singerman	LJ,	Stockdale	CR	(2007)	A	phase	II	randomized	clinical	trial	of	intravitreal	bevacizumab	for	diabetic	macular	edema.	Ophthalmology	114:	1860-1867	DOI	10.1016/j.ophtha.2007.05.062	76.	 Lam	DS,	Lai	TY,	Lee	VY,	Chan	CK,	Liu	DT,	Mohamed	S,	Li	CL	(2009)	Efficacy	of	1.25	MG	versus	2.5	MG	intravitreal	bevacizumab	for	diabetic	
	 -225-	
macular	edema:	six-month	results	of	a	randomized	controlled	trial.	Retina	29:	292-299	DOI	10.1097/IAE.0b013e31819a2d61	77.	 Diabetic	Retinopathy	Clinical	Research	Network,	Wells	JA,	Glassman	AR,	Ayala	AR,	Jampol	LM,	Aiello	LP,	Antoszyk	AN,	Arnold-Bush	B,	Baker	CW,	Bressler	NM,	Browning	DJ,	Elman	MJ,	Ferris	FL,	Friedman	SM,	Melia	M,	Pieramici	DJ,	Sun	JK,	Beck	RW	(2015)	Aflibercept,	bevacizumab,	or	ranibizumab	for	diabetic	macular	edema.	The	New	England	journal	of	medicine	372:	1193-1203	DOI	10.1056/NEJMoa1414264	78.	 Wells	JA,	Glassman	AR,	Ayala	AR,	Jampol	LM,	Bressler	NM,	Bressler	SB,	Brucker	AJ,	Ferris	FL,	Hampton	GR,	Jhaveri	C,	Melia	M,	Beck	RW,	Diabetic	Retinopathy	Clinical	Research	N	(2016)	Aflibercept,	Bevacizumab,	or	Ranibizumab	for	Diabetic	Macular	Edema:	Two-Year	Results	from	a	Comparative	Effectiveness	Randomized	Clinical	Trial.	Ophthalmology	123:	1351-1359	DOI	10.1016/j.ophtha.2016.02.022	79.	 Bressler	SB,	Liu	D,	Glassman	AR,	Blodi	BA,	Castellarin	AA,	Jampol	LM,	Kaufman	PL,	Melia	M,	Singh	H,	Wells	JA,	Diabetic	Retinopathy	Clinical	Research	N	(2017)	Change	in	Diabetic	Retinopathy	Through	2	Years:	Secondary	Analysis	of	a	Randomized	Clinical	Trial	Comparing	Aflibercept,	Bevacizumab,	and	Ranibizumab.	JAMA	ophthalmology		DOI	10.1001/jamaophthalmol.2017.0821	80.	 Dhoot	DS,	Pieramici	DJ,	Nasir	M,	Castellarin	AA,	Couvillion	S,	See	RF,	Steinle	N,	Bennett	M,	Rabena	M,	Avery	RL	(2015)	Residual	edema	evaluation	with	ranibizumab	0.5	mg	and	2.0	mg	formulations	for	diabetic	macular	edema	(REEF	study).	Eye	29:	534-541	DOI	10.1038/eye.2014.338	81.	 Ciulla	TA,	Hussain	RM,	Ciulla	LM,	Sink	B,	Harris	A	(2015)	Ranibizumab	for	Diabetic	Macular	Edema	Refractory	to	Multiple	Prior	Treatments.	Retina		DOI	10.1097/IAE.0000000000000876	82.	 Hanhart	J,	Chowers	I	(2015)	Evaluation	of	the	Response	to	Ranibizumab	Therapy	following	Bevacizumab	Treatment	Failure	in	Eyes	with	Diabetic	Macular	Edema.	Case	reports	in	ophthalmology	6:	44-50	DOI	10.1159/000375230	83.	 Ashraf	M,	Souka	AA,	ElKayal	H	(2017)	Short-Term	Effects	of	Early	Switching	to	Ranibizumab	or	Aflibercept	in	Diabetic	Macular	Edema	Cases	With	Non-Response	to	Bevacizumab.	Ophthalmic	surgery,	lasers	&	imaging	retina	48:	230-236	DOI	10.3928/23258160-20170301-06	84.	 Lim	LS,	Ng	WY,	Mathur	R,	Wong	D,	Wong	EY,	Yeo	I,	Cheung	CM,	Lee	SY,	Wong	TY,	Papakostas	TD,	Kim	LA	(2015)	Conversion	to	aflibercept	for	diabetic	macular	edema	unresponsive	to	ranibizumab	or	bevacizumab.	Clinical	ophthalmology	9:	1715-1718	DOI	10.2147/OPTH.S81523	85.	 Rahimy	E,	Shahlaee	A,	Khan	MA,	Ying	GS,	Maguire	JI,	Ho	AC,	Regillo	CD,	Hsu	J	(2016)	Conversion	to	Aflibercept	After	Prior	Anti-VEGF	Therapy	for	Persistent	Diabetic	Macular	Edema.	American	journal	of	ophthalmology	164:	118-127	e112	DOI	10.1016/j.ajo.2015.12.030	86.	 Wood	EH,	Karth	PA,	Moshfeghi	DM,	Leng	T	(2015)	Short-Term	Outcomes	of	Aflibercept	Therapy	for	Diabetic	Macular	Edema	in	Patients	With	Incomplete	Response	to	Ranibizumab	and/or	Bevacizumab.	Ophthalmic	surgery,	lasers	&	imaging	retina	46:	950-954	DOI	10.3928/23258160-20151008-08	
	 -226-	
87.	 Ip	MS,	Domalpally	A,	Sun	JK,	Ehrlich	JS	(2015)	Long-term	effects	of	therapy	with	ranibizumab	on	diabetic	retinopathy	severity	and	baseline	risk	factors	for	worsening	retinopathy.	Ophthalmology	122:	367-374	DOI	10.1016/j.ophtha.2014.08.048	88.	 Simunovic	MP,	Maberley	DA	(2015)	ANTI-VASCULAR	ENDOTHELIAL	GROWTH	FACTOR	THERAPY	FOR	PROLIFERATIVE	DIABETIC	RETINOPATHY:	A	Systematic	Review	and	Meta-Analysis.	Retina	35:	1931-1942	DOI	10.1097/IAE.0000000000000723	89.	 Writing	Committee	for	the	Diabetic	Retinopathy	Clinical	Research	N,	Gross	JG,	Glassman	AR,	Jampol	LM,	Inusah	S,	Aiello	LP,	Antoszyk	AN,	Baker	CW,	Berger	BB,	Bressler	NM,	Browning	D,	Elman	MJ,	Ferris	FL,	3rd,	Friedman	SM,	Marcus	DM,	Melia	M,	Stockdale	CR,	Sun	JK,	Beck	RW	(2015)	Panretinal	Photocoagulation	vs	Intravitreous	Ranibizumab	for	Proliferative	Diabetic	Retinopathy:	A	Randomized	Clinical	Trial.	Jama	314:	2137-2146	DOI	10.1001/jama.2015.15217	90.	 Gross	JG,	Glassman	AR,	Klein	MJ,	Jampol	LM,	Ferris	FL,	3rd,	Bressler	NM,	Beck	RW	(2017)	Interim	Safety	Data	Comparing	Ranibizumab	With	Panretinal	Photocoagulation	Among	Participants	With	Proliferative	Diabetic	Retinopathy.	JAMA	ophthalmology		DOI	10.1001/jamaophthalmol.2017.0969	91.	 Sivaprasad	S,	Prevost	AT,	Vasconcelos	JC,	Riddell	A,	Murphy	C,	Kelly	J,	Bainbridge	J,	Tudor-Edwards	R,	Hopkins	D,	Hykin	P,	Group	CS	(2017)	Clinical	efficacy	of	intravitreal	aflibercept	versus	panretinal	photocoagulation	for	best	corrected	visual	acuity	in	patients	with	proliferative	diabetic	retinopathy	at	52	weeks	(CLARITY):	a	multicentre,	single-blinded,	randomised,	controlled,	phase	2b,	non-inferiority	trial.	Lancet		DOI	10.1016/S0140-6736(17)31193-5	92.	 Javitt	JC,	Canner	JK,	Sommer	A	(1989)	Cost	effectiveness	of	current	approaches	to	the	control	of	retinopathy	in	type	I	diabetics.	Ophthalmology	96:	255-264	93.	 Hutton	DW,	Stein	JD,	Bressler	NM,	Jampol	LM,	Browning	D,	Glassman	AR,	Diabetic	Retinopathy	Clinical	Research	N	(2017)	Cost-effectiveness	of	Intravitreous	Ranibizumab	Compared	With	Panretinal	Photocoagulation	for	Proliferative	Diabetic	Retinopathy:	Secondary	Analysis	From	a	Diabetic	Retinopathy	Clinical	Research	Network	Randomized	Clinical	Trial.	JAMA	ophthalmology		DOI	10.1001/jamaophthalmol.2017.0837	94.	 Huang	YH,	Yeh	PT,	Chen	MS,	Yang	CH,	Yang	CM	(2009)	Intravitreal	bevacizumab	and	panretinal	photocoagulation	for	proliferative	diabetic	retinopathy	associated	with	vitreous	hemorrhage.	Retina	29:	1134-1140	DOI	10.1097/IAE.0b013e3181b094b7	95.	 Diabetic	Retinopathy	Clinical	Research	N	(2013)	Randomized	clinical	trial	evaluating	intravitreal	ranibizumab	or	saline	for	vitreous	hemorrhage	from	proliferative	diabetic	retinopathy.	JAMA	ophthalmology	131:	283-293	DOI	10.1001/jamaophthalmol.2013.2015	96.	 Smith	JM,	Steel	DH	(2015)	Anti-vascular	endothelial	growth	factor	for	prevention	of	postoperative	vitreous	cavity	haemorrhage	after	vitrectomy	for	proliferative	diabetic	retinopathy.	The	Cochrane	database	of	systematic	reviews:	CD008214	DOI	10.1002/14651858.CD008214.pub3	
	 -227-	
97.	 Zhang	ZH,	Liu	HY,	Hernandez-Da	Mota	SE,	Romano	MR,	Falavarjani	KG,	Ahmadieh	H,	Xu	X,	Liu	K	(2013)	Vitrectomy	with	or	without	preoperative	intravitreal	bevacizumab	for	proliferative	diabetic	retinopathy:	a	meta-analysis	of	randomized	controlled	trials.	American	journal	of	ophthalmology	156:	106-115	e102	DOI	10.1016/j.ajo.2013.02.008	98.	 Zhao	LQ,	Zhu	H,	Zhao	PQ,	Hu	YQ	(2011)	A	systematic	review	and	meta-analysis	of	clinical	outcomes	of	vitrectomy	with	or	without	intravitreal	bevacizumab	pretreatment	for	severe	diabetic	retinopathy.	The	British	journal	of	ophthalmology	95:	1216-1222	DOI	10.1136/bjo.2010.189514	99.	 Comyn	O,	Wickham	L,	Charteris	DG,	Sullivan	PM,	Ezra	E,	Gregor	Z,	Aylward	GW,	da	Cruz	L,	Fabinyi	D,	Peto	T,	Restori	M,	Xing	W,	Bunce	C,	Hykin	PG,	Bainbridge	JW	(2017)	Ranibizumab	pretreatment	in	diabetic	vitrectomy:	a	pilot	randomised	controlled	trial	(the	RaDiVit	study).	Eye	31:	1253-1258	DOI	10.1038/eye.2017.75	100.	 Ribeiro	JA,	Messias	A,	de	Almeida	FP,	Costa	RA,	Scott	IU,	de	Figueiredo-Pontes	LL,	Jorge	R	(2011)	The	effect	of	intravitreal	ranibizumab	on	intraoperative	bleeding	during	pars	plana	vitrectomy	for	diabetic	traction	retinal	detachment.	The	British	journal	of	ophthalmology	95:	1337-1339	DOI	10.1136/bjo.2010.195693	101.	 El-Sabagh	HA,	Abdelghaffar	W,	Labib	AM,	Mateo	C,	Hashem	TM,	Al-Tamimi	DM,	Selim	AA	(2011)	Preoperative	intravitreal	bevacizumab	use	as	an	adjuvant	to	diabetic	vitrectomy:	histopathologic	findings	and	clinical	implications.	Ophthalmology	118:	636-641	DOI	10.1016/j.ophtha.2010.08.038	102.	 Arevalo	JF,	Maia	M,	Flynn	HW,	Jr.,	Saravia	M,	Avery	RL,	Wu	L,	Eid	Farah	M,	Pieramici	DJ,	Berrocal	MH,	Sanchez	JG	(2008)	Tractional	retinal	detachment	following	intravitreal	bevacizumab	(Avastin)	in	patients	with	severe	proliferative	diabetic	retinopathy.	The	British	journal	of	ophthalmology	92:	213-216	DOI	10.1136/bjo.2007.127142	103.	 Castillo	J,	Aleman	I,	Rush	SW,	Rush	RB	(2017)	Preoperative	Bevacizumab	Administration	in	Proliferative	Diabetic	Retinopathy	Patients	Undergoing	Vitrectomy:	a	Randomized	and	Controlled	Trial	Comparing	Interval	Variation.	American	journal	of	ophthalmology		DOI	10.1016/j.ajo.2017.08.013	104.	 Tripathi	RC,	Li	J,	Tripathi	BJ,	Chalam	KV,	Adamis	AP	(1998)	Increased	level	of	vascular	endothelial	growth	factor	in	aqueous	humor	of	patients	with	neovascular	glaucoma.	Ophthalmology	105:	232-237	105.	 Simha	A,	Braganza	A,	Abraham	L,	Samuel	P,	Lindsley	K	(2013)	Anti-vascular	endothelial	growth	factor	for	neovascular	glaucoma.	The	Cochrane	database	of	systematic	reviews:	CD007920	DOI	10.1002/14651858.CD007920.pub2	106.	 Olmos	LC,	Sayed	MS,	Moraczewski	AL,	Gedde	SJ,	Rosenfeld	PJ,	Shi	W,	Feuer	WJ,	Lee	RK	(2016)	Long-term	outcomes	of	neovascular	glaucoma	treated	with	and	without	intravitreal	bevacizumab.	Eye	30:	463-472	DOI	10.1038/eye.2015.259	107.	 Ehlers	JP,	Spirn	MJ,	Lam	A,	Sivalingam	A,	Samuel	MA,	Tasman	W	(2008)	Combination	intravitreal	bevacizumab/panretinal	photocoagulation	versus	panretinal	photocoagulation	alone	in	the	treatment	of	neovascular	glaucoma.	Retina	28:	696-702	DOI	10.1097/IAE.0b013e3181679c0b	
	 -228-	
108.	 SooHoo	JR,	Seibold	LK,	Pantcheva	MB,	Kahook	MY	(2015)	Aflibercept	for	the	treatment	of	neovascular	glaucoma.	Clinical	&	experimental	ophthalmology	43:	803-807	DOI	10.1111/ceo.12559	109.	 Bhisitkul	RB	(2006)	Vascular	endothelial	growth	factor	biology:	clinical	implications	for	ocular	treatments.	The	British	journal	of	ophthalmology	90:	1542-1547	DOI	10.1136/bjo.2006.098426	110.	 An	MM,	Zou	Z,	Shen	H,	Liu	P,	Chen	ML,	Cao	YB,	Jiang	YY	(2010)	Incidence	and	risk	of	significantly	raised	blood	pressure	in	cancer	patients	treated	with	bevacizumab:	an	updated	meta-analysis.	European	journal	of	clinical	pharmacology	66:	813-821	DOI	10.1007/s00228-010-0815-4	111.	 Van	Cutsem	E,	Tabernero	J,	Lakomy	R,	Prenen	H,	Prausova	J,	Macarulla	T,	Ruff	P,	van	Hazel	GA,	Moiseyenko	V,	Ferry	D,	McKendrick	J,	Polikoff	J,	Tellier	A,	Castan	R,	Allegra	C	(2012)	Addition	of	aflibercept	to	fluorouracil,	leucovorin,	and	irinotecan	improves	survival	in	a	phase	III	randomized	trial	in	patients	with	metastatic	colorectal	cancer	previously	treated	with	an	oxaliplatin-based	regimen.	Journal	of	clinical	oncology	:	official	journal	of	the	American	Society	of	Clinical	Oncology	30:	3499-3506	DOI	10.1200/JCO.2012.42.8201	112.	 Scappaticci	FA,	Skillings	JR,	Holden	SN,	Gerber	HP,	Miller	K,	Kabbinavar	F,	Bergsland	E,	Ngai	J,	Holmgren	E,	Wang	J,	Hurwitz	H	(2007)	Arterial	thromboembolic	events	in	patients	with	metastatic	carcinoma	treated	with	chemotherapy	and	bevacizumab.	Journal	of	the	National	Cancer	Institute	99:	1232-1239	DOI	10.1093/jnci/djm086	113.	 Nalluri	SR,	Chu	D,	Keresztes	R,	Zhu	X,	Wu	S	(2008)	Risk	of	venous	thromboembolism	with	the	angiogenesis	inhibitor	bevacizumab	in	cancer	patients:	a	meta-analysis.	Jama	300:	2277-2285	DOI	10.1001/jama.2008.656	114.	 Ranpura	V,	Hapani	S,	Chuang	J,	Wu	S	(2010)	Risk	of	cardiac	ischemia	and	arterial	thromboembolic	events	with	the	angiogenesis	inhibitor	bevacizumab	in	cancer	patients:	a	meta-analysis	of	randomized	controlled	trials.	Acta	oncologica	49:	287-297	DOI	10.3109/02841860903524396	115.	 Hang	XF,	Xu	WS,	Wang	JX,	Wang	L,	Xin	HG,	Zhang	RQ,	Ni	W	(2011)	Risk	of	high-grade	bleeding	in	patients	with	cancer	treated	with	bevacizumab:	a	meta-analysis	of	randomized	controlled	trials.	European	journal	of	clinical	pharmacology	67:	613-623	DOI	10.1007/s00228-010-0988-x	116.	 Scappaticci	FA,	Fehrenbacher	L,	Cartwright	T,	Hainsworth	JD,	Heim	W,	Berlin	J,	Kabbinavar	F,	Novotny	W,	Sarkar	S,	Hurwitz	H	(2005)	Surgical	wound	healing	complications	in	metastatic	colorectal	cancer	patients	treated	with	bevacizumab.	Journal	of	surgical	oncology	91:	173-180	DOI	10.1002/jso.20301	117.	 Etminan	M,	Maberley	DA,	Babiuk	DW,	Carleton	BC	(2016)	Risk	of	Myocardial	Infarction	and	Stroke	With	Single	or	Repeated	Doses	of	Intravitreal	Bevacizumab	in	Age-Related	Macular	Degeneration.	American	journal	of	ophthalmology	163:	53-58	DOI	10.1016/j.ajo.2015.11.030	118.	 Zarbin	MA,	Dunger-Baldauf	C,	Haskova	Z,	Koovejee	P,	Mousseau	MC,	Margaron	P,	Snow	H,	Beaumont	PE,	Staurenghi	G,	Francom	S	(2017)	Vascular	Safety	of	Ranibizumab	in	Patients	With	Diabetic	Macular	Edema:	A	Pooled	Analysis	of	Patient-Level	Data	From	Randomized	Clinical	Trials.	
	 -229-	
JAMA	ophthalmology	135:	424-431	DOI	10.1001/jamaophthalmol.2017.0455	119.	 Bressler	NM,	Boyer	DS,	Williams	DF,	Butler	S,	Francom	SF,	Brown	B,	Di	Nucci	F,	Cramm	T,	Tuomi	LL,	Ianchulev	T,	Rubio	RG	(2012)	Cerebrovascular	accidents	in	patients	treated	for	choroidal	neovascularization	with	ranibizumab	in	randomized	controlled	trials.	Retina	32:	1821-1828	DOI	10.1097/IAE.0b013e31825db6ba	120.	 Avery	RL,	Gordon	GM	(2016)	Systemic	Safety	of	Prolonged	Monthly	Anti-Vascular	Endothelial	Growth	Factor	Therapy	for	Diabetic	Macular	Edema:	A	Systematic	Review	and	Meta-analysis.	JAMA	ophthalmology	134:	21-29	DOI	10.1001/jamaophthalmol.2015.4070	121.	 Mitchell	P,	Bandello	F,	Schmidt-Erfurth	U,	Lang	GE,	Massin	P,	Schlingemann	RO,	Sutter	F,	Simader	C,	Burian	G,	Gerstner	O,	Weichselberger	A,	group	Rs	(2011)	The	RESTORE	study:	ranibizumab	monotherapy	or	combined	with	laser	versus	laser	monotherapy	for	diabetic	macular	edema.	Ophthalmology	118:	615-625	DOI	10.1016/j.ophtha.2011.01.031	122.	 Nguyen	QD,	Brown	DM,	Marcus	DM,	Boyer	DS,	Patel	S,	Feiner	L,	Gibson	A,	Sy	J,	Rundle	AC,	Hopkins	JJ,	Rubio	RG,	Ehrlich	JS,	Rise,	Group	RR	(2012)	Ranibizumab	for	diabetic	macular	edema:	results	from	2	phase	III	randomized	trials:	RISE	and	RIDE.	Ophthalmology	119:	789-801	DOI	10.1016/j.ophtha.2011.12.039	123.	 McCannel	CA	(2011)	Meta-analysis	of	endophthalmitis	after	intravitreal	injection	of	anti-vascular	endothelial	growth	factor	agents:	causative	organisms	and	possible	prevention	strategies.	Retina	31:	654-661	DOI	10.1097/IAE.0b013e31820a67e4	124.	 Moshfeghi	AA,	Rosenfeld	PJ,	Flynn	HW,	Jr.,	Schwartz	SG,	Davis	JL,	Murray	TG,	Smiddy	WE,	Berrocal	AM,	Dubovy	SR,	Lee	WH,	Albini	TA,	Lalwani	GA,	Kovach	JL,	Puliafito	CA	(2011)	Endophthalmitis	after	intravitreal	vascular	[corrected]	endothelial	growth	factor	antagonists:	a	six-year	experience	at	a	university	referral	center.	Retina	31:	662-668	DOI	10.1097/IAE.0b013e31821067c4	125.	 Gillies	MC,	Lim	LL,	Campain	A,	Quin	GJ,	Salem	W,	Li	J,	Goodwin	S,	Aroney	C,	McAllister	IL,	Fraser-Bell	S	(2014)	A	randomized	clinical	trial	of	intravitreal	bevacizumab	versus	intravitreal	dexamethasone	for	diabetic	macular	edema:	the	BEVORDEX	study.	Ophthalmology	121:	2473-2481	DOI	10.1016/j.ophtha.2014.07.002	126.	 Schwartz	SG,	Flynn	HW,	Jr.	(2014)	Endophthalmitis	Associated	with	Intravitreal	Anti-Vascular	Endothelial	Growth	Factor	Injections.	Current	ophthalmology	reports	2:	1-5	DOI	10.1007/s40135-013-0033-1	127.	 Palmer	JM,	Amoaku	WM,	Kamali	F	(2013)	Quality	of	bevacizumab	compounded	for	intravitreal	administration.	Eye	27:	1090-1097	DOI	10.1038/eye.2013.139	128.	 Gonzalez	S,	Rosenfeld	PJ,	Stewart	MW,	Brown	J,	Murphy	SP	(2012)	Avastin	doesn't	blind	people,	people	blind	people.	American	journal	of	ophthalmology	153:	196-203	e191	DOI	10.1016/j.ajo.2011.11.023	129.	 Entezari	M,	Karimi	S,	Ahmadieh	H,	Mahmoudi	AH,	Parhizgar	H,	Yaseri	M	(2016)	A	Large	Outbreak	of	Fulminant	Bacterial	Endophthalmitis	after	Intravitreal	Injection	of	Counterfeit	Bevacizumab.	Graefe's	archive	for	
	 -230-	
clinical	and	experimental	ophthalmology	=	Albrecht	von	Graefes	Archiv	fur	klinische	und	experimentelle	Ophthalmologie	254:	1851-1856	DOI	10.1007/s00417-016-3426-7	130.	 Sun	X,	Xu	X,	Zhang	X	(2011)	Counterfeit	bevacizumab	and	endophthalmitis.	The	New	England	journal	of	medicine	365:	378-379;	author	reply	379	DOI	10.1056/NEJMc1106415#SA1	131.	 Meyer	CH,	Michels	S,	Rodrigues	EB,	Hager	A,	Mennel	S,	Schmidt	JC,	Helb	HM,	Farah	ME	(2011)	Incidence	of	rhegmatogenous	retinal	detachments	after	intravitreal	antivascular	endothelial	factor	injections.	Acta	Ophthalmol	89:	70-75	DOI	10.1111/j.1755-3768.2010.02064.x	132.	 Hoang	QV,	Mendonca	LS,	Della	Torre	KE,	Jung	JJ,	Tsuang	AJ,	Freund	KB	(2012)	Effect	on	intraocular	pressure	in	patients	receiving	unilateral	intravitreal	anti-vascular	endothelial	growth	factor	injections.	Ophthalmology	119:	321-326	DOI	10.1016/j.ophtha.2011.08.011	133.	 Good	TJ,	Kimura	AE,	Mandava	N,	Kahook	MY	(2011)	Sustained	elevation	of	intraocular	pressure	after	intravitreal	injections	of	anti-VEGF	agents.	The	British	journal	of	ophthalmology	95:	1111-1114	DOI	10.1136/bjo.2010.180729	134.	 Zhang	Q,	Qi	Y,	Chen	L,	Shi	X,	Bai	Y,	Huang	L,	Yu	W,	Jiang	Y,	Zhao	M,	Li	X	(2016)	The	relationship	between	anti-vascular	endothelial	growth	factor	and	fibrosis	in	proliferative	retinopathy:	clinical	and	laboratory	evidence.	The	British	journal	of	ophthalmology	100:	1443-1450	DOI	10.1136/bjophthalmol-2015-308199	135.	 Kuiper	EJ,	Van	Nieuwenhoven	FA,	de	Smet	MD,	van	Meurs	JC,	Tanck	MW,	Oliver	N,	Klaassen	I,	Van	Noorden	CJ,	Goldschmeding	R,	Schlingemann	RO	(2008)	The	angio-fibrotic	switch	of	VEGF	and	CTGF	in	proliferative	diabetic	retinopathy.	PloS	one	3:	e2675	DOI	10.1371/journal.pone.0002675	136.	 Amato	R,	Biagioni	M,	Cammalleri	M,	Dal	Monte	M,	Casini	G	(2016)	VEGF	as	a	Survival	Factor	in	Ex	Vivo	Models	of	Early	Diabetic	Retinopathy.	Investigative	ophthalmology	&	visual	science	57:	3066-3076	DOI	10.1167/iovs.16-19285	137.	 Hombrebueno	JR,	Ali	IH,	Xu	H,	Chen	M	(2015)	Sustained	intraocular	VEGF	neutralization	results	in	retinal	neurodegeneration	in	the	Ins2(Akita)	diabetic	mouse.	Scientific	reports	5:	18316	DOI	10.1038/srep18316	138.	 Fu	S,	Dong	S,	Zhu	M,	Sherry	DM,	Wang	C,	You	Z,	Haigh	JJ,	Le	YZ	(2015)	Muller	Glia	Are	a	Major	Cellular	Source	of	Survival	Signals	for	Retinal	Neurons	in	Diabetes.	Diabetes	64:	3554-3563	DOI	10.2337/db15-0180	139.	 Mori	Y,	Suzuma	K,	Uji	A,	Ishihara	K,	Yoshitake	S,	Fujimoto	M,	Dodo	Y,	Yoshitake	T,	Miwa	Y,	Murakami	T	(2016)	Restoration	of	foveal	photoreceptors	after	intravitreal	ranibizumab	injections	for	diabetic	macular	edema.	Scientific	reports	6:	39161	DOI	10.1038/srep39161	140.	 Manousaridis	K,	Talks	J	(2012)	Macular	ischaemia:	a	contraindication	for	anti-VEGF	treatment	in	retinal	vascular	disease?	The	British	journal	of	ophthalmology	96:	179-184	DOI	10.1136/bjophthalmol-2011-301087	141.	 Michaelides	M,	Fraser-Bell	S,	Hamilton	R,	Kaines	A,	Egan	C,	Bunce	C,	Peto	T,	Hykin	P	(2010)	Macular	perfusion	determined	by	fundus	fluorescein	angiography	at	the	4-month	time	point	in	a	prospective	randomized	trial	
	 -231-	
of	intravitreal	bevacizumab	or	laser	therapy	in	the	management	of	diabetic	macular	edema	(Bolt	Study):	Report	1.	Retina	30:	781-786	142.	 Holz	FG,	Dugel	PU,	Weissgerber	G,	Hamilton	R,	Silva	R,	Bandello	F,	Larsen	M,	Weichselberger	A,	Wenzel	A,	Schmidt	A,	Escher	D,	Sararols	L,	Souied	E	(2016)	Single-Chain	Antibody	Fragment	VEGF	Inhibitor	RTH258	for	Neovascular	Age-Related	Macular	Degeneration:	A	Randomized	Controlled	Study.	Ophthalmology	123:	1080-1089	DOI	10.1016/j.ophtha.2015.12.030	143.	 Xu	Y,	Rong	A,	Bi	Y,	Xu	W	(2016)	Intravitreal	Conbercept	Injection	with	and	without	Grid	Laser	Photocoagulation	in	the	Treatment	of	Diffuse	Diabetic	Macular	Edema	in	Real-Life	Clinical	Practice.	Journal	of	ophthalmology	2016:	2143082	DOI	10.1155/2016/2143082	144.	 Campochiaro	PA,	Channa	R,	Berger	BB,	Heier	JS,	Brown	DM,	Fiedler	U,	Hepp	J,	Stumpp	MT	(2013)	Treatment	of	diabetic	macular	edema	with	a	designed	ankyrin	repeat	protein	that	binds	vascular	endothelial	growth	factor:	a	phase	I/II	study.	American	journal	of	ophthalmology	155:	697-704,	704	e691-692	DOI	10.1016/j.ajo.2012.09.032	145.	 Rakoczy	EP,	Lai	CM,	Magno	AL,	Wikstrom	ME,	French	MA,	Pierce	CM,	Schwartz	SD,	Blumenkranz	MS,	Chalberg	TW,	Degli-Esposti	MA,	Constable	IJ	(2015)	Gene	therapy	with	recombinant	adeno-associated	vectors	for	neovascular	age-related	macular	degeneration:	1	year	follow-up	of	a	phase	1	randomised	clinical	trial.	Lancet	386:	2395-2403	DOI	10.1016/S0140-6736(15)00345-1	146.	 Jeong	JH,	Nguyen	HK,	Lee	JE,	Suh	W	(2016)	Therapeutic	effect	of	apatinib-loaded	nanoparticles	on	diabetes-induced	retinal	vascular	leakage.	International	journal	of	nanomedicine	11:	3101-3109	DOI	10.2147/IJN.S108452	147.	 Humayun	M,	Santos	A,	Altamirano	JC,	Ribeiro	R,	Gonzalez	R,	de	la	Rosa	A,	Shih	J,	Pang	C,	Jiang	F,	Calvillo	P,	Huculak	J,	Zimmerman	J,	Caffey	S	(2014)	Implantable	MicroPump	for	Drug	Delivery	in	Patients	with	Diabetic	Macular	Edema.	Translational	vision	science	&	technology	3:	5	DOI	10.1167/tvst.3.6.5	148.	 Liew	G,	Michaelides	M,	Bunce	C	(2014)	A	comparison	of	the	causes	of	blindness	certifications	in	England	and	Wales	in	working	age	adults	(16-64	years),	1999-2000	with	2009-2010.	BMJ	open	4:	e004015	DOI	10.1136/bmjopen-2013-004015	149.	 Gonder	JR,	Walker	VM,	Barbeau	M,	Zaour	N,	Zachau	BH,	Hartje	JR,	Li	R	(2014)	Costs	and	Quality	of	Life	in	Diabetic	Macular	Edema:	Canadian	Burden	of	Diabetic	Macular	Edema	Observational	Study	(C-REALITY).	Journal	of	ophthalmology	2014:	939315	DOI	10.1155/2014/939315	150.	 Pierro	L,	Giatsidis	SM,	Mantovani	E,	Gagliardi	M	(2010)	Macular	thickness	interoperator	and	intraoperator	reproducibility	in	healthy	eyes	using	7	optical	coherence	tomography	instruments.	American	journal	of	ophthalmology	150:	199-204	e191	DOI	10.1016/j.ajo.2010.03.015	151.	 Bressler	SB,	Qin	H,	Beck	RW,	Chalam	KV,	Kim	JE,	Melia	M,	Wells	JA,	3rd,	Diabetic	Retinopathy	Clinical	Research	N	(2012)	Factors	associated	with	changes	in	visual	acuity	and	central	subfield	thickness	at	1	year	after	treatment	for	diabetic	macular	edema	with	ranibizumab.	Archives	of	ophthalmology	130:	1153-1161	DOI	10.1001/archophthalmol.2012.1107	
	 -232-	
152.	 Klaassen	I,	Van	Noorden	CJ,	Schlingemann	RO	(2013)	Molecular	basis	of	the	inner	blood-retinal	barrier	and	its	breakdown	in	diabetic	macular	edema	and	other	pathological	conditions.	Progress	in	retinal	and	eye	research	34:	19-48	DOI	10.1016/j.preteyeres.2013.02.001	153.	 Dong	N,	Xu	B,	Chu	L,	Tang	X	(2015)	Study	of	27	Aqueous	Humor	Cytokines	in	Type	2	Diabetic	Patients	with	or	without	Macular	Edema.	PloS	one	10:	e0125329	DOI	10.1371/journal.pone.0125329	154.	 Funk	M,	Schmidinger	G,	Maar	N,	Bolz	M,	Benesch	T,	Zlabinger	GJ,	Schmidt-Erfurth	UM	(2010)	Angiogenic	and	inflammatory	markers	in	the	intraocular	fluid	of	eyes	with	diabetic	macular	edema	and	influence	of	therapy	with	bevacizumab.	Retina	30:	1412-1419	DOI	10.1097/IAE.0b013e3181e095c0	155.	 Cameron	NE,	Cotter	MA	(1997)	Metabolic	and	vascular	factors	in	the	pathogenesis	of	diabetic	neuropathy.	Diabetes	46	Suppl	2:	S31-37	156.	 Das	Evcimen	N,	King	GL	(2007)	The	role	of	protein	kinase	C	activation	and	the	vascular	complications	of	diabetes.	Pharmacological	research	55:	498-510	DOI	10.1016/j.phrs.2007.04.016	157.	 Stitt	AW,	Moore	JE,	Sharkey	JA,	Murphy	G,	Simpson	DA,	Bucala	R,	Vlassara	H,	Archer	DB	(1998)	Advanced	glycation	end	products	in	vitreous:	Structural	and	functional	implications	for	diabetic	vitreopathy.	Investigative	ophthalmology	&	visual	science	39:	2517-2523	158.	 Goldin	A,	Beckman	JA,	Schmidt	AM,	Creager	MA	(2006)	Advanced	glycation	end	products:	sparking	the	development	of	diabetic	vascular	injury.	Circulation	114:	597-605	DOI	10.1161/CIRCULATIONAHA.106.621854	159.	 Arjamaa	O,	Minn	H	(2012)	Resistance,	not	tachyphylaxis	or	tolerance.	The	British	journal	of	ophthalmology	96:	1153-1154	DOI	10.1136/bjophthalmol-2012-301823	160.	 Alshahrani	ST,	Dolz-Marco	R,	Gallego-Pinazo	R,	Diaz-Llopis	M,	Arevalo	JF,	Group	KICRS	(2016)	INTRAVITREAL	DEXAMETHASONE	IMPLANT	FOR	THE	TREATMENT	OF	REFRACTORY	MACULAR	EDEMA	IN	RETINAL	VASCULAR	DISEASES:	Results	of	the	KKESH	International	Collaborative	Retina	Study	Group.	Retina	36:	131-136	DOI	10.1097/IAE.0000000000000616	161.	 Bansal	P,	Gupta	V,	Gupta	A,	Dogra	MR,	Ram	J	(2015)	Efficacy	of	Ozurdex	implant	in	recalcitrant	diabetic	macular	edema-a	single-center	experience.	International	ophthalmology		DOI	10.1007/s10792-015-0103-5	162.	 Dutra	Medeiros	M,	Postorino	M,	Navarro	R,	Garcia-Arumi	J,	Mateo	C,	Corcostegui	B	(2014)	Dexamethasone	intravitreal	implant	for	treatment	of	patients	with	persistent	diabetic	macular	edema.	Ophthalmologica	Journal	international	d'ophtalmologie	International	journal	of	ophthalmology	Zeitschrift	fur	Augenheilkunde	231:	141-146	DOI	10.1159/000356413	163.	 Escobar-Barranco	JJ,	Pina-Marin	B,	Fernandez-Bonet	M	(2015)	Dexamethasone	Implants	in	Patients	with	Naive	or	Refractory	Diffuse	Diabetic	Macular	Edema.	Ophthalmologica	Journal	international	d'ophtalmologie	International	journal	of	ophthalmology	Zeitschrift	fur	Augenheilkunde	233:	176-185	DOI	10.1159/000371770	
	 -233-	
164.	 Gutierrez-Benitez	L,	Millan	E,	Arias	L,	Garcia	P,	Cobos	E,	Caminal	M	(2015)	Dexamethasone	intravitreal	implants	for	diabetic	macular	edema	refractory	to	ranibizumab	monotherapy	or	combination	therapy.	Archivos	de	la	Sociedad	Espanola	de	Oftalmologia		DOI	10.1016/j.oftal.2015.04.003	165.	 Haritoglou	C,	Kook	D,	Neubauer	A,	Wolf	A,	Priglinger	S,	Strauss	R,	Gandorfer	A,	Ulbig	M,	Kampik	A	(2006)	Intravitreal	bevacizumab	(Avastin)	therapy	for	persistent	diffuse	diabetic	macular	edema.	Retina	26:	999-1005	DOI	10.1097/01.iae.0000247165.38655.bf	166.	 Jeon	S,	Lee	WK	(2014)	Effect	of	intravitreal	triamcinolone	in	diabetic	macular	edema	unresponsive	to	intravitreal	bevacizumab.	Retina	34:	1606-1611	DOI	10.1097/IAE.0000000000000109	167.	 Kim	YT,	Kang	SW,	Kim	SJ,	Kim	SM,	Chung	SE	(2012)	Combination	of	vitrectomy,	IVTA,	and	laser	photocoagulation	for	diabetic	macular	edema	unresponsive	to	prior	treatments;	3-year	results.	Graefe's	archive	for	clinical	and	experimental	ophthalmology	=	Albrecht	von	Graefes	Archiv	fur	klinische	und	experimentelle	Ophthalmologie	250:	679-684	DOI	10.1007/s00417-011-1888-1	168.	 Kim	JH,	Lee	TG,	Lew	YJ	(2015)	Short-term	efficacy	of	intravitreal	triamcinolone	acetonide	for	bevacizumab-resistant	diabetic	macular	oedema.	Acta	Ophthalmol	93:	e178-179	DOI	10.1111/aos.12504	169.	 Lazic	R,	Lukic	M,	Boras	I,	Draca	N,	Vlasic	M,	Gabric	N,	Tomic	Z	(2014)	Treatment	of	anti-vascular	endothelial	growth	factor-resistant	diabetic	macular	edema	with	dexamethasone	intravitreal	implant.	Retina	34:	719-724	DOI	10.1097/IAE.0b013e3182a48958	170.	 Maturi	RK,	Bleau	L,	Saunders	J,	Mubasher	M,	Stewart	MW	(2015)	A	12-Month,	Single-Masked,	Randomized	Controlled	Study	of	Eyes	with	Persistent	Diabetic	Macular	Edema	after	Multiple	Anti-Vegf	Injections	to	Assess	the	Efficacy	of	the	Dexamethasone-Delayed	Delivery	System	as	an	Adjunct	to	Bevacizumab	Compared	with	Continued	Bevacizumab	Monotherapy.	Retina	35:	1604-1614	DOI	10.1097/IAE.0000000000000533	171.	 Ornek	K,	Ornek	N	(2008)	Intravitreal	bevacizumab	treatment	for	refractory	diabetic	macular	edema.	Journal	of	ocular	pharmacology	and	therapeutics	:	the	official	journal	of	the	Association	for	Ocular	Pharmacology	and	Therapeutics	24:	403-407	DOI	10.1089/jop.2007.0128	172.	 Totan	Y,	Guler	E,	Guragac	FB	(2015)	Dexamethasone	Intravitreal	Implant	for	Chronic	Diabetic	Macular	Edema	Resistant	to	Intravitreal	Bevacizumab	Treatment.	Current	eye	research:	1-7	DOI	10.3109/02713683.2014.1002048	173.	 Yolcu	U,	Sobaci	G	(2014)	The	effect	of	combined	treatment	of	bevacizumab	and	triamcinolone	for	diabetic	macular	edema	refractory	to	previous	intravitreal	mono-injections.	International	ophthalmology		DOI	10.1007/s10792-014-0019-5	174.	 Yuksel	E,	Ozdek	S,	Yuksel	N,	Hasanreisoglu	B	(2013)	Intravitreal	bevacizumab	treatment	for	refractory	diabetic	macular	edema.	International	ophthalmology	33:	659-663	DOI	10.1007/s10792-013-9758-y	
	 -234-	
175.	 Zhioua	I,	Semoun	O,	Lalloum	F,	Souied	EH	(2015)	Intravitreal	Dexamethasone	Implant	in	Patients	with	Ranibizumab	Persistent	Diabetic	Macular	Edema.	Retina	35:	1429-1435	DOI	10.1097/IAE.0000000000000490	176.	 Patel	RD,	Messner	LV,	Teitelbaum	B,	Michel	KA,	Hariprasad	SM	(2013)	Characterization	of	ischemic	index	using	ultra-widefield	fluorescein	angiography	in	patients	with	focal	and	diffuse	recalcitrant	diabetic	macular	edema.	American	journal	of	ophthalmology	155:	1038-1044	e1032	DOI	10.1016/j.ajo.2013.01.007	177.	 Regatieri	CV,	Branchini	L,	Carmody	J,	Fujimoto	JG,	Duker	JS	(2012)	Choroidal	thickness	in	patients	with	diabetic	retinopathy	analyzed	by	spectral-domain	optical	coherence	tomography.	Retina	32:	563-568	DOI	10.1097/IAE.0b013e31822f5678	178.	 Sun	JK,	Lin	MM,	Lammer	J,	Prager	S,	Sarangi	R,	Silva	PS,	Aiello	LP	(2014)	Disorganization	of	the	retinal	inner	layers	as	a	predictor	of	visual	acuity	in	eyes	with	center-involved	diabetic	macular	edema.	JAMA	ophthalmology	132:	1309-1316	DOI	10.1001/jamaophthalmol.2014.2350	179.	 Otani	T,	Yamaguchi	Y,	Kishi	S	(2010)	Correlation	between	visual	acuity	and	foveal	microstructural	changes	in	diabetic	macular	edema.	Retina	30:	774-780	DOI	10.1097/IAE.0b013e3181c2e0d6	180.	 Murakami	T,	Nishijima	K,	Sakamoto	A,	Ota	M,	Horii	T,	Yoshimura	N	(2011)	Association	of	pathomorphology,	photoreceptor	status,	and	retinal	thickness	with	visual	acuity	in	diabetic	retinopathy.	American	journal	of	ophthalmology	151:	310-317	DOI	10.1016/j.ajo.2010.08.022	181.	 Maheshwary	AS,	Oster	SF,	Yuson	RM,	Cheng	L,	Mojana	F,	Freeman	WR	(2010)	The	association	between	percent	disruption	of	the	photoreceptor	inner	segment-outer	segment	junction	and	visual	acuity	in	diabetic	macular	edema.	American	journal	of	ophthalmology	150:	63-67	e61	DOI	10.1016/j.ajo.2010.01.039	182.	 Virgili	G,	Menchini	F,	Casazza	G,	Hogg	R,	Das	RR,	Wang	X,	Michelessi	M	(2015)	Optical	coherence	tomography	(OCT)	for	detection	of	macular	oedema	in	patients	with	diabetic	retinopathy.	The	Cochrane	database	of	systematic	reviews	1:	CD008081	DOI	10.1002/14651858.CD008081.pub3	183.	 Chung	EJ,	Roh	MI,	Kwon	OW,	Koh	HJ	(2008)	Effects	of	macular	ischemia	on	the	outcome	of	intravitreal	bevacizumab	therapy	for	diabetic	macular	edema.	Retina	28:	957-963	DOI	10.1097/IAE.0b013e3181754209	184.	 de	Carlo	TE,	Chin	AT,	Joseph	T,	Baumal	CR,	Witkin	AJ,	Duker	JS,	Waheed	NK	(2016)	Distinguishing	Diabetic	Macular	Edema	From	Capillary	Nonperfusion	Using	Optical	Coherence	Tomography	Angiography.	Ophthalmic	surgery,	lasers	&	imaging	retina	47:	108-114	DOI	10.3928/23258160-20160126-02	185.	 Lopes	de	Faria	JM,	Jalkh	AE,	Trempe	CL,	McMeel	JW	(1999)	Diabetic	macular	edema:	risk	factors	and	concomitants.	Acta	ophthalmologica	Scandinavica	77:	170-175	186.	 Chew	EY,	Davis	MD,	Danis	RP,	Lovato	JF,	Perdue	LH,	Greven	C,	Genuth	S,	Goff	DC,	Leiter	LA,	Ismail-Beigi	F,	Ambrosius	WT,	Action	to	Control	Cardiovascular	Risk	in	Diabetes	Eye	Study	Research	G	(2014)	The	effects	of	medical	management	on	the	progression	of	diabetic	retinopathy	in	
	 -235-	
persons	with	type	2	diabetes:	the	Action	to	Control	Cardiovascular	Risk	in	Diabetes	(ACCORD)	Eye	Study.	Ophthalmology	121:	2443-2451	DOI	10.1016/j.ophtha.2014.07.019	187.	 Das	R,	Kerr	R,	Chakravarthy	U,	Hogg	RE	(2015)	Dyslipidemia	and	Diabetic	Macular	Edema:	A	Systematic	Review	and	Meta-Analysis.	Ophthalmology	122:	1820-1827	DOI	10.1016/j.ophtha.2015.05.011	188.	 Li	J,	Wang	JJ,	Chen	D,	Mott	R,	Yu	Q,	Ma	JX,	Zhang	SX	(2009)	Systemic	administration	of	HMG-CoA	reductase	inhibitor	protects	the	blood-retinal	barrier	and	ameliorates	retinal	inflammation	in	type	2	diabetes.	Experimental	eye	research	89:	71-78	DOI	10.1016/j.exer.2009.02.013	189.	 Keech	AC,	Mitchell	P,	Summanen	PA,	O'Day	J,	Davis	TM,	Moffitt	MS,	Taskinen	MR,	Simes	RJ,	Tse	D,	Williamson	E,	Merrifield	A,	Laatikainen	LT,	d'Emden	MC,	Crimet	DC,	O'Connell	RL,	Colman	PG,	investigators	Fs	(2007)	Effect	of	fenofibrate	on	the	need	for	laser	treatment	for	diabetic	retinopathy	(FIELD	study):	a	randomised	controlled	trial.	Lancet	370:	1687-1697	DOI	10.1016/S0140-6736(07)61607-9	190.	 Group	AS,	Group	AES,	Chew	EY,	Ambrosius	WT,	Davis	MD,	Danis	RP,	Gangaputra	S,	Greven	CM,	Hubbard	L,	Esser	BA,	Lovato	JF,	Perdue	LH,	Goff	DC,	Jr.,	Cushman	WC,	Ginsberg	HN,	Elam	MB,	Genuth	S,	Gerstein	HC,	Schubart	U,	Fine	LJ	(2010)	Effects	of	medical	therapies	on	retinopathy	progression	in	type	2	diabetes.	The	New	England	journal	of	medicine	363:	233-244	DOI	10.1056/NEJMoa1001288	191.	 Wessel	MM,	Nair	N,	Aaker	GD,	Ehrlich	JR,	D'Amico	DJ,	Kiss	S	(2012)	Peripheral	retinal	ischaemia,	as	evaluated	by	ultra-widefield	fluorescein	angiography,	is	associated	with	diabetic	macular	oedema.	The	British	journal	of	ophthalmology	96:	694-698	DOI	10.1136/bjophthalmol-2011-300774	192.	 Awata	T,	Kurihara	S,	Takata	N,	Neda	T,	Iizuka	H,	Ohkubo	T,	Osaki	M,	Watanabe	M,	Nakashima	Y,	Inukai	K,	Inoue	I,	Kawasaki	I,	Mori	K,	Yoneya	S,	Katayama	S	(2005)	Functional	VEGF	C-634G	polymorphism	is	associated	with	development	of	diabetic	macular	edema	and	correlated	with	macular	retinal	thickness	in	type	2	diabetes.	Biochemical	and	biophysical	research	communications	333:	679-685	DOI	10.1016/j.bbrc.2005.05.167	193.	 Churchill	AJ,	Carter	JG,	Ramsden	C,	Turner	SJ,	Yeung	A,	Brenchley	PE,	Ray	DW	(2008)	VEGF	polymorphisms	are	associated	with	severity	of	diabetic	retinopathy.	Investigative	ophthalmology	&	visual	science	49:	3611-3616	DOI	10.1167/iovs.07-1383	194.	 Abhary	S,	Hewitt	AW,	Burdon	KP,	Craig	JE	(2009)	A	systematic	meta-analysis	of	genetic	association	studies	for	diabetic	retinopathy.	Diabetes	58:	2137-2147	DOI	10.2337/db09-0059	195.	 Lee	CM,	Olk	RJ	(1991)	Modified	grid	laser	photocoagulation	for	diffuse	diabetic	macular	edema.	Long-term	visual	results.	Ophthalmology	98:	1594-1602	196.	 Stefansson	E	(2006)	Ocular	oxygenation	and	the	treatment	of	diabetic	retinopathy.	Survey	of	ophthalmology	51:	364-380	DOI	10.1016/j.survophthal.2006.04.005	197.	 Matsumoto	M,	Yoshimura	N,	Honda	Y	(1994)	Increased	production	of	transforming	growth	factor-beta	2	from	cultured	human	retinal	pigment	
	 -236-	
epithelial	cells	by	photocoagulation.	Investigative	ophthalmology	&	visual	science	35:	4245-4252	198.	 Lewis	H,	Schachat	AP,	Haimann	MH,	Haller	JA,	Quinlan	P,	von	Fricken	MA,	Fine	SL,	Murphy	RP	(1990)	Choroidal	neovascularization	after	laser	photocoagulation	for	diabetic	macular	edema.	Ophthalmology	97:	503-510;	discussion	510-501	199.	 Figueira	J,	Khan	J,	Nunes	S,	Sivaprasad	S,	Rosa	A,	de	Abreu	JF,	Cunha-Vaz	JG,	Chong	NV	(2009)	Prospective	randomised	controlled	trial	comparing	sub-threshold	micropulse	diode	laser	photocoagulation	and	conventional	green	laser	for	clinically	significant	diabetic	macular	oedema.	The	British	journal	of	ophthalmology	93:	1341-1344	DOI	10.1136/bjo.2008.146712	200.	 Harbour	JW,	Smiddy	WE,	Flynn	HW,	Jr.,	Rubsamen	PE	(1996)	Vitrectomy	for	diabetic	macular	edema	associated	with	a	thickened	and	taut	posterior	hyaloid	membrane.	American	journal	of	ophthalmology	121:	405-413	201.	 Gaucher	D,	Tadayoni	R,	Erginay	A,	Haouchine	B,	Gaudric	A,	Massin	P	(2005)	Optical	coherence	tomography	assessment	of	the	vitreoretinal	relationship	in	diabetic	macular	edema.	American	journal	of	ophthalmology	139:	807-813	DOI	10.1016/j.ajo.2004.12.084	202.	 Abrishami	M,	Moosavi	MN,	Shoeibi	N,	Hosseinpoor	SS	(2011)	Intravitreal	tissue	plasminogen	activator	to	treat	refractory	diabetic	macular	edema	by	induction	of	posterior	vitreous	detachment.	Retina	31:	2065-2070	DOI	10.1097/IAE.0b013e31820f49ff	203.	 Dillinger	P,	Mester	U	(2004)	Vitrectomy	with	removal	of	the	internal	limiting	membrane	in	chronic	diabetic	macular	oedema.	Graefe's	archive	for	clinical	and	experimental	ophthalmology	=	Albrecht	von	Graefes	Archiv	fur	klinische	und	experimentelle	Ophthalmologie	242:	630-637	DOI	10.1007/s00417-003-0849-8	204.	 Quiram	PA,	Leverenz	VR,	Baker	RM,	Dang	L,	Giblin	FJ,	Trese	MT	(2007)	Microplasmin-induced	posterior	vitreous	detachment	affects	vitreous	oxygen	levels.	Retina	27:	1090-1096	DOI	10.1097/IAE.0b013e3180654229	205.	 Simunovic	MP,	Hunyor	AP,	Ho	IV	(2014)	Vitrectomy	for	diabetic	macular	edema:	a	systematic	review	and	meta-analysis.	Canadian	journal	of	ophthalmology	Journal	canadien	d'ophtalmologie	49:	188-195	DOI	10.1016/j.jcjo.2013.11.012	206.	 Kakinoki	M,	Sawada	O,	Sawada	T,	Saishin	Y,	Kawamura	H,	Ohji	M	(2012)	Effect	of	vitrectomy	on	aqueous	VEGF	concentration	and	pharmacokinetics	of	bevacizumab	in	macaque	monkeys.	Investigative	ophthalmology	&	visual	science	53:	5877-5880	DOI	10.1167/iovs.12-10164	207.	 Mehta	S,	Blinder	KJ,	Shah	GK,	Kymes	SM,	Schlief	SL,	Grand	MG	(2010)	Intravitreal	bevacizumab	for	the	treatment	of	refractory	diabetic	macular	edema.	Ophthalmic	surgery,	lasers	&	imaging	:	the	official	journal	of	the	International	Society	for	Imaging	in	the	Eye	41:	323-329	DOI	10.3928/15428877-20100430-05	208.	 Omri	S,	Behar-Cohen	F,	de	Kozak	Y,	Sennlaub	F,	Verissimo	LM,	Jonet	L,	Savoldelli	M,	Omri	B,	Crisanti	P	(2011)	Microglia/macrophages	migrate	through	retinal	epithelium	barrier	by	a	transcellular	route	in	diabetic	
	 -237-	
retinopathy:	role	of	PKCzeta	in	the	Goto	Kakizaki	rat	model.	The	American	journal	of	pathology	179:	942-953	DOI	10.1016/j.ajpath.2011.04.018	209.	 Joussen	AM,	Murata	T,	Tsujikawa	A,	Kirchhof	B,	Bursell	SE,	Adamis	AP	(2001)	Leukocyte-mediated	endothelial	cell	injury	and	death	in	the	diabetic	retina.	The	American	journal	of	pathology	158:	147-152	DOI	10.1016/S0002-9440(10)63952-1	210.	 Miyamoto	K,	Khosrof	S,	Bursell	SE,	Rohan	R,	Murata	T,	Clermont	AC,	Aiello	LP,	Ogura	Y,	Adamis	AP	(1999)	Prevention	of	leukostasis	and	vascular	leakage	in	streptozotocin-induced	diabetic	retinopathy	via	intercellular	adhesion	molecule-1	inhibition.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	96:	10836-10841	211.	 Brooks	HL,	Jr.,	Caballero	S,	Jr.,	Newell	CK,	Steinmetz	RL,	Watson	D,	Segal	MS,	Harrison	JK,	Scott	EW,	Grant	MB	(2004)	Vitreous	levels	of	vascular	endothelial	growth	factor	and	stromal-derived	factor	1	in	patients	with	diabetic	retinopathy	and	cystoid	macular	edema	before	and	after	intraocular	injection	of	triamcinolone.	Archives	of	ophthalmology	122:	1801-1807	DOI	10.1001/archopht.122.12.1801	212.	 Felinski	EA,	Cox	AE,	Phillips	BE,	Antonetti	DA	(2008)	Glucocorticoids	induce	transactivation	of	tight	junction	genes	occludin	and	claudin-5	in	retinal	endothelial	cells	via	a	novel	cis-element.	Experimental	eye	research	86:	867-878	DOI	10.1016/j.exer.2008.01.002	213.	 Gillies	MC,	McAllister	IL,	Zhu	M,	Wong	W,	Louis	D,	Arnold	JJ,	Wong	TY	(2011)	Intravitreal	triamcinolone	prior	to	laser	treatment	of	diabetic	macular	edema:	24-month	results	of	a	randomized	controlled	trial.	Ophthalmology	118:	866-872	DOI	10.1016/j.ophtha.2010.09.029	214.	 Chang	AA,	Li	H,	Broadhead	GK,	Luo	K,	Zhu	M	(2015)	Safety	and	Efficacy	of	Intravitreal	Preservative-Free	Triamcinolone	Acetonide	(Triesence)	for	Macular	Edema.	Journal	of	ocular	pharmacology	and	therapeutics	:	the	official	journal	of	the	Association	for	Ocular	Pharmacology	and	Therapeutics	31:	563-569	DOI	10.1089/jop.2015.0021	215.	 Gillies	MC,	Simpson	JM,	Gaston	C,	Hunt	G,	Ali	H,	Zhu	M,	Sutter	F	(2009)	Five-year	results	of	a	randomized	trial	with	open-label	extension	of	triamcinolone	acetonide	for	refractory	diabetic	macular	edema.	Ophthalmology	116:	2182-2187	DOI	10.1016/j.ophtha.2009.04.049	216.	 Ip	MS,	Bressler	SB,	Antoszyk	AN,	Flaxel	CJ,	Kim	JE,	Friedman	SM,	Qin	H,	Diabetic	Retinopathy	Clinical	Research	N	(2008)	A	randomized	trial	comparing	intravitreal	triamcinolone	and	focal/grid	photocoagulation	for	diabetic	macular	edema:	baseline	features.	Retina	28:	919-930	DOI	10.1097/IAE.0b013e31818144a7	217.	 Haller	JA,	Kuppermann	BD,	Blumenkranz	MS,	Williams	GA,	Weinberg	DV,	Chou	C,	Whitcup	SM,	Dexamethasone	DDSPIISG	(2010)	Randomized	controlled	trial	of	an	intravitreous	dexamethasone	drug	delivery	system	in	patients	with	diabetic	macular	edema.	Archives	of	ophthalmology	128:	289-296	DOI	10.1001/archophthalmol.2010.21	218.	 Boyer	DS,	Yoon	YH,	Belfort	R,	Jr.,	Bandello	F,	Maturi	RK,	Augustin	AJ,	Li	XY,	Cui	H,	Hashad	Y,	Whitcup	SM,	Ozurdex	MSG	(2014)	Three-year,	randomized,	sham-controlled	trial	of	dexamethasone	intravitreal	implant	in	patients	with	diabetic	macular	edema.	Ophthalmology	121:	1904-1914	DOI	10.1016/j.ophtha.2014.04.024	
	 -238-	
219.	 Pearson	PA,	Comstock	TL,	Ip	M,	Callanan	D,	Morse	LS,	Ashton	P,	Levy	B,	Mann	ES,	Eliott	D	(2011)	Fluocinolone	acetonide	intravitreal	implant	for	diabetic	macular	edema:	a	3-year	multicenter,	randomized,	controlled	clinical	trial.	Ophthalmology	118:	1580-1587	DOI	10.1016/j.ophtha.2011.02.048	220.	 Campochiaro	PA,	Brown	DM,	Pearson	A,	Chen	S,	Boyer	D,	Ruiz-Moreno	J,	Garretson	B,	Gupta	A,	Hariprasad	SM,	Bailey	C,	Reichel	E,	Soubrane	G,	Kapik	B,	Billman	K,	Kane	FE,	Green	K,	Group	FS	(2012)	Sustained	delivery	fluocinolone	acetonide	vitreous	inserts	provide	benefit	for	at	least	3	years	in	patients	with	diabetic	macular	edema.	Ophthalmology	119:	2125-2132	DOI	10.1016/j.ophtha.2012.04.030	221.	 Russo	A,	Costagliola	C,	Delcassi	L,	Parmeggiani	F,	Romano	MR,	Dell'Omo	R,	Semeraro	F	(2013)	Topical	nonsteroidal	anti-inflammatory	drugs	for	macular	edema.	Mediators	of	inflammation	2013:	476525	DOI	10.1155/2013/476525	222.	 Friedman	SM,	Almukhtar	TH,	Baker	CW,	Glassman	AR,	Elman	MJ,	Bressler	NM,	Maker	MP,	Jampol	LM,	Melia	M,	Diabetic	Retinopathy	Clinical	Research	N	(2015)	Topical	nepafenec	in	eyes	with	noncentral	diabetic	macular	edema.	Retina	35:	944-956	DOI	10.1097/IAE.0000000000000403	223.	 Joussen	AM,	Poulaki	V,	Tsujikawa	A,	Qin	W,	Qaum	T,	Xu	Q,	Moromizato	Y,	Bursell	SE,	Wiegand	SJ,	Rudge	J,	Ioffe	E,	Yancopoulos	GD,	Adamis	AP	(2002)	Suppression	of	diabetic	retinopathy	with	angiopoietin-1.	The	American	journal	of	pathology	160:	1683-1693	DOI	10.1016/S0002-9440(10)61115-7	224.	 Funatsu	H,	Noma	H,	Mimura	T,	Eguchi	S,	Hori	S	(2009)	Association	of	vitreous	inflammatory	factors	with	diabetic	macular	edema.	Ophthalmology	116:	73-79	DOI	10.1016/j.ophtha.2008.09.037	225.	 Chang	AA,	Li	H,	Broadhead	GK,	Hong	T,	Schlub	TE,	Wijeyakumar	W,	Zhu	M	(2014)	Intravitreal	aflibercept	for	treatment-resistant	neovascular	age-related	macular	degeneration.	Ophthalmology	121:	188-192	DOI	10.1016/j.ophtha.2013.08.035	226.	 Papadopoulos	N,	Martin	J,	Ruan	Q,	Rafique	A,	Rosconi	MP,	Shi	E,	Pyles	EA,	Yancopoulos	GD,	Stahl	N,	Wiegand	SJ	(2012)	Binding	and	neutralization	of	vascular	endothelial	growth	factor	(VEGF)	and	related	ligands	by	VEGF	Trap,	ranibizumab	and	bevacizumab.	Angiogenesis	15:	171-185	DOI	10.1007/s10456-011-9249-6	227.	 Pfister	M,	Koch	FH,	Cinatl	J,	Rothweiler	F,	Schubert	R,	Singh	P,	Ackermann	H,	Koss	MJ	(2013)	[Cytokine	determination	from	vitreous	samples	in	retinal	vascular	diseases].	Der	Ophthalmologe	:	Zeitschrift	der	Deutschen	Ophthalmologischen	Gesellschaft	110:	746-754	DOI	10.1007/s00347-012-2719-4	228.	 Do	DV,	Sepah	YJ,	Boyer	D,	Callanan	D,	Gallemore	R,	Bennett	M,	Marcus	DM,	Halperin	L,	Sadiq	MA,	Rajagopalan	N,	Campochiaro	PA,	Nguyen	QD	(2015)	Month-6	primary	outcomes	of	the	READ-3	study	(Ranibizumab	for	Edema	of	the	mAcula	in	Diabetes-Protocol	3	with	high	dose).	Eye		DOI	10.1038/eye.2015.142	229.	 Faghihi	H,	Roohipoor	R,	Mohammadi	SF,	Hojat-Jalali	K,	Mirshahi	A,	Lashay	A,	Piri	N,	Faghihi	S	(2008)	Intravitreal	bevacizumab	versus	combined	
	 -239-	
bevacizumab-triamcinolone	versus	macular	laser	photocoagulation	in	diabetic	macular	edema.	European	journal	of	ophthalmology	18:	941-948	230.	 Solaiman	KA,	Diab	MM,	Abo-Elenin	M	(2010)	Intravitreal	bevacizumab	and/or	macular	photocoagulation	as	a	primary	treatment	for	diffuse	diabetic	macular	edema.	Retina	30:	1638-1645	DOI	10.1097/IAE.0b013e3181e1ed07	231.	 Gonzalez	VH,	Campbell	J,	Holekamp	NM,	Kiss	S,	Loewenstein	A,	Augustin	AJ,	Ma	J,	Ho	AC,	Patel	V,	Whitcup	SM,	Dugel	PU	(2016)	Early	and	Long-Term	Responses	to	Anti-Vascular	Endothelial	Growth	Factor	Therapy	in	Diabetic	Macular	Edema:	Analysis	of	Protocol	I	Data.	American	journal	of	ophthalmology	172:	72-79	DOI	10.1016/j.ajo.2016.09.012	232.	 Do	DV,	Nguyen	QD,	Vitti	R,	Berliner	AJ,	Gibson	A,	Saroj	N,	Soo	Y,	Boyer	DS	(2016)	Intravitreal	Aflibercept	Injection	in	Diabetic	Macular	Edema	Patients	with	and	without	Prior	Anti-Vascular	Endothelial	Growth	Factor	Treatment:	Outcomes	from	the	Phase	3	Program.	Ophthalmology	123:	850-857	DOI	10.1016/j.ophtha.2015.11.008	233.	 Silva	PS,	Cavallerano	JD,	Haddad	NM,	Kwak	H,	Dyer	KH,	Omar	AF,	Shikari	H,	Aiello	LM,	Sun	JK,	Aiello	LP	(2015)	Peripheral	Lesions	Identified	on	Ultrawide	Field	Imaging	Predict	Increased	Risk	of	Diabetic	Retinopathy	Progression	over	4	Years.	Ophthalmology	122:	949-956	DOI	10.1016/j.ophtha.2015.01.008	234.	 Wessel	MM,	Aaker	GD,	Parlitsis	G,	Cho	M,	D'Amico	DJ,	Kiss	S	(2012)	Ultra-wide-field	angiography	improves	the	detection	and	classification	of	diabetic	retinopathy.	Retina	32:	785-791	DOI	10.1097/IAE.0b013e3182278b64	235.	 Laiginhas	R,	Silva	MI,	Rosas	V,	Penas	S,	Fernandes	VA,	Rocha-Sousa	A,	Carneiro	A,	Falcao-Reis	F,	Falcao	MS	(2018)	Aflibercept	in	diabetic	macular	edema	refractory	to	previous	bevacizumab:	outcomes	and	predictors	of	success.	Graefe's	archive	for	clinical	and	experimental	ophthalmology	=	Albrecht	von	Graefes	Archiv	fur	klinische	und	experimentelle	Ophthalmologie	256:	83-89	DOI	10.1007/s00417-017-3836-1	236.	 El-Shazly	SF,	El-Bradey	MH,	Tameesh	MK	(2014)	Vascular	endothelial	growth	factor	gene	polymorphism	prevalence	in	patients	with	diabetic	macular	oedema	and	its	correlation	with	anti-vascular	endothelial	growth	factor	treatment	outcomes.	Clinical	&	experimental	ophthalmology	42:	369-378	DOI	10.1111/ceo.12182	237.	 Mehta	H,	Fraser-Bell	S,	Nguyen	V,	Lim	LL,	Gillies	MC	(2017)	Short-term	vision	gains	at	12	weeks	correlate	with	long-term	vision	gains	at	2	years:	results	from	the	BEVORDEX	randomised	clinical	trial	of	bevacizumab	versus	dexamethasone	implants	for	diabetic	macular	oedema.	The	British	journal	of	ophthalmology	[EPub	ahead	of	print]:	10.1136/bjophthalmol-2017-310737	DOI	10.1136/bjophthalmol-2017-310737	238.	 Al-Khersan	H,	Hariprasad	SM,	Chhablani	J,	Dex	Implant	Study	G	(2017)	Early	Response	to	Intravitreal	Dexamethasone	Implant	Therapy	in	Diabetic	Macular	Edema	May	Predict	Visual	Outcome.	American	journal	of	ophthalmology	184:	121-128	DOI	10.1016/j.ajo.2017.10.004	239.	 Sophie	R,	Lu	N,	Campochiaro	PA	(2015)	Predictors	of	Functional	and	Anatomic	Outcomes	in	Patients	with	Diabetic	Macular	Edema	Treated	
	 -240-	
with	Ranibizumab.	Ophthalmology	122:	1395-1401	DOI	10.1016/j.ophtha.2015.02.036	240.	 Chung	H,	Park	B,	Shin	HJ,	Kim	HC	(2012)	Correlation	of	fundus	autofluorescence	with	spectral-domain	optical	coherence	tomography	and	vision	in	diabetic	macular	edema.	Ophthalmology	119:	1056-1065	DOI	10.1016/j.ophtha.2011.11.018	241.	 Kang	JW,	Chung	H,	Chan	Kim	H	(2016)	Correlation	of	Optical	Coherence	Tomographic	Hyperreflective	Foci	with	Visual	Outcomes	in	Different	Patterns	of	Diabetic	Macular	Edema.	Retina	36:	1630-1639	DOI	10.1097/IAE.0000000000000995	242.	 Silva	PS,	El-Rami	H,	Barham	R,	Gupta	A,	Fleming	A,	van	Hemert	J,	Cavallerano	JD,	Sun	JK,	Aiello	LP	(2017)	Hemorrhage	and/or	Microaneurysm	Severity	and	Count	in	Ultrawide	Field	Images	and	Early	Treatment	Diabetic	Retinopathy	Study	Photography.	Ophthalmology	124:	970-976	DOI	10.1016/j.ophtha.2017.02.012	243.	 Ferris	FL,	3rd,	Maguire	MG,	Glassman	AR,	Ying	GS,	Martin	DF	(2016)	Evaluating	Effects	of	Switching	Anti-Vascular	Endothelial	Growth	Factor	Drugs	for	Age-Related	Macular	Degeneration	and	Diabetic	Macular	Edema.	JAMA	ophthalmology	[Epub	ahead	of	print]:	10.1001/jamaophthalmol.2016.4820	DOI	10.1001/jamaophthalmol.2016.4820	244.	 Swanson	EA	(2015)	OCT	Technology	Transfer	and	the	OCT	Market.	In:	Drexler	W,		Fujimoto	JG	(eds)	Optical	coherence	tomography	:	technology	and	applications.	Springer,	Berlin,	pp.	3	volumes	(xxx,	2571	pages).	245.	 Ho	J,	Sull	AC,	Vuong	LN,	Chen	Y,	Liu	J,	Fujimoto	JG,	Schuman	JS,	Duker	JS	(2009)	Assessment	of	artifacts	and	reproducibility	across	spectral-	and	time-domain	optical	coherence	tomography	devices.	Ophthalmology	116:	1960-1970	DOI	10.1016/j.ophtha.2009.03.034	246.	 Wolf-Schnurrbusch	UE,	Ceklic	L,	Brinkmann	CK,	Iliev	ME,	Frey	M,	Rothenbuehler	SP,	Enzmann	V,	Wolf	S	(2009)	Macular	thickness	measurements	in	healthy	eyes	using	six	different	optical	coherence	tomography	instruments.	Investigative	ophthalmology	&	visual	science	50:	3432-3437	DOI	10.1167/iovs.08-2970	247.	 Giani	A,	Cigada	M,	Choudhry	N,	Deiro	AP,	Oldani	M,	Pellegrini	M,	Invernizzi	A,	Duca	P,	Miller	JW,	Staurenghi	G	(2010)	Reproducibility	of	retinal	thickness	measurements	on	normal	and	pathologic	eyes	by	different	optical	coherence	tomography	instruments.	American	journal	of	ophthalmology	150:	815-824	DOI	10.1016/j.ajo.2010.06.025	248.	 Bressler	SB,	Edwards	AR,	Andreoli	CM,	Edwards	PA,	Glassman	AR,	Jaffe	GJ,	Melia	M,	Sun	JK,	for	the	Diabetic	Retinopathy	Clinical	Research	Network/Writing	C	(2015)	Reproducibility	of	Optovue	RTVue	Optical	Coherence	Tomography	Retinal	Thickness	Measurements	and	Conversion	to	Equivalent	Zeiss	Stratus	Metrics	in	Diabetic	Macular	Edema.	Translational	vision	science	&	technology	4:	5	DOI	10.1167/tvst.4.1.5	249.	 Forooghian	F,	Cukras	C,	Meyerle	CB,	Chew	EY,	Wong	WT	(2008)	Evaluation	of	time	domain	and	spectral	domain	optical	coherence	tomography	in	the	measurement	of	diabetic	macular	edema.	Investigative	ophthalmology	&	visual	science	49:	4290-4296	DOI	10.1167/iovs.08-2113	
	 -241-	
250.	 Han	IC,	Jaffe	GJ	(2009)	Comparison	of	spectral-	and	time-domain	optical	coherence	tomography	for	retinal	thickness	measurements	in	healthy	and	diseased	eyes.	American	journal	of	ophthalmology	147:	847-858,	858	e841	DOI	10.1016/j.ajo.2008.11.019	251.	 Leung	CK,	Cheung	CY,	Weinreb	RN,	Lee	G,	Lin	D,	Pang	CP,	Lam	DS	(2008)	Comparison	of	macular	thickness	measurements	between	time	domain	and	spectral	domain	optical	coherence	tomography.	Investigative	ophthalmology	&	visual	science	49:	4893-4897	DOI	10.1167/iovs.07-1326	252.	 Tan	CS,	Chan	JC,	Cheong	KX,	Ngo	WK,	Sadda	SR	(2015)	Comparison	of	retinal	thicknesses	measured	using	swept-source	and	spectral-domain	optical	coherence	tomography	devices.	Ophthalmic	surgery,	lasers	&	imaging	retina	46:	172-179	DOI	10.3928/23258160-20150213-23	253.	 Comyn	O,	Heng	LZ,	Ikeji	F,	Bibi	K,	Hykin	PG,	Bainbridge	JW,	Patel	PJ	(2012)	Repeatability	of	Spectralis	OCT	measurements	of	macular	thickness	and	volume	in	diabetic	macular	edema.	Investigative	ophthalmology	&	visual	science	53:	7754-7759	DOI	10.1167/iovs.12-10895	254.	 Mylonas	G,	Ahlers	C,	Malamos	P,	Golbaz	I,	Deak	G,	Schuetze	C,	Sacu	S,	Schmidt-Erfurth	U	(2009)	Comparison	of	retinal	thickness	measurements	and	segmentation	performance	of	four	different	spectral	and	time	domain	OCT	devices	in	neovascular	age-related	macular	degeneration.	The	British	journal	of	ophthalmology	93:	1453-1460	DOI	10.1136/bjo.2008.153643	255.	 Diabetic	Retinopathy	Clinical	Research	N,	Wells	JA,	Glassman	AR,	Ayala	AR,	Jampol	LM,	Aiello	LP,	Antoszyk	AN,	Arnold-Bush	B,	Baker	CW,	Bressler	NM,	Browning	DJ,	Elman	MJ,	Ferris	FL,	Friedman	SM,	Melia	M,	Pieramici	DJ,	Sun	JK,	Beck	RW	(2015)	Aflibercept,	bevacizumab,	or	ranibizumab	for	diabetic	macular	edema.	The	New	England	journal	of	medicine	372:	1193-1203	DOI	10.1056/NEJMoa1414264	256.	 Rofagha	S,	Bhisitkul	RB,	Boyer	DS,	Sadda	SR,	Zhang	K,	Group	S-US	(2013)	Seven-year	outcomes	in	ranibizumab-treated	patients	in	ANCHOR,	MARINA,	and	HORIZON:	a	multicenter	cohort	study	(SEVEN-UP).	Ophthalmology	120:	2292-2299	DOI	10.1016/j.ophtha.2013.03.046	257.	 Diabetic	Retinopathy	Clinical	Research	N,	Elman	MJ,	Aiello	LP,	Beck	RW,	Bressler	NM,	Bressler	SB,	Edwards	AR,	Ferris	FL,	3rd,	Friedman	SM,	Glassman	AR,	Miller	KM,	Scott	IU,	Stockdale	CR,	Sun	JK	(2010)	Randomized	trial	evaluating	ranibizumab	plus	prompt	or	deferred	laser	or	triamcinolone	plus	prompt	laser	for	diabetic	macular	edema.	Ophthalmology	117:	1064-1077	e1035	DOI	10.1016/j.ophtha.2010.02.031	258.	 Do	DV,	Schmidt-Erfurth	U,	Gonzalez	VH,	Gordon	CM,	Tolentino	M,	Berliner	AJ,	Vitti	R,	Ruckert	R,	Sandbrink	R,	Stein	D,	Yang	K,	Beckmann	K,	Heier	JS	(2011)	The	DA	VINCI	Study:	phase	2	primary	results	of	VEGF	Trap-Eye	in	patients	with	diabetic	macular	edema.	Ophthalmology	118:	1819-1826	DOI	10.1016/j.ophtha.2011.02.018	259.	 Korobelnik	JF,	Do	DV,	Schmidt-Erfurth	U,	Boyer	DS,	Holz	FG,	Heier	JS,	Midena	E,	Kaiser	PK,	Terasaki	H,	Marcus	DM,	Nguyen	QD,	Jaffe	GJ,	Slakter	JS,	Simader	C,	Soo	Y,	Schmelter	T,	Yancopoulos	GD,	Stahl	N,	Vitti	R,	Berliner	AJ,	Zeitz	O,	Metzig	C,	Brown	DM	(2014)	Intravitreal	aflibercept	
	 -242-	
for	diabetic	macular	edema.	Ophthalmology	121:	2247-2254	DOI	10.1016/j.ophtha.2014.05.006	260.	 Podoleanu	AG	(2012)	Optical	coherence	tomography.	Journal	of	microscopy	247:	209-219	DOI	10.1111/j.1365-2818.2012.03619.x	261.	 Patel	PJ,	Chen	FK,	Ikeji	F,	Xing	W,	Bunce	C,	Da	Cruz	L,	Tufail	A	(2008)	Repeatability	of	stratus	optical	coherence	tomography	measures	in	neovascular	age-related	macular	degeneration.	Investigative	ophthalmology	&	visual	science	49:	1084-1088	DOI	10.1167/iovs.07-1203	262.	 Haller	JA,	Stalmans	P,	Benz	MS,	Gandorfer	A,	Pakola	SJ,	Girach	A,	Kampik	A,	Jaffe	GJ,	Toth	CA,	Group	M-TS	(2015)	Efficacy	of	intravitreal	ocriplasmin	for	treatment	of	vitreomacular	adhesion:	subgroup	analyses	from	two	randomized	trials.	Ophthalmology	122:	117-122	DOI	10.1016/j.ophtha.2014.07.045	263.	 Han	IC,	Jaffe	GJ	(2010)	Evaluation	of	artifacts	associated	with	macular	spectral-domain	optical	coherence	tomography.	Ophthalmology	117:	1177-1189	e1174	DOI	10.1016/j.ophtha.2009.10.029	264.	 Krebs	I,	Hagen	S,	Smretschnig	E,	Womastek	I,	Brannath	W,	Binder	S	(2011)	Conversion	of	Stratus	optical	coherence	tomography	(OCT)	retinal	thickness	to	Cirrus	OCT	values	in	age-related	macular	degeneration.	The	British	journal	of	ophthalmology	95:	1552-1554	DOI	10.1136/bjo.2010.194670	265.	 Tsui	I,	Kaines	A,	Havunjian	MA,	Hubschman	S,	Heilweil	G,	Prasad	PS,	Oliver	SC,	Yu	F,	Bitrian	E,	Hubschman	JP,	Friberg	T,	Schwartz	SD	(2011)	Ischemic	index	and	neovascularization	in	central	retinal	vein	occlusion.	Retina	31:	105-110	DOI	10.1097/IAE.0b013e3181e36c6d	266.	 Nicholson	L,	Vazquez-Alfageme	C,	Ramu	J,	Triantafyllopoulou	I,	Patrao	NV,	Muwas	M,	Islam	F,	Hykin	PG,	Sivaprasad	S	(2015)	Validation	of	Concentric	Rings	Method	as	a	Topographic	Measure	of	Retinal	Nonperfusion	in	Ultra-Widefield	Fluorescein	Angiography.	American	journal	of	ophthalmology	160:	1217-1225	e1212	DOI	10.1016/j.ajo.2015.09.003	267.	 Samara	WA,	Shahlaee	A,	Adam	MK,	Khan	MA,	Chiang	A,	Maguire	JI,	Hsu	J,	Ho	AC	(2017)	Quantification	of	Diabetic	Macular	Ischemia	Using	Optical	Coherence	Tomography	Angiography	and	Its	Relationship	with	Visual	Acuity.	Ophthalmology	124:	235-244	DOI	10.1016/j.ophtha.2016.10.008	268.	 Gaucher	D,	Fortunato	P,	LeCleire-Collet	A,	Bourcier	T,	Speeg-Schatz	C,	Tadayoni	R,	Massin	P	(2009)	Spontaneous	resolution	of	macular	edema	after	panretinal	photocoagulation	in	florid	proliferative	diabetic	retinopathy.	Retina	29:	1282-1288	DOI	10.1097/IAE.0b013e3181a91e9f	269.	 Takamura	Y,	Tomomatsu	T,	Matsumura	T,	Arimura	S,	Gozawa	M,	Takihara	Y,	Inatani	M	(2014)	The	effect	of	photocoagulation	in	ischemic	areas	to	prevent	recurrence	of	diabetic	macular	edema	after	intravitreal	bevacizumab	injection.	Investigative	ophthalmology	&	visual	science	55:	4741-4746	DOI	10.1167/iovs.14-14682	270.	 McDonald	HR,	Schatz	H	(1985)	Macular	edema	following	panretinal	photocoagulation.	Retina	5:	5-10	271.	 Ito	A,	Hirano	Y,	Nozaki	M,	Ashikari	M,	Sugitani	K,	Ogura	Y	(2015)	Short	pulse	laser	induces	less	inflammatory	cytokines	in	the	murine	retina	after	
	 -243-	
laser	photocoagulation.	Ophthalmic	research	53:	65-73	DOI	10.1159/000366520	272.	 Brown	DM,	Ou	WC,	Wong	TP,	Kim	RY,	Croft	DE,	Wykoff	CC,	Group	DS	(2018)	Targeted	Retinal	Photocoagulation	for	Diabetic	Macular	Edema	with	Peripheral	Retinal	Nonperfusion:	Three-Year	Randomized	DAVE	Trial.	Ophthalmology		DOI	10.1016/j.ophtha.2017.11.026	273.	 Campochiaro	PA,	Hafiz	G,	Mir	TA,	Scott	AW,	Solomon	S,	Zimmer-Galler	I,	Sodhi	A,	Duh	E,	Ying	H,	Wenick	A,	Shah	SM,	Do	DV,	Nguyen	QD,	Kherani	S,	Sophie	R	(2015)	Scatter	Photocoagulation	Does	Not	Reduce	Macular	Edema	or	Treatment	Burden	in	Patients	with	Retinal	Vein	Occlusion:	The	RELATE	Trial.	Ophthalmology	122:	1426-1437	DOI	10.1016/j.ophtha.2015.04.006	274.	 Campochiaro	PA,	Wykoff	CC,	Shapiro	H,	Rubio	RG,	Ehrlich	JS	(2014)	Neutralization	of	vascular	endothelial	growth	factor	slows	progression	of	retinal	nonperfusion	in	patients	with	diabetic	macular	edema.	Ophthalmology	121:	1783-1789	DOI	10.1016/j.ophtha.2014.03.021	275.	 Levin	AM,	Rusu	I,	Orlin	A,	Gupta	MP,	Coombs	P,	D'Amico	DJ,	Kiss	S	(2017)	Retinal	reperfusion	in	diabetic	retinopathy	following	treatment	with	anti-VEGF	intravitreal	injections.	Clinical	ophthalmology	11:	193-200	DOI	10.2147/OPTH.S118807	276.	 Querques	L,	Parravano	M,	Sacconi	R,	Rabiolo	A,	Bandello	F,	Querques	G	(2017)	Ischemic	index	changes	in	diabetic	retinopathy	after	intravitreal	dexamethasone	implant	using	ultra-widefield	fluorescein	angiography:	a	pilot	study.	Acta	diabetologica	54:	769-773	DOI	10.1007/s00592-017-1010-1	277.	 Tanchon	C,	Srivastava	SK,	Ehlers	JP	(2015)	Automated	Quantitative	Analysis	of	Leakage	and	Ischemia	for	Ultra-widefield	Angiography	in	Retinal	Vascular	Disease.	Investigative	ophthalmology	&	visual	science	56:	3067-3067	278.	 Tan	CS,	Chew	MC,	van	Hemert	J,	Singer	MA,	Bell	D,	Sadda	SR	(2016)	Measuring	the	precise	area	of	peripheral	retinal	non-perfusion	using	ultra-widefield	imaging	and	its	correlation	with	the	ischaemic	index.	The	British	journal	of	ophthalmology	100:	235-239	DOI	10.1136/bjophthalmol-2015-306652	279.	 Bressler	NM,	Varma	R,	Suner	IJ,	Dolan	CM,	Ward	J,	Ehrlich	JS,	Colman	S,	Turpcu	A,	Ride,	Groups	RR	(2014)	Vision-related	function	after	ranibizumab	treatment	for	diabetic	macular	edema:	results	from	RIDE	and	RISE.	Ophthalmology	121:	2461-2472	DOI	10.1016/j.ophtha.2014.07.008	280.	 Tomkins-Netzer	O,	Ismetova	F,	Bar	A,	Seguin-Greenstein	S,	Kramer	M,	Lightman	S	(2015)	Functional	outcome	of	macular	edema	in	different	retinal	disorders.	Progress	in	retinal	and	eye	research	48:	119-136	DOI	10.1016/j.preteyeres.2015.05.002	281.	 Sohn	EH,	van	Dijk	HW,	Jiao	C,	Kok	PH,	Jeong	W,	Demirkaya	N,	Garmager	A,	Wit	F,	Kucukevcilioglu	M,	van	Velthoven	ME,	DeVries	JH,	Mullins	RF,	Kuehn	MH,	Schlingemann	RO,	Sonka	M,	Verbraak	FD,	Abramoff	MD	(2016)	Retinal	neurodegeneration	may	precede	microvascular	changes	characteristic	of	diabetic	retinopathy	in	diabetes	mellitus.	Proceedings	of	
	 -244-	
the	National	Academy	of	Sciences	of	the	United	States	of	America	113:	E2655-2664	DOI	10.1073/pnas.1522014113	282.	 Parisi	V,	Uccioli	L	(2001)	Visual	electrophysiological	responses	in	persons	with	type	1	diabetes.	Diabetes/metabolism	research	and	reviews	17:	12-18	283.	 Vujosevic	S,	Midena	E,	Pilotto	E,	Radin	PP,	Chiesa	L,	Cavarzeran	F	(2006)	Diabetic	macular	edema:	correlation	between	microperimetry	and	optical	coherence	tomography	findings.	Investigative	ophthalmology	&	visual	science	47:	3044-3051	DOI	10.1167/iovs.05-1141	284.	 Yohannan	J,	Bittencourt	M,	Sepah	YJ,	Hatef	E,	Sophie	R,	Moradi	A,	Liu	H,	Ibrahim	M,	Do	DV,	Coulantuoni	E,	Nguyen	QD	(2013)	Association	of	retinal	sensitivity	to	integrity	of	photoreceptor	inner/outer	segment	junction	in	patients	with	diabetic	macular	edema.	Ophthalmology	120:	1254-1261	DOI	10.1016/j.ophtha.2012.12.003	285.	 Landa	G,	Su	E,	Garcia	PM,	Seiple	WH,	Rosen	RB	(2011)	Inner	segment-outer	segment	junctional	layer	integrity	and	corresponding	retinal	sensitivity	in	dry	and	wet	forms	of	age-related	macular	degeneration.	Retina	31:	364-370	DOI	10.1097/IAE.0b013e3181e91132	286.	 Battu	R,	Khanna	A,	Hegde	B,	Berendschot	TT,	Grover	S,	Schouten	JS	(2015)	Correlation	of	structure	and	function	of	the	macula	in	patients	with	retinitis	pigmentosa.	Eye	29:	895-901	DOI	10.1038/eye.2015.61	287.	 Sugawara	T,	Sato	E,	Baba	T,	Hagiwara	A,	Tawada	A,	Yamamoto	S	(2011)	Relationship	between	vision-related	quality	of	life	and	microperimetry-determined	macular	sensitivity	in	patients	with	retinitis	pigmentosa.	Japanese	journal	of	ophthalmology	55:	643-646	DOI	10.1007/s10384-011-0080-9	288.	 Mangione	CM,	Lee	PP,	Gutierrez	PR,	Spritzer	K,	Berry	S,	Hays	RD,	National	Eye	Institute	Visual	Function	Questionnaire	Field	Test	I	(2001)	Development	of	the	25-item	National	Eye	Institute	Visual	Function	Questionnaire.	Archives	of	ophthalmology	119:	1050-1058	289.	 Ramu	J,	Chatziralli	I,	Yang	Y,	Menon	G,	Bailey	C,	Eckstein	M,	Hykin	P,	Sivaprasad	S	(2017)	Health-related	quality	of	life,	visual	function	and	treatment	satisfaction	following	intravitreal	dexamethasone	implant	for	diabetic	macular	edema.	Patient	preference	and	adherence	11:	579-586	DOI	10.2147/PPA.S132859	290.	 Okamoto	Y,	Okamoto	F,	Hiraoka	T,	Oshika	T	(2014)	Vision-related	quality	of	life	and	visual	function	following	intravitreal	bevacizumab	injection	for	persistent	diabetic	macular	edema	after	vitrectomy.	Japanese	journal	of	ophthalmology	58:	369-374	DOI	10.1007/s10384-014-0323-7	291.	 Okada	K,	Yamamoto	S,	Mizunoya	S,	Hoshino	A,	Arai	M,	Takatsuna	Y	(2006)	Correlation	of	retinal	sensitivity	measured	with	fundus-related	microperimetry	to	visual	acuity	and	retinal	thickness	in	eyes	with	diabetic	macular	edema.	Eye	20:	805-809	DOI	10.1038/sj.eye.6702014	292.	 Nakamura	Y,	Mitamura	Y,	Ogata	K,	Arai	M,	Takatsuna	Y,	Yamamoto	S	(2010)	Functional	and	morphological	changes	of	macula	after	subthreshold	micropulse	diode	laser	photocoagulation	for	diabetic	macular	oedema.	Eye	24:	784-788	DOI	10.1038/eye.2009.207	293.	 Deak	GG,	Bolz	M,	Ritter	M,	Prager	S,	Benesch	T,	Schmidt-Erfurth	U,	Diabetic	Retinopathy	Research	Group	V	(2010)	A	systematic	correlation	
	 -245-	
between	morphology	and	functional	alterations	in	diabetic	macular	edema.	Investigative	ophthalmology	&	visual	science	51:	6710-6714	DOI	10.1167/iovs.09-5064	294.	 Shen	Y,	Liu	K,	Xu	X	(2016)	Correlation	Between	Visual	Function	and	Photoreceptor	Integrity	in	Diabetic	Macular	Edema:	Spectral-Domain	Optical	Coherence	Tomography.	Current	eye	research	41:	391-399	DOI	10.3109/02713683.2015.1019003	295.	 Sun	JK,	Radwan	SH,	Soliman	AZ,	Lammer	J,	Lin	MM,	Prager	SG,	Silva	PS,	Aiello	LB,	Aiello	LP	(2015)	Neural	Retinal	Disorganization	as	a	Robust	Marker	of	Visual	Acuity	in	Current	and	Resolved	Diabetic	Macular	Edema.	Diabetes	64:	2560-2570	DOI	10.2337/db14-0782	296.	 Das	R,	Spence	G,	Hogg	RE,	Stevenson	M,	Chakravarthy	U	(2018)	Disorganization	of	Inner	Retina	and	Outer	Retinal	Morphology	in	Diabetic	Macular	Edema.	JAMA	ophthalmology	136:	202-208	DOI	10.1001/jamaophthalmol.2017.6256	297.	 Striph	GG,	Hart	WM,	Jr.,	Olk	RJ	(1988)	Modified	grid	laser	photocoagulation	for	diabetic	macular	edema.	The	effect	on	the	central	visual	field.	Ophthalmology	95:	1673-1679	298.	 Vujosevic	S,	Bottega	E,	Casciano	M,	Pilotto	E,	Convento	E,	Midena	E	(2010)	Microperimetry	and	fundus	autofluorescence	in	diabetic	macular	edema:	subthreshold	micropulse	diode	laser	versus	modified	early	treatment	diabetic	retinopathy	study	laser	photocoagulation.	Retina	30:	908-916	DOI	10.1097/IAE.0b013e3181c96986	299.	 Bahrami	B,	Hong	T,	Gilles	MC,	Chang	A	(2017)	Anti-VEGF	Therapy	for	Diabetic	Eye	Diseases.	Asia-Pacific	journal	of	ophthalmology	6:	535-545	DOI	10.22608/APO.2017350	300.	 Wu	L,	Fernandez-Loaiza	P,	Sauma	J,	Hernandez-Bogantes	E,	Masis	M	(2013)	Classification	of	diabetic	retinopathy	and	diabetic	macular	edema.	World	journal	of	diabetes	4:	290-294	DOI	10.4239/wjd.v4.i6.290	301.	 Lynch	SK,	Abramoff	MD	(2017)	Diabetic	retinopathy	is	a	neurodegenerative	disorder.	Vision	research	139:	101-107	DOI	10.1016/j.visres.2017.03.003	302.	 van	Dijk	HW,	Verbraak	FD,	Kok	PH,	Garvin	MK,	Sonka	M,	Lee	K,	Devries	JH,	Michels	RP,	van	Velthoven	ME,	Schlingemann	RO,	Abramoff	MD	(2010)	Decreased	retinal	ganglion	cell	layer	thickness	in	patients	with	type	1	diabetes.	Investigative	ophthalmology	&	visual	science	51:	3660-3665	DOI	10.1167/iovs.09-5041	303.	 Park	HY,	Kim	JH,	Park	CK	(2014)	Neuronal	cell	death	in	the	inner	retina	and	the	influence	of	vascular	endothelial	growth	factor	inhibition	in	a	diabetic	rat	model.	The	American	journal	of	pathology	184:	1752-1762	DOI	10.1016/j.ajpath.2014.02.016	304.	 Shin	HJ,	Kim	SN,	Chung	H,	Kim	TE,	Kim	HC	(2016)	Intravitreal	Anti-Vascular	Endothelial	Growth	Factor	Therapy	and	Retinal	Nerve	Fiber	Layer	Loss	in	Eyes	With	Age-Related	Macular	Degeneration:	A	Meta-Analysis.	Investigative	ophthalmology	&	visual	science	57:	1798-1806	DOI	10.1167/iovs.15-18404	305.	 Joachim	SC,	Renner	M,	Reinhard	J,	Theiss	C,	May	C,	Lohmann	S,	Reinehr	S,	Stute	G,	Faissner	A,	Marcus	K,	Dick	HB	(2017)	Protective	effects	on	the	
	 -246-	
retina	after	ranibizumab	treatment	in	an	ischemia	model.	PloS	one	12:	e0182407	DOI	10.1371/journal.pone.0182407	306.	 Ponnalagu	M,	Subramani	M,	Jayadev	C,	Shetty	R,	Das	D	(2017)	Retinal	pigment	epithelium-secretome:	A	diabetic	retinopathy	perspective.	Cytokine	95:	126-135	DOI	10.1016/j.cyto.2017.02.013	307.	 Wang	GL,	Semenza	GL	(1993)	General	involvement	of	hypoxia-inducible	factor	1	in	transcriptional	response	to	hypoxia.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America	90:	4304-4308	308.	 Park	H,	Lee	DS,	Yim	MJ,	Choi	YH,	Park	S,	Seo	SK,	Choi	JS,	Jang	WH,	Yea	SS,	Park	WS,	Lee	CM,	Jung	WK,	Choi	IW	(2015)	3,3'-Diindolylmethane	inhibits	VEGF	expression	through	the	HIF-1alpha	and	NF-kappaB	pathways	in	human	retinal	pigment	epithelial	cells	under	chemical	hypoxic	conditions.	International	journal	of	molecular	medicine	36:	301-308	DOI	10.3892/ijmm.2015.2202	309.	 Semenza	GL	(1998)	Hypoxia-inducible	factor	1:	master	regulator	of	O2	homeostasis.	Current	opinion	in	genetics	&	development	8:	588-594	310.	 O'Brien	J,	Wilson	I,	Orton	T,	Pognan	F	(2000)	Investigation	of	the	Alamar	Blue	(resazurin)	fluorescent	dye	for	the	assessment	of	mammalian	cell	cytotoxicity.	European	journal	of	biochemistry	267:	5421-5426	311.	 Malik	D,	Tarek	M,	Caceres	del	Carpio	J,	Ramirez	C,	Boyer	D,	Kenney	MC,	Kuppermann	BD	(2014)	Safety	profiles	of	anti-VEGF	drugs:	bevacizumab,	ranibizumab,	aflibercept	and	ziv-aflibercept	on	human	retinal	pigment	epithelium	cells	in	culture.	The	British	journal	of	ophthalmology	98	Suppl	1:	i11-16	DOI	10.1136/bjophthalmol-2014-305302	312.	 Heimsath	EG,	Jr.,	Unda	R,	Vidro	E,	Muniz	A,	Villazana-Espinoza	ET,	Tsin	A	(2006)	ARPE-19	cell	growth	and	cell	functions	in	euglycemic	culture	media.	Current	eye	research	31:	1073-1080	DOI	10.1080/02713680601052320	313.	 Villarroel	M,	Garcia-Ramirez	M,	Corraliza	L,	Hernandez	C,	Simo	R	(2009)	Effects	of	high	glucose	concentration	on	the	barrier	function	and	the	expression	of	tight	junction	proteins	in	human	retinal	pigment	epithelial	cells.	Experimental	eye	research	89:	913-920	DOI	10.1016/j.exer.2009.07.017	314.	 Kolomeyer	AM,	Zarbin	MA	(2014)	Trophic	factors	in	the	pathogenesis	and	therapy	for	retinal	degenerative	diseases.	Survey	of	ophthalmology	59:	134-165	DOI	10.1016/j.survophthal.2013.09.004	315.	 Dai	M,	Xia	XB,	Xiong	SQ	(2012)	BDNF	regulates	GLAST	and	glutamine	synthetase	in	mouse	retinal	Muller	cells.	Journal	of	cellular	physiology	227:	596-603	DOI	10.1002/jcp.22762	316.	 Ola	MS,	Nawaz	MI,	El-Asrar	AA,	Abouammoh	M,	Alhomida	AS	(2013)	Reduced	levels	of	brain	derived	neurotrophic	factor	(BDNF)	in	the	serum	of	diabetic	retinopathy	patients	and	in	the	retina	of	diabetic	rats.	Cellular	and	molecular	neurobiology	33:	359-367	DOI	10.1007/s10571-012-9901-8	317.	 Casson	RJ,	Chidlow	G,	Wood	JP,	Osborne	NN	(2004)	The	effect	of	hyperglycemia	on	experimental	retinal	ischemia.	Archives	of	ophthalmology	122:	361-366	DOI	10.1001/archopht.122.3.361	
	 -247-	
318.	 Casson	RJ,	Han	G,	Ebneter	A,	Chidlow	G,	Glihotra	J,	Newland	H,	Wood	JP	(2014)	Glucose-induced	temporary	visual	recovery	in	primary	open-angle	glaucoma:	a	double-blind,	randomized	study.	Ophthalmology	121:	1203-1211	DOI	10.1016/j.ophtha.2013.12.011	319.	 Notari	L,	Miller	A,	Martinez	A,	Amaral	J,	Ju	M,	Robinson	G,	Smith	LE,	Becerra	SP	(2005)	Pigment	epithelium-derived	factor	is	a	substrate	for	matrix	metalloproteinase	type	2	and	type	9:	implications	for	downregulation	in	hypoxia.	Investigative	ophthalmology	&	visual	science	46:	2736-2747	DOI	10.1167/iovs.04-1489	320.	 Unterlauft	JD,	Eichler	W,	Kuhne	K,	Yang	XM,	Yafai	Y,	Wiedemann	P,	Reichenbach	A,	Claudepierre	T	(2012)	Pigment	epithelium-derived	factor	released	by	Muller	glial	cells	exerts	neuroprotective	effects	on	retinal	ganglion	cells.	Neurochemical	research	37:	1524-1533	DOI	10.1007/s11064-012-0747-8	321.	 Ortin-Martinez	A,	Valiente-Soriano	FJ,	Garcia-Ayuso	D,	Alarcon-Martinez	L,	Jimenez-Lopez	M,	Bernal-Garro	JM,	Nieto-Lopez	L,	Nadal-Nicolas	FM,	Villegas-Perez	MP,	Wheeler	LA,	Vidal-Sanz	M	(2014)	A	novel	in	vivo	model	of	focal	light	emitting	diode-induced	cone-photoreceptor	phototoxicity:	neuroprotection	afforded	by	brimonidine,	BDNF,	PEDF	or	bFGF.	PloS	one	9:	e113798	DOI	10.1371/journal.pone.0113798	322.	 Ohno-Matsui	K,	Yoshida	T,	Uetama	T,	Mochizuki	M,	Morita	I	(2003)	Vascular	endothelial	growth	factor	upregulates	pigment	epithelium-derived	factor	expression	via	VEGFR-1	in	human	retinal	pigment	epithelial	cells.	Biochemical	and	biophysical	research	communications	303:	962-967	323.	 Wang	JW,	Zhou	MW,	Zhang	X,	Huang	WB,	Gao	XB,	Wang	W,	Chen	S,	Zhang	XY,	Ding	XY,	Jonas	JB	(2015)	Short-term	effect	of	intravitreal	ranibizumab	on	intraocular	concentrations	of	vascular	endothelial	growth	factor-A	and	pigment	epithelium-derived	factor	in	neovascular	glaucoma.	Clinical	&	experimental	ophthalmology	43:	415-421	DOI	10.1111/ceo.12477	324.	 Nagineni	CN,	Kommineni	VK,	William	A,	Detrick	B,	Hooks	JJ	(2012)	Regulation	of	VEGF	expression	in	human	retinal	cells	by	cytokines:	implications	for	the	role	of	inflammation	in	age-related	macular	degeneration.	Journal	of	cellular	physiology	227:	116-126	DOI	10.1002/jcp.22708	325.	 Takeyama	M,	Yoneda	M,	Gosho	M,	Iwaki	M,	Zako	M	(2015)	Decreased	VEGF-A	and	sustained	PEDF	expression	in	a	human	retinal	pigment	epithelium	cell	line	cultured	under	hypothermia.	Biological	research	48:	42	DOI	10.1186/s40659-015-0034-7	326.	 Shen	W,	Yau	B,	Lee	SR,	Zhu	L,	Yam	M,	Gillies	MC	(2017)	Effects	of	Ranibizumab	and	Aflibercept	on	Human	Muller	Cells	and	Photoreceptors	under	Stress	Conditions.	International	journal	of	molecular	sciences	18	DOI	10.3390/ijms18030533		
